

665	<p><a href="#">The potential role of purinergic signaling in cancer therapy: perspectives on anti-CD73 strategies for prostate cancer</a> CFF Gardani, FM Diz, LB Dondé, L Rockenbach, <b>S Laufer</b>, FB Morrone Frontiers in Immunology 15, 1455469</p>	2024	
664	<p><a href="#">Das molekulare Interaktionsmuster von Lenvatinib ermöglicht die Inhibierung von Cholangiokarzinomen mit wildtype und rezeptormutierten FGFR2-Fusionen</a> S Spahn, F Kleinhenz, E Shevchenko, A Stahl, Y Rasen, C Geisler, K Ruhm, M Klaumuenzer, T Kronenberger, <b>S Laufer</b>, H Sundberg-Malek, KC Buie, M Holger, S Biskup, K Schulze-Osthoff, M Templin, N Malek, M Bitzer Zeitschrift für Gastroenterologie 62 (09), KV 261</p>	2024	
663	<p><a href="#">An Investigation of the Drug Release Kinetics of 3D-Printed Two Compartment Theophylline and Prednisolone Tablets</a> T Pflieger, R Venkatesh, M Dachtler, <b>S Laufer</b>, DJ Lunter Available at SSRN 4932428</p>	2024	
662	<p><a href="#">30 Years of Kinase Inhibitors: A Historical Overview and some Brazilian Contributions</a> JGB Pedreira, <b>S Laufer</b> Journal of the Brazilian Chemical Society 35 (10), e-20240107</p>	2024	
661	<p><a href="#">Wound healing potential and anti-inflammatory action of extracts and compounds of <i>Myrciaria plinioides</i> D. Legrand leaves</a> DJ Marmitt, G Vettorazzi, L Bortoluzzi, C Alves, J Silva, S Pinteus, A Martins, H Gaspar, R Pedrosa, J da Silva, JAP Henriques, <b>S Laufer</b>, MI Goettert Inflammopharmacology, 1-19</p>	2024	
660	<p><a href="#">Novel Small-Molecule Atypical Chemokine Receptor 3 Agonists: Design, Synthesis, and Pharmacological Evaluation for Antiplatelet Therapy</a> A Bayrak, M Szpakowska, V Dicenta-Baunach, M Counson, A Rasch, AK Rohlfing, A Chevigné, M Gawaz, <b>SA Laufer</b>, T Pillaiyar Journal of Medicinal Chemistry 67 (16), 14553-14573</p>	2024	
659	<p><a href="#">3.2. 2 Synthesis of a biocompatible benzophenone-substituted chitosan hydrogel as novel coating for PEEK with extraordinary strong antibacterial and anti-biofilm properties</a> M Borgolte, O Riester, I Quint, F Blendinger, V Bucher, <b>S Laufer</b>, R Csuk A Multifaceted Approach to Preserve Effective Antibiotics Utilizing ...</p>	2024	

658	<p><a href="#">Supporting Information Synthesis of a biocompatible benzophenone-substituted chitosan hydrogel as novel coating for PEEK with extraordinary strong antibacterial and anti ...</a>  M Borgolte, O Riester, I Quint, F Blending, V Bucher, <b>S Laufer</b>, R Csuk, L Scotti, HP Deigner  A Multifaceted Approach to Preserve Effective Antibiotics Utilizing ...</p>	2024	
657	<p><a href="#">A. 1.2 Supporting Material: Rapid Phenotypic Antibiotics Susceptibility Analysis by a 3D Printed Prototype</a>  O Riester, L Kaiser, <b>S Laufer</b>, HP Deigner  A Multifaceted Approach to Preserve Effective Antibiotics Utilizing ...</p>	2024	
656	<p><a href="#">Influence of design parameters on sustained drug release properties of 3D-printed theophylline tablets</a>  T Pflieger, R Venkatesh, M Dachtler, K Cooke, <b>S Laufer</b>, D Lunter  International Journal of Pharmaceutics 658, 124207</p>	2024	
655	<p><a href="#">Targeting Lewy body dementia with neflamapimod-rasagiline hybrids</a>  C Albertini, S Petralla, F Massenzio, B Monti, N Rizzardi, C Bergamini, E Uliassi, F Borges, D Chavarria, G Fricker, M Goettert, T Kronenberger, M Gehringer, <b>S Laufer</b>, ML Bolognesi  Archiv der Pharmazie 357 (6), 2300525</p>	2024	
654	<p><a href="#">Hemin-induced platelet activation is regulated via ACKR3 chemokine surface receptor-implications for passivation of vulnerable atherosclerotic plaque</a>  Z Laspa, V Dicenta-Baunach, D Schaale, M Sigle, R Hochuli, T Castor, A Bayrak, T Harm, KAL Mueller, T Pillaiyar, <b>S Laufer</b>, AK Rohlfing, MP Gawaz  bioRxiv, 2024.05. 13.593847</p>	2024	
653	<p><a href="#">Towards a zero-waste sustainable biorefinery of Codium sp. seaweed: From bioactives application to soil enhancement materials</a>  A Martins, J Silva, C Alves, S Pinteus, C Félix, A Augusto, R Pedrosa, AS Mestre, RMM Santos, AP Carvalho, M Goettert, <b>S Laufer</b>, MFL Lemos  Journal of Cleaner Production 453, 142191</p>	2024	
652	<p><a href="#">Protein kinase mkk4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death</a>  B Praefke, P Klövekorn, R Selig, W Albrecht, <b>S Laufer</b>  US Patent App. 18/388,084</p>	2024	
651	<p><a href="#">Development of Highly Potent and Selective Covalent FGFR4 Inhibitors Based on S<sub>N</sub>Ar Electrophiles</a>  M Schwarz, M Kurkunov, F Wittlinger, R Rudalska, G Wang, MP Schwalm, A Rasch, B Wagner, <b>SA Laufer</b>, S Knapp, D Dauch, M Gehringer  Journal of medicinal chemistry 67 (8), 6549-6569</p>	2024	

650	<a href="#">Protein-protein interaction modulators of aurora kinase a and their use in the prevention and/or treatment of cancer</a> JJ Reiner, T Pantsar, D Flötgen, <b>S Laufer</b> , L Zender, M Henning US Patent App. 18/035,671	2024	
649	<a href="#">First-in-class MKK4 inhibitors enhance liver regeneration and prevent liver failure</a> S Zwirner, AAA Rmilah, S Klotz, B Pfaffenroth, P Kloevekorn, AA Moschopoulou, S Schuette, M Haag, R Selig, K Li, W Zhou, E Nelson, A Poso, H Chen, B Amiot, Y Jia, A Minshew, G Michalak, W Cui, E Rist, T Longerich, B Jung, P Felgendreff, O Trompak, PK Premrsirut, K Gries, TE Muerdter, G Heinkele, T Wuestefeld, D Shapiro, M Weissbach, A Koenigsrainer, B Sipos, AB Eiso, MO Zacarias, S Theisgen, N Gruenheit, S Biskup, M Schwab, W Albrecht, <b>S Laufer</b> , S Nyberg, L Zender Cell 187 (7), 1666-1684. e26	2024	
648	<a href="#">Rapid Phenotypic Antibiotics Susceptibility Analysis by a 3D Printed Prototype</a> O Riester, L Kaiser, <b>S Laufer</b> , HP Deigner Advanced Science, 2308806	2024	
647	<a href="#">Development and characterization of kinase sparing TPX2-tethering Aurora kinase A ligands for cancer therapy</a> AA Moschopoulou, M Henning, B Wagner, D Flötgen, J Reiner, Y Skliarenko, S Zwirner, C Hinterleitner, M Seehawer, L dArtista, E Rist, T Pantsar, T Kronenberger, D Dauch, C Gehring-Khav, A Poso, L Andreeva, M Schwab, M Forster, W Albrecht, <b>S Laufer</b> , L Zender Cancer Research 84 (6_Supplement), 4478-4478	2024	
646	<a href="#">Correction to “Cathepsin-Targeting SARS-CoV-2 Inhibitors: Design, Synthesis, and Biological Activity”</a> P Flury, J Breidenbach, N Krüger, R Voget, L Schäkel, Y Si, V Krasniqi, S Calistri, M Olfert, K Sylvester, C Rocha, R Ditzinger, A Rasch, S Pöhlmann, T Kronenberger, A Poso, K Rox, <b>SA Laufer</b> , CE Müller, M Gütschow, T Pillaiyar ACS Pharmacology & Translational Science 7 (4), 1195-1196	2024	
645	<a href="#">Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in KRAS-mutant cancers</a> RA Jansen, S Mainardi, MH Dias, A Bosma, E van Dijk, R Selig, W Albrecht, <b>SA Laufer</b> , L Zender, R Bernards Proceedings of the National Academy of Sciences 121 (9), e2319492121	2024	
644	<a href="#">Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death</a> W Albrecht, <b>S Laufer</b> , R Selig, P Klövekorn, B Präfke US Patent 11,912,701	2024	

643	<a href="#">Linking ATP and allosteric sites to achieve superadditive binding with bivalent EGFR kinase inhibitors</a> F Wittlinger, BC Ogboo, E Shevchenko, T Damghani, CD Pham, IK Schaeffner, BT Oligny, SP Chitnis, TS Beyett, A Rasch, B Buckley, DA Urul, T Shaurova, EW May, EM Schaefer, MJ Eck, PA Hershberger, A Poso, <b>SA Laufer</b> , DE Heppner Communications Chemistry 7 (1), 38	2024	
642	<a href="#">Journal of Medicinal Chemistry Collection: Drug Discovery in Germany</a> <b>S Laufer</b> , M Gehringer, A Titz Journal of Medicinal Chemistry 67 (4), 2237-2237	2024	
641	<a href="#">Cathepsin-Targeting SARS-CoV-2 Inhibitors: Design, Synthesis, and Biological Activity</a> P Flury, J Breidenbach, N Krüger, R Voget, L Schäkel, Y Si, V Krasniqi, S Calistri, M Olfert, K Sylvester, C Rocha, R Ditzinger, A Rasch, S Pöhlmann, T Kronenberger, A Poso, K Rox, <b>SA Laufer</b> , CE Müller, M Gütschow, T Pillaiyar ACS Pharmacology & Translational Science 7 (2), 493-514	2024	
640	<a href="#">HDAC specificity and kinase off-targeting by purine-benzohydroxamate anti-hematological tumor agents</a> KB Waitman, LC de Almeida, MC Primi, JAEG Carlos, C Ruiz, T Kronenberger, <b>S Laufer</b> , MI Goettert, A Poso, SV Vassiliades, VAM de Souza, MFZJ Toledo, NMA Hassimotto, MD Cameron, TD Bannister, LV Costa-Lotuf, JA Machado-Neto, MT Tavares, R Parise-Filho European Journal of Medicinal Chemistry 263, 115935	2024	
639	<a href="#">Development of Highly Potent and Selective FGFR4 Inhibitors Based on SNAr Electrophiles</a> M Schwarz, M Kurkunov, F Wittlinger, R Rudalska, G Wang, MP Schwalm, A Rasch, B Wagner, <b>SA Laufer</b> , S Knapp, D Dauch, M Gehringer	2024	
638	<a href="#">Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death</a> B Praefke, P Klövekorn, R Selig, W Albrecht, <b>S Laufer</b> US Patent 11,858,927	2024	
637	<a href="#">Sensors for Antibiotics Susceptibility Testing—Recent Advances</a> O Riester, <b>S Laufer</b> , R Mertelsmann, HP Deigner Advanced Sensor Research, 2400046	2024	
636	<a href="#">ACKR3 agonism induces heterodimerization with chemokine receptor CXCR4 and attenuates platelet function</a> V Dicenta-Baunach, Z Laspa, D Schaale, M Sigle, A Bayrak, T Castor T Pillaiyar, <b>S Laufer</b> , MP Gawaz, AK Rohlfing bioRxiv, 2024.05. 10.593491	2024	

635	<a href="#">Toward more sustainable enzyme reactions: enhancing kinetics by polydimethylacrylamide implementation</a> S Rentschler, M Borgolte, R Csuk, <b>S Laufer</b> , HP Deigner Green Chemistry 26 (3), 1653-1659	2024	
634	<a href="#">Development of Ligands for the Super Conserved Orphan G Protein-Coupled Receptor GPR27 with Improved Efficacy and Potency</a> T Pillaiyar, M Wozniak, D Abboud, A Rasch, AD Liebing, A Poso, T Kronenberger, C Stäubert, <b>SA Laufer</b> , J Hanson Journal of Medicinal Chemistry; DOI: 10.1021/acs.jmedchem.3c02030	2023	
633	<a href="#">Ready-to-use nanopore platform for label-free small molecule quantification: Ethanolamine as first example</a> I Quint, J Simantzik, L Kaiser, <b>S Laufer</b> , D Smith, M Kohl, HP Deigner Nanomedicine: Nanotechnology, Biology and Medicine, 102724	2023	
632	<a href="#">HDAC specificity and kinase off-targeting by purine-benzohydroxamate anti-hematological tumor agents</a> KB Waitman, LC de Almeida, MC Primi, JAEG Carlos, C Ruiz, T Kronenberger, <b>S Laufer</b> , MI Goettert, A Poso, SV Vassiliades, VAM de Souza, MFZJ Toledo, NMA Hassimotto, MD Cameron, TD Bannister, LV Costa-Lotufu, JA Machado-Neto, MT Tavares, RParise-Filho European Journal of Medicinal Chemistry, DOI: 10.1016/j.ejmech.2023.115935	2023	
631	<a href="#">Cathepsin-Targeting SARS-CoV-2 Inhibitors: Design, Synthesis, and Biological Activity</a> P Flury, J Breidenbach, N Krüger, R Voget, L Schäkel, Y Si, V Krasniqi, S Calistri, M Olfert, K Sylvester, C Rocha, R Ditzinger, A Rasch, S Pöhlmann, T Kronenberger, A Poso, K Rox, <b>SA Laufer</b> , CE Müller, M Gütschow, T Pillaiyar ChemRxiv; DOI: 10.26434/chemrxiv-2023-ns203	2023	
630	<a href="#">Imidazo [4, 5-c] quinoline compounds and their use as atm kinase inhibitors</a> <b>S Laufer</b> , M Forster, T Dimitrov, L Zender, A Moschopoulou US Patent App. 18/141,656	2023	
629	<a href="#">The origin of potency and mutant-selective inhibition by bivalent ATP-allosteric EGFR inhibitors</a> F Wittlinger, SP Chitnis, CD Pham, T Damghani, IK Schaeffner, MQ Deng, BC Ogboo, A Rasch, TS Beyett, B Buckley, F Feru, T Shaurova, C Knappe, MJ Eck, PA Hershberger, DA Scott, <b>SA Laufer</b> , DE Heppner ChemRxiv; DOI: 10.26434/chemrxiv-2023-zzfc3	2023	
628	<a href="#">Inherent Fluorescence Demonstrates Immunotropic Properties for Novel Janus Kinase 3 Inhibitors</a>	2023	

	J Laux, M Martorelli, S Strass, D Schollmeyer, F Maier, M Burnet, <b>SA Laufer</b> ACS Pharmacology & Translational Science 2023, 6, 10, 1433-1452; doi.org/10.1021/acscptsci.3c00119		
627	<a href="#">Linking ATP and allosteric sites to achieve superadditive binding with bivalent EGFR kinase inhibitors</a> F Wittlinger, BC Ogboo, E Shevchenko, T Damghani, CD Pham, IK Schaeffner, BT Oligny, SP Chitnis, TS Beyett, A Rasch, B Buckley, DA Urul, T Shaurova, EW May, EM Schaefer, MJ Eck, PA Hershberger, A Poso, <b>SA Laufer</b> , DE Heppner ChemRxiv; DOI: 10.26434/chemrxiv-2023-cs3xn-v2	2023	
626	<a href="#">Pitfalls and considerations in determining the potency and mutant selectivity of covalent epidermal growth factor receptor inhibitors</a> KW Hoyt, DA Urul, BC Ogboo, F Wittlinger, <b>SA Laufer</b> , EM Schaefer, EW May, DE Heppner ChemRxiv; DOI: 10.26434/chemrxiv-2023-tkqqk	2023	
625	<a href="#">Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death</a> M Juchum, R Selig, <b>S Laufer</b> , W Albrecht <b>US Patent</b> 11,731,968	2023	
624	<a href="#">Isolation and Identification of Phytochemicals from Maytenus dhofarensis and Their Biological Potentials</a> F Al-Rubaii, ZZ Al-Shariqi, KS Al-Shabibi, J Husband, AM Al-Hattali, M Goettert, <b>S Laufer</b> , Y Baqi, SI Hassan, MO Fatope Molecules 28 (16), 6077	2023	
623	<a href="#">Imidazoquinolines with improved pharmacokinetic properties induce a high IFN<math>\alpha</math> to TNF<math>\alpha</math> ratio in vitro and in vivo</a> M Keppler, S Straß, S Geiger, T Fischer, N Späth, T Weinstein, A Schwamborn, J Guezguez, JH Guse, <b>S Laufer</b> , M Burnet Frontiers in Immunology 14, 1168252	2023	
622	<a href="#">Targeting SARS-CoV-2 Main Protease (MPro) with Kinase Inhibitors: A Promising Approach for Discovering Antiviral and Anti-inflammatory Molecules against SARS-CoV-2</a> DB Anton, J Galvez Bulhões Pedreira, ML Zvirtes, <b>SA Laufer</b> , RG Ducati, M Goettert, LF Saraiva Macedo Timmers Journal of Chemical Information and Modeling; doi.org/10.1021/acs.jcim.3c00324	2023	
621	<a href="#">Luteolin-7-O-Glucoside 对 6-OHDA 诱导的未分化和 RA 分化 SH-SY5Y 细胞损伤的神经保护作用</a> LF Hoffmann, A Martins, F Majolo, V Contini, <b>S Laufer</b> , MI Goettert 中国神经再生研究 (英文版) 18 (6), 1265	2023	

620	<a href="#">A patent review of MAPK inhibitors (2018–present)</a> VR Wydra, RB Ditzinger, NJ Seidler, FW Hacker, <b>SA Laufer</b> Expert Opinion on Therapeutic Patents 33 (6), 421-444	2023	
619	<a href="#">Immune cell targeted fumaric esters support a role of GPR109A as a primary target of monomethyl fumarate in vivo</a> S Straß, J Geiger, N Cloos, N Späth, S Geiger, A Schwamborn, L De Oliveira da Cunha, M Martorelli, JH Guse, T Lucas Sandri, M Burnet, <b>S Laufer</b> Inflammopharmacology 31 (3), 1223-1239	2023	
618	<a href="#">Neural regeneration research model to be explored: SH-SY5Y human neuroblastoma cells</a> LF Hoffmann, A Martins, F Majolo, V Contini, <b>S Laufer</b> , MI Goettert Neural Regeneration Research 18 (6), 1265-1266	2023	
617	<a href="#">Design and Optimization of Novel Benzimidazole- and Imidazo[4,5-b]pyridine-Based ATM Kinase Inhibitors with Subnanomolar Activities</a> T Dimitrov, AA Moschopoulou, L Seidel, T Kronenberger, M Kudolo, A Poso, C Geibel, P Wölffing, D Dauch, L Zender, D Schollmeyer, J Bajorath, M Forster, <b>S Laufer</b> Journal of Medicinal Chemistry; doi.org/10.1021/acs.jmedchem.2c02104	2023	
616	<a href="#">Selective Inhibitors of Janus Kinase 3 Modify Responses to Lipopolysaccharides by Increasing the Interleukin-10-to-Tumor Necrosis Factor <math>\alpha</math> Ratio</a> J Laux, M Martorelli, N Späth, F Maier, M Burnet, <b>SA Laufer</b> ACS Pharmacology & Translational Science; doi.org/10.1021/acsptsci.3c00043	2023	
615	<a href="#">The European Federation for Medicinal Chemistry and Chemical Biology (EFMC) Best Practice Initiative: Hit Generation</a> J Quancard, A Vulpetti, A Bach, B Cox, SM Guéret, IV Hartung, HF Koolman, <b>S Laufer</b> , J Messinger, G Sbardella, R Craft ChemMedChem 18 (9), e202300002	2023	
614	<a href="#">MKK4 Inhibitors—Recent Development Status and Therapeutic Potential</a> L Katzengruber, P Sander, <b>S Laufer</b> International Journal of Molecular Sciences 24 (8), 7495	2023	
613	<a href="#">COVID-19 therapeutics: small-molecule drug development targeting SARS-CoV-2 main protease</a> T Kronenberger, <b>SA Laufer</b> , T Pillaiyar Drug Discovery Today, 103579	2023	
612	<a href="#">Isostearic acid is an active component of imiquimod formulations used to induce psoriaform disease models</a>	2023	

	S Straß, J Geiger, M Martorelli, S Geiger, N Cloos, M Keppler, T Fischer, L Riexinger, A Schwamborn, J Guezguez, N Späth, S Cruces, JH Guse, T Lucas Sandri, M Burnet, <b>S Laufer</b> Inflammopharmacology 31 (2), 799-812		
611	<a href="#">3-benzoyl-1h-pyrrolo [2, 3-b] pyridine derivatives as mkk4 inhibitors for treating liver diseases</a> R Selig, S Laufer, W Albrecht US Patent App. 17/792,685	2023	
610	<a href="#">Structural elements that enable specificity for mutant EGFR kinase domains with next-generation small-molecule inhibitors.</a> T Damghani, F Wittlinger, TS Beyett, MJ Eck, <b>SA Laufer</b> , DE Heppner Methods Enzymology 2023:685:171-198. Doi: 10.1016/bs.mie.2023.03.013	2023	
609	<a href="#">Examining molecular factors of inactive versus active bivalent EGFR inhibitors: A missing link in fragment-based drug design.</a> F Wittlinger, BC Ogboo, CD Pham, IK Schaeffner, SP Chitnis, T Damghani, TS Beyett, A Rasch, B Buckley, DA Urul, T Shaurova, EW May, EM Schaefer, MJ Eck, PA Hershberger, SA Laufer, DE Heppner ChemRxiv 2023. DOI: 10.26434(chemrxiv-2023-cs3xn-v2	2023	
608	<a href="#">Discovery of Polyphenolic Natural Products as SARS-CoV-2 M<sup>pro</sup> Inhibitors for COVID-19</a> N Krüger, T Kronenberger, H Xie, C Rocha, S Pöhlmann, H Su, Y Xu, <b>SA Laufer</b> , T Pillaiyar Pharmaceuticals 16 (2), 190	2023	
607	<a href="#">Centrally active p38alpha inhibiting compounds</a> <b>S Laufer</b> , W Albrecht, P Koch, N Walter US Patent App. 17/638,751	2023	
606	<a href="#">Ready-to-use nanopore platform for ethanolamine quantification using an aptamer-based strand displacement assay.</a> I Quint, J Simantzik, L Kaiser, <b>S Laufer</b> , R Csuk, D Smith, M Kohl, HP Deigner bioRxiv, 2023.02. 27.530168	2023	
605	<a href="#">Pharmacy Archives</a> A Link, <b>S Laufer</b> , W Diederich, C Veale, A Artese, K Augustyns, ... ARCHIV DER PHARMAZIE 356 (1)	2023	
604	<a href="#">Anticancer Drug Conjugates Incorporating Estrogen Receptor Ligands</a> DP Zlotos, T Kronenberger, <b>SA Laufer</b> Pharmaceutics 15 (1), 67	2023	

603	<a href="#">Antiulcerogenic Potential of the Ethanolic Extract of <i>Ceiba speciosa</i> (A. St.-Hil.) Ravenna Evaluated by In Vitro and In Vivo Studies</a> JA Dörr, F Majolo, L Bortoluzzi, EZ de Vargas, J Silva, M Pasini, SN Stoll, R Lopes da Rosa, M Moreira Figueira, M Fronza, WO Beys-da-Silva, A Martins, H Gaspar, RP Pedrosa, <b>S Laufer</b> , MI Goettert International Journal of Molecular Sciences 23 (24), 15634	2022	
602	<a href="#">Direct 3D printed biocompatible microfluidics: assessment of human mesenchymal stem cell differentiation and cytotoxic drug screening in a dynamic culture system</a> O Riester, <b>S Laufer</b> , HP Deigner Journal of Nanobiotechnology 20 (1), 1-18	2022	
601	<a href="#">Synthesis of a biocompatible benzophenone-substituted chitosan hydrogel as novel coating for PEEK with extraordinary strong antibacterial and anti-biofilm properties</a> M Borgolte, O Riester, I Quint, F Blending, V Bucher, <b>S Laufer</b> , R Csuk, L Scotti, H-P Deigner Materials Today Chemistry 26, 101176	2022	
600	<a href="#">Structural Basis for Inhibition of Mutant EGFR with Lazertinib (YH25448)</a> DE Heppner, F Wittlinger, TS Beyett, T Shaurova, DA Urul, B Buckley, CD Pham, IK Schaeffner, B Yang, BC Ogboo, EW May, EM Schaefer, MJ Eck, <b>SA Laufer</b> , PA Hershberger ACS Medicinal Chemistry Letters 13 (12), 1856-1863	2022	
599	<a href="#">Novel Approach to Pharmaceutical 3D-Printing Omitting the Need for Filament—Investigation of Materials, Process, and Product Characteristics</a> T Pflieger, R Venkatesh, M Dachtler, K Eggenreich, <b>S Laufer</b> , D Lunter Pharmaceutics 14 (11), 2488	2022	
598	<a href="#">Heteroaryl-substituted pyrazolo-pyridine protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death</a> B Pfaffenrot, R Selig, <b>S Laufer</b> , W Albrecht US Patent App. 17/630,105	2022	
597	<a href="#">Synergy of R-(–) carvone and cyclohexenone-based carbasugar precursors with antibiotics to enhance antibiotic potency and inhibit biofilm formation</a> O Riester, P Burkhardtmaier, Y Gurung, <b>S Laufer</b> , HP Deigner, MS Schmidt Scientific Reports 12 (1), 18019	2022	
596	<a href="#">Influence of diet and MOG35-55 peptide preparation on severity, survival, incidence and body weight in murine experimental autoimmune encephalomyelitis</a>	2022	

	M Martorelli, J Laux, M Dengler, T Fischer, D Canjuga, A Vaiceliunaite, F Maier, M Burnet, <b>S Laufer</b> MULTIPLE SCLEROSIS JOURNAL 28 (3_ SUPPL), 221-221		
595	<a href="#">Discovery and Development of First-in-Class ACKR3/CXCR7 Superagonists for Platelet Degranulation Modulation</a> A Bayrak, F Mohr, K Kolb, M Szpakowska, E Shevchenko, V Dicenta, A-K Rohlfing, M Kudolo, T Pantsar, M Günther, AA Kaczor, A Poso, A Chevigné, T Pillaiyar, M Gawaz, <b>SA Laufer</b> Journal of Medicinal Chemistry 65 (19), 13365-13384	2022	
594	<a href="#">Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death</a> W Albrecht, S Laufer, R Selig, P Klövekorn, B Präfke US Patent App. 17/260,519	2022	
593	<a href="#">Pivotal blinded randomized trial of a novel pro-regenerative drug in post-resection liver failure</a> A Abu Rmilah, K Li, E Larson, S Ellias, S Klotz, B Pfaffenroth, P Kloevekorn, R Selig, W Zhou, E Nelson, A Poso, H Chen, B Amiot, A Minshew, G Michalak, W Cui, W Albrecht, B Jung, O Trompak, S Zwirner, M Lutz, T Wuestefeld, <b>S Laufer</b> , L Zender, S Nyberg Transplantation 106 (8 S), 19-20	2022	
592	<a href="#">Scaffold modified Vemurafenib analogues as highly selective mitogen activated protein kinase kinase 4 (MKK4) inhibitors</a> M Juchum, B Pfaffenrot, P Klövekorn, R Selig, W Albrecht, L Zender, <b>SA Laufer</b> European Journal of Medicinal Chemistry 240, 114584	2022	
591	<a href="#">Pharmacokinetic Optimization of Small Molecule Janus Kinase 3 Inhibitors to Target Immune Cells</a> J Laux, M Forster, L Riexinger, A Schwamborn, J Guezguez, C Pokoj, M Kudolo, LM Berger, S Knapp, D Schollmeyer, J Guse, M Burnet, <b>SA Laufer</b> ACS Pharmacology & Translational Science	2022	
590	<a href="#">Novel avenue towards liver regeneration and treatment of acute and chronic liver diseases: safety and PK profile from a first-in human (FIH) clinical trial for HRX-0215 as first in class MKK4 inhibitor</a> B Jung, M Weissbach, M Lutz, R Selig, <b>S Laufer</b> , L Zender, M Feigh, M Berse, J Penski, E Kosmella, W Albrecht Journal of Hepatology 77, S737-S738	2022	
589	<a href="#">Small-Molecule Thioesters as SARS-CoV-2 Main Protease Inhibitors: Enzyme Inhibition, Structure–Activity Relationships, Antiviral Activity, and X-ray Structure Determination</a> T Pillaiyar, P Flury, N Krüger, H Su, L Schäkel, E Barbosa Da Silva, O Eppler, T Kronenberger, T Nie, S Luedtke, C Rocha, K Sylvester, MRI Petry, JH McKerrow, A Poso, S Pöhlmann, M Gütschow, AJ O’Donoghue,	2022	

	Y Xu, CE Müller, <b>SA Laufer</b> Journal of Medicinal Chemistry 65 (13), 9376-9395		
588	<a href="#">Super-conserved receptors expressed in the brain: biology and medicinal chemistry efforts</a> A Bayrak, J Hanson, <b>S Laufer</b> , T Pillaiyar Future Medicinal Chemistry 14 (12), 899-913	2022	
587	<a href="#">Publication Criteria and Requirements for Studies on Protein Kinase Inhibitors— What Is Expected? (“It is pretty easy to make a bad kinase inhibitor”)</a> <b>S Laufer</b> , J Bajorath, M Gehringer, N Gray, S Frye, CW Lindsley Journal of Medicinal Chemistry 65 (10), 6973 - 6974	2022	
586	<a href="#">Development of novel urea-based ATM kinase inhibitors with subnanomolar cellular potency and high kinome selectivity</a> T Dimitrov, C Anli, AA Moschopoulou, T Kronenberger, M Kudolo, C Geibel, MP Schwalm, L Zender, M Forster, <b>S Laufer</b> European Journal of Medicinal Chemistry 235, 114234	2022	
585	<a href="#">2, 2, 2-Trifluoroethanol-mediated hydroarylation of fluorinated alkynes with indoles: Application to diindolylmethanes</a> P Flury, O Eppler, D Schollmeyer, <b>S Laufer</b> , T Pillaiyar Archiv der Pharmazie, e2100488	2022	
584	<a href="#">Target Hopping from Protein Kinases to PXR: Identification of Small-Molecule Protein Kinase Inhibitors as Selective Modulators of Pregnane X Receptor from TüKIC Library</a> EK Mustonen, T Pansar, A Rashidian, J Reiner, M Schwab, <b>S Laufer</b> , O Burk Cells 11 (8), 1299	2022	
583	<a href="#">ACKR3 regulates platelet activation and ischemia-reperfusion tissue injury</a> AK Rohlfing, K Kolb, M Sigle, M Ziegler, A Bild, P Münzer, J Sudmann, V Dicenta, T Harm, MC Manke, S Geue, M Kremser, M Chatterjee, C Liang, H von Eysmond, T Dandekar, D Heinzmann, M Günter, S von Ungern-Sternberg, M Büttcher, T Castor, S Mencl, F Langhauser, K Sies, D Ashour, MC Beker, M Lämmerhofer, SE Autenrieth, TE Schäffer, <b>S Laufer</b> , P Szklanna, P Maguire, M Heikenwalder, KAL Müller, DM Hermann, E Kilic, R Stumm, G Ramos, C Kleinschnitz, O Borste, HF Langer, D Rath, M Gawaz Nature Communications 13 (1), 1-20	2022	
582	<a href="#">In vitro and in vivo anti-inflammatory and anticoagulant activities of Myrciaria plinioides D. Legrand ethanol leaf extract</a> DJ Marmitt, S Bitencourt, CO Coura, M Berger, D Faleiro, DM Kich, B Caye, SM Immich, A Fernandes Frota, WO Beys-da-Silva, J Almeida Guimaraes, NM Barros Benevides, <b>S Laufer</b> , MI Goettert Inflammopharmacology 30 (2), 565-577	2022	

581	<a href="#">Gefitinib-Tamoxifen Hybrid Ligands as Potent Agents against Triple-Negative Breast Cancer</a> CM Abdelmalek, Z Hu, T Kronenberger, J Küblbeck, FJM Kinnen, SS Hesse, A Malik, M Kudolo, R Niess, M Gehringer, L Zender, PA Witt-Enderby, DP Zlotos, <b>SA Laufer</b> Journal of Medicinal Chemistry 65 (6), 4616-4632	2022	
580	<a href="#">Neuroprotective Effect of Luteolin-7-O-Glucoside against 6-OHDA-Induced Damage in Undifferentiated and RA-Differentiated SH-SY5Y Cells</a> SCH Rehfeldt, J Silva, C Alves, S Pinteus, R Pedrosa, <b>S Laufer</b> , MI Goettert International Journal of Molecular Sciences 23 (6), 2914	2022	
579	<a href="#">Development of the first covalent monopolar spindle kinase 1 (MPS1/TTK) Inhibitor</a> RA M. Serafim, A da Silva Santiago, MP Schwalm, Z Hu, CV Dos Reis, JE Takarada, P Mezzomo, KB Massirer, M Kudolo, S Gerstenecker, A Chaikuad, L Zender, S Knapp, <b>S Laufer</b> , RM Counago, M Gehringer Journal of Medicinal Chemistry 65 (4), 3173-3192	2022	
578	<a href="#">Decisive role of water and protein dynamics in residence time of p38<math>\alpha</math> MAP kinase inhibitors</a> T Pantsar, PD Kaiser, M Kudolo, M Forster, U Rothbauer, <b>SA Laufer</b> Nature Communications 13 (1), 1-14	2022	
577	<a href="#">The functional role of p38 MAPK pathway in malignant brain tumors</a> N Grave, TB Scheffel, FF Cruz, L Rockenbach, MI Goettert, S Laufer, ... Frontiers in Pharmacology 13	2022	
576	<a href="#">Discrepancy in interactions and conformational dynamics of pregnane X receptor (PXR) bound to an agonist and a novel competitive antagonist</a> A Rashidian, EK Mustonen, T Kronenberger, M Schwab, O Burk, <b>SA Laufer</b> , T Pantsar Computational and Structural Biotechnology Journal 20, 3004-3018	2022	
575	<a href="#">New Horizons in Drug Discovery-Understanding and Advancing Different Types of Kinase Inhibitors: Seven Years in Kinase Inhibitor Research with Impressive Achievements and New Future Prospects</a> <b>S Laufer</b> , J Bajorath Journal of Medicinal Chemistry 65 (2), 891-892	2021	
574	<a href="#">High-Throughput Screening Platform in Postnatal Heart Cells and Chemical Probe Toolbox to Assess Cardiomyocyte Proliferation</a> C Carrillo García, C Becker, M Forster, S Lohmann, P Freitag, <b>S Laufer</b> , S Sievers, BK Fleischmann, M Hesse, D Schade	2021	

	Journal of Medicinal Chemistry 65 (2), 1505-1524		
573	<a href="#">Design of a “two-in-one” mutant-selective epidermal growth factor receptor inhibitor that spans the orthosteric and allosteric sites</a> F Wittlinger, DE Heppner, C To, M Günther, BH Shin, JK Rana, AM Schmoker, TS Beyett, LM Berger, BT Berger, N Bauer, JD Vasta, CR Corona, MB Robers, S Knapp, PA Janne, MJ Eck, <b>SA Laufer</b> Journal of Medicinal Chemistry 65 (2), 1370-1383	2021	
572	<a href="#">Biosynthesis of iron oxide magnetic nanoparticles using clinically isolated Pseudomonas aeruginosa</a> AA Khan, S Khan, S Khan, S Rentschler, <b>S Laufer</b> , HP Deigner Scientific Reports 11 (1), 1-10	2021	
571	<a href="#">Dataset (X) related to publication: Decisive Role of Water and Protein Dynamics in Residence Time of p38a MAP Kinase Inhibitors</a> T Pantsar, <b>S Laufer</b>	2021	
570	<a href="#">Discovery of a Potent and Highly Isoform-Selective Inhibitor of the Neglected Ribosomal Protein S6 Kinase Beta 2 (S6K2)</a> S Gerstenecker, L Haarer, M Schröder, M Kudolo, MP Schwalm, V Wydra, RAM Serafim, A Chaikuad, S Knapp, <b>S Laufer</b> , M Gehringer Cancers 13 (20), 5133	2021	
569	<a href="#">Methacryloyl-GlcNAc Derivatives Copolymerized with Dimethacrylamide as a Novel Antibacterial and Biocompatible Coating</a> M Borgolte, O Riester, T Kacerova, S Rentschler, MS Schmidt, S Jacksch, M Egert, <b>S Laufer</b> , R Csuk, HP Deigner Pharmaceutics 13 (10), 1647	2021	
568	<a href="#">The pre-clinical discovery and development of osimertinib used to treat non-small cell lung cancer</a> F Wittlinger, <b>SA Laufer</b> Expert Opinion on Drug Discovery 16 (10), 1091-1103	2021	
567	<a href="#">1st IN CLASS SMALL MOLECULE INHIBITORS OF MKK4 EXERT PRONOUNCED THERAPEUTIC EFFICACY IN RODENT AND NON-RODENT MODELS OF ACUTE AND CHRONIC LIVER FAILURE</a> S Klotz, A Abu Rmilah, B Pfaffenrot, P Kloevokorn, R Selig, K Li, W Zhou, E Nelson, A Poso, H Chen, B Amiot, Y Jia, A Minshew, G Michalak, W Cui, W Albrecht, J Birgit, O Trompak, S Zwirner, M Lutz, T Wuestefeld, <b>S Laufer</b> , SL Nyberg, L Zender HEPATOLOGY 74, 157A-157A	2021	
566	<a href="#">Neuropsychiatric Disorders and COVID-19: What We Know So Far</a> F Majolo, GL Silva, L Vieira, C Anli, LFSM Timmers, <b>S Laufer</b> , MI Goettert Pharmaceutics 14 (9), 933	2021	

565	<a href="#">Development of a Selective Dual Discoidin Domain Receptor (DDR)/p38 Kinase Chemical Probe</a> S Röhm, BT Berger, M Schröder, D Chatterjee, S Mathea, AC Joerger, DM Pinkas, JC Bufton, A Tjaden, L Kovooru, M Kudolo, C Pohl, AN Bullock, S Müller, <b>S Laufer</b> , S Knapp Journal of Medicinal Chemistry 64 (18), 13451-13474	2021	
564	<a href="#">Controlling the covalent reactivity of a kinase inhibitor with light</a> M Reynders, A Chaikuad, BT Berger, K Bauer, P Koch, <b>S Laufer</b> , S Knapp, .D Trauner Angewandte Chemie International Edition 60 (37), 20178-20183	2021	
563	<a href="#">Chemical Probes for Understudied Kinases: Challenges and Opportunities</a> RAM Serafim, JM Elkins, WJ Zuercher, <b>SA Laufer</b> , M Gehringer Journal of Medicinal Chemistry 65 (2), 1132-1170	2021	
562	<a href="#">Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death</a> M Juchum, R Selig, S Laufer, W Albrecht US Patent App. 17/254,071	2021	
561	<a href="#">Improved Multigram Route to a Tricyclic Key Intermediate for Dibenzosuberone-Based p38 Inhibitors via an Optimized Early-Stage Heck Coupling</a> M Forster, HK Wentsch-Teltschik, <b>SA Laufer</b> Organic Process Research & Development 25 (8), 1831-1840	2021	
560	<a href="#">Synthesis, Characterization, and in vivo Distribution of Intracellular Delivered Macrolide Short-Chain Fatty Acid Derivatives</a> S Straß, A Schwamborn, M Keppler, N Cloos, J Guezguez, JH Guse, M Burnet, <b>S Laufer</b> ChemMedChem 16 (14), 2254-2269	2021	
559	<a href="#">Design, Synthesis and Biological Evaluation of Novel Pyrazolo [1, 2, 4] triazolopyrimidine Derivatives as Potential Anticancer Agents</a> S Aliwaini, B Abu Thaher, I Al-Masri, N Shurrab, S El-Kurdi, D Schollmeyer, B Qeshta, M Ghunaim, R Csuk, S Laufer, L Kaiser, HP Deigner Molecules 26 (13), 4065	2021	
558	<a href="#">Addressing a Trapped High-Energy Water: Design and Synthesis of Highly Potent Pyrimidoindole-Based Glycogen Synthase Kinase-3<math>\beta</math> Inhibitors</a> S Andreev, T Pantsar, R Tesch, N Kahlke, A El-Gokha, F Ansideri, L Grätz, J Romaco, G Sita, C Geibel, M Lämmerhofer, A Tarozzi, S Knapp, <b>SA Laufer</b> , P Koch Journal of Medicinal Chemistry 65 (2), 1283-1301	2021	
557	<a href="#">Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death</a>	2021	

	W Albrecht, <b>S Laufer</b> , R Selig, P Klövekorn, B Präfke US Patent 11,040,027		
556	<a href="#">Simplifying Submission Requirements for the <i>Journal of Medicinal Chemistry</i></a> CW Lindsley, J Barrow, K Chibale, ML Bolognesi, S Conway, W Denny, K Ding, <b>S Laufer</b> , L Lai, H Liu, N Neamati, T Suzuki, N Meanwell, W Young Journal of Medicinal Chemistry 64 (12), 7877-7878	2021	
555	<a href="#">SARS-CoV-2 mutations in Brazil: from genomics to putative clinical conditions</a> LFSM Timmers, JV Peixoto, RG Ducati, JFR Bachega, L de Mattos Pereira, RA Caceres, F Majolo, G Liberato da Silva, D Bublitz Anton, OA Dallagostin, JA Pegas Henriques, LL Xavier, MI Goettert, <b>S Laufer</b> Scientific Reports 11 (1), 1-14	2021	
554	<a href="#">The European Federation for Medicinal Chemistry and Chemical Biology (EFMC) Best Practice Initiative: Phenotypic Drug Discovery</a> J Quancard, A Bach, B Cox, R Craft, D Finsinger, SM Guéret, IV Hartung, <b>S Laufer</b> , J Messinger, G Sbardella, HF Koolman ChemMedChem 16 (11), 1737-1740	2021	
553	<a href="#">Design and synthesis of 1H-pyrazolo [3, 4-b] pyridines targeting mitogen-activated protein kinase kinase 4 (MKK4)-A promising target for liver regeneration</a> B Pfaffenrot, P Klövekorn, M Juchum, R Selig, W Albrecht, L Zender, <b>SA Laufer</b> European Journal of Medicinal Chemistry 218, 113371	2021	
552	<a href="#">Kinases as potential therapeutic targets for anti-coronaviral therapy</a> T Pillaiyar, <b>S Laufer</b> Journal of Medicinal Chemistry 65 (2), 955-982	2021	
551	<a href="#">Current jakinibs for the treatment of rheumatoid arthritis: a systematic review</a> CM Rocha, AM Alves, BF Bettanin, F Majolo, M Gehringer, <b>S Laufer</b> , MI Goettert Inflammopharmacology 29 (3), 595-615	2021	
550	<a href="#">Design and Synthesis of Highly Selective Brain Penetrant p38<math>\alpha</math> Mitogen-Activated Protein Kinase Inhibitors</a> NM Tormählen, M Martorelli, A Kuhn, F Maier, J Guezguez, M Burnet, W Albrecht, <b>SA Laufer</b> , P Koch Journal of Medicinal Chemistry 65 (2), 1225-1242	2021	
549	<a href="#">Combining aptamers and antibodies: Lateral flow quantification for thrombin and interleukin-6 with smartphone readout</a> M Mahmoud, C Ruppert, S Rentschler, <b>S Laufer</b> , HP Digner Sensors and Actuators B: Chemical 333, 129246	2021	

548	<a href="#">A highly selective in vitro jnk3 inhibitor, fmu200, restores mitochondrial membrane potential and reduces oxidative stress and apoptosis in sh-sy5y cells</a> SCH Rehfeldt, <b>S Laufer</b> , MI Goettert International Journal of Molecular Sciences 22 (7), 3701	2021	
547	<a href="#">A special view of what was almost forgotten: p38<math>\delta</math> MAPK</a> DB Anton, RG Ducati, LFSM Timmers, S Laufer, MI Goettert Cancers 13 (9), 2077	2021	
546	<a href="#">Synthesis, characterization and in vivo distribution of intracellular delivered macrolide SCFA derivatives.</a> M Burnet, S Strass, A Schwamborn, M Keppler, J Guezguez, JH Guse, <b>S Laufer</b> , N Cloos ChemMedChem 16 (14), 2254-2269	2021	
545	<a href="#">Proteinkinase Inhibitors</a> <b>S Laufer</b> (Editor) Topics in Medicinal Chemistry, Springer ISBN 978-3-030-68179-1	2021	
544	<a href="#">Protein kinase mkk4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death</a> B Praefke, P Klövekorn, R Selig, W Albrecht, <b>S Laufer</b> US Patent App. 16/965,912	2021	
543	<a href="#">Identification of novel pregnane X receptor antagonists in the Tübingen kinase inhibitor collection (TuKIC) compound library</a> EK Mustonen, T Pantsar, A Rashidian, <b>S Laufer</b> , M Schwab, O Burk NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY 394 (SUPPL 1), S43-S43	2021	
542	<a href="#">SARS-CoV-2 mutations in Brazil: from genomics to clinical conditions</a> L Timmers, J Peixoto, R Ducati, JF Bachega, LM Pereira, RA Caceres, F Majolo, G Liberato Da Silva, D Bublitz Anton, MI Goettert, OA Dellagostin, J Henriques, L Xavier, <b>S Laufer</b> Scientific Reports 11	2021	
541	<a href="#">Review of trials currently testing stem cells for treatment of respiratory diseases: Facts known to date and possible applications to COVID-19</a> F Majolo, GL da Silva, L Vieira, LFSM Timmers, <b>S Laufer</b> , MI Goettert Stem Cell Reviews and Reports 17 (1), 44-55	2021	
540	<a href="#">LXR<math>\alpha</math> activation and Raf inhibition trigger lethal lipotoxicity in liver cancer</a> R Rudalska, J Harbig, MT Snaebjornsson, S Klotz, S Zwirner, L Taranets, F Heinzmann, T Kronenberger, M Forster, W Cui, L	2021	

	D'Artista, E Einig, M Hinterleitner, W Schmitz, A Dylawerska, TW Kang, A Poso, MT Rosenfeldt, NP Malek, M Bitzer, <b>S Laufer</b> , BJ Pichler, N Popov, A Schulze, L Zender, D Dauch Nature Cancer 2 (2), 201-217		
539	<a href="#">N-(6-Chloro-3-nitropyridin-2-yl)-5-(1-methyl-1H-pyrazol-4-yl)isoquinolin-3-amine</a> V Wydra, S Gerstenecker, D Schollmeyer, S Andreev, T Dimitrov, RAM Serafim, <b>S Laufer</b> , M Gehringer Molbank 2021 (1), M1181	2021	
538	<a href="#">From off-to on-target: New BRAF-inhibitor-template-derived compounds selectively targeting mitogen activated protein kinase kinase 4 (MKK4)</a> P Kloevekor, B Pfaffenrot, M Juchum, R Selig, W Albrecht, L Zender, <b>SA Laufer</b> European Journal of Medicinal Chemistry 210, 112963	2021	
537	<a href="#">Design and synthesis of novel fluorescently labeled analogs of vemurafenib targeting MKK4</a> T Kircher, T Pantsar, A Oder, JP von Kries, M Juchum, B Pfaffenrot, P Kloevekor, W Albrecht, R Selig, <b>S Laufer</b> European Journal of Medicinal Chemistry 209, 112901	2021	
536	<a href="#">Molecular Design of a "Two-in-One" Orthosteric-Allosteric Chimeric Mutant Selective EGFR Inhibitor</a> F Wittlinger, DE Heppner, C To, M Guenther, BH Shin, JK Rana, AM Schmoker, TS Beyett, PA Jänne, MJ Eck, <b>S Laufer</b> Journal of Medicinal Chemistry 65 (2), 1370-1383	2021	
535	<a href="#">c-Jun N-terminal kinase inhibitors as potential leads for new therapeutics for Alzheimer's diseases</a> SC Hepp Rehfeldt, F Majolo, MI Goettert, <b>S Laufer</b> International Journal of Molecular Sciences 21 (24), 9677	2020	
534	<a href="#">The European Federation for Medicinal Chemistry (EFMC) Best Practice Initiative: Validating Chemical Probes</a> J Quancard, B Cox, D Finsinger, SM Guéret, IV Hartung, HF Koolman, J Messinger, G Sbardella, <b>S Laufer</b> ChemMedChem 15 (24), 2388-2390	2020	
533	<a href="#">Selective targeting of the <math>\alpha</math>C and DFG-out pocket in p38 MAPK</a> S Roehm, M Schröder, JE Dwyer, CS Widdowson, A Chaikuad, BT Berger, AC Joerger, A Krämer, J Harbig, D Dauch, M Kudolo, <b>S Laufer</b> , MC Bagley, S Knapp European Journal of Medicinal Chemistry 208, 112721	2020	
532	<a href="#">Discovery of a novel class of covalent dual inhibitors targeting the protein kinases BMX and BTK</a> M Forster, XJ Liang, M Schröder, S Gerstenecker, A Chaikuad, S Knapp, <b>S Laufer</b> , M Gehringer	2020	

	International Journal of Molecular Sciences 21 (23), 9269		
531	<a href="#">Duplex Shiny app quantification of the sepsis biomarkers C-reactive protein and interleukin-6 in a fast quantum dot labeled lateral flow assay</a> C Ruppert, L Kaiser, LJ Jacob, <b>S Laufer</b> , M Kohl, HP Deigner Journal of Nanobiotechnology 18 (1), 1-11	2020	
530	<a href="#">Chemical Space Exploration of Oxetanes</a> FRS Alves, RM Couñago, <b>S Laufer</b> International Journal of Molecular Sciences 21 (21), 8199	2020	
529	<a href="#">Discovery and Evaluation of Enantiopure 9H-pyrimido[4,5-b]indoles as Nanomolar GSK-3<math>\beta</math> Inhibitors with Improved Metabolic Stability</a> S Andreev, T Pantsar, A El-Gokha, F Ansideri, M Kudolo, DB Anton, G Sita, J Romasco, C Geibel, M Lämmerhofer, MI Goettert, A Tarozzi, <b>SA Laufer</b> , P Koch International Journal of Molecular Sciences 21 (21), 7823	2020	
528	<a href="#">Identifying representative kinases for inhibitor evaluation via systematic analysis of compound-based target relationships</a> O Laufkötter, <b>S Laufer</b> , J Bajorath European Journal of Medicinal Chemistry 204, 112641	2020	
527	<a href="#">Kinase inhibitor data set for systematic analysis of representative kinases across the human kinome</a> O Laufkötter, <b>S Laufer</b> , J Bajorath Data in Brief 32, 106189	2020	
526	<a href="#">New Horizons in Drug Discovery-Understanding and Advancing Kinase Inhibitors: Special Issue and Call for Papers</a> <b>S Laufer</b> , K Briner, J Bajorath, GI Georg, S Wang Journal of Medicinal Chemistry 63 (15), 7921-7922	2020	
525	<a href="#">Candidate drugs against SARS-CoV-2 and COVID-19</a> DL McKee, A Sternberg, U Stange, <b>S Laufer</b> , C Naujokat Pharmacological Research 157, 104859	2020	
524	<a href="#">An updated patent review of p38 MAP kinase inhibitors (2014-2019)</a> V Haller, P Nahidino, M Forster, <b>SA Laufer</b> Expert Opinion on Therapeutic Patents 30 (6), 453-466	2020	
523	<a href="#">Neuroprotective potential of Myrciaria plinioides D. Legrand extract in an in vitro human neuroblastoma model</a> DJ Marmitt, C Alves, J Silva, S Pinteus, T Schneider, RCV Santos, EM de Freitas, R Pedrosa, <b>S Laufer</b> , MI Goettert Inflammopharmacology 28 (3), 737-748	2020	
522	<a href="#">Dapsone is not a pharmacodynamic lead compound for its aryl derivatives</a> T Scior, HH Abdallah, K Salvador-Atonal, <b>S Laufer</b>	2020	

	Current Computer-aided Drug Design 16 (3), 327-339		
521	<a href="#">Bioisosteric Replacement of Arylamide-Linked Spine Residues with N-Acylhydrazones and Selenophenes as a Design Strategy to Novel Dibenzosuberone Derivatives as Type I ½ p38α MAP Kinase Inhibitors</a> JGB Pedreira, P Nahidino, M Kudolo, T Pantsar, BT Berger, M Forster, S Knapp, <b>S Laufer</b> , EJ Barreiro Journal of Medicinal Chemistry 63 (13), 7347-7354	2020	
520	<a href="#">Antimicrobial and antileukemic effects: in vitro activity of Calyptanthes grandifolia aqueous leaf extract</a> F Majolo, S Bitencourt, B Wissmann Monteiro, G Viegas Haute, C Alves, J Silva, S Pinteus, RC Vianna Santos, HF Vieira Torquato, EJ Paredes-Gamero, JR Oliveira, CF Volken De Souza, RF Pinto Pedrosa, <b>S Laufer</b> , MI Goettert Journal of Toxicology and Environmental Health, Part A 83 (8), 289-301	2020	
519	<a href="#">Structural basis for EGFR mutant inhibition by trisubstituted imidazole inhibitors</a> DE Heppner, M Günther, F Wittlinger, <b>SA Laufer</b> , MJ Eck Journal of Medicinal Chemistry 63 (8), 4293-4305	2020	
518	<a href="#">The Investigation of Lipoxygenases as Therapeutic Targets in Malignant Pleural Mesothelioma</a> L Oguh-Olayinka, V Agarwal, D Ranatunge, A Campbell, <b>S Laufer</b> , L Cawkwell, MJ Lind Pathology & Oncology Research 26 (2), 985-995	2020	
517	<a href="#">Mapping the S1 and S1' subsites of cysteine proteases with new dipeptidyl nitrile inhibitors as trypanocidal agents</a> L Cianni, C Lemke, E Gilberg, C Feldmann, F Rosini, FR Rocho, JFR Ribeiro, DY Tezuka, CD Lopes, S de Albuquerque, J Bajorath, <b>S Laufer</b> , A Leitao, M Gütschow, CA Montanari PLoS Neglected Tropical Diseases 14 (3), e0007755	2020	
516	<a href="#">Promiscuity analysis of a kinase panel screen with designated p38 alpha inhibitors</a> M González-Medina, F Miljković, GS Haase, P Drueckes, J Trappe, <b>S Laufer</b> , J Bajorath European Journal of Medicinal Chemistry 187, 112004	2020	
515	<a href="#">P139 EFFECT OF LYSOSOMAL SHORT CHAIN FATTY ACID DELIVERY ON IMMUNE RESPONSE</a> S Strass, C Heinzl, N Cloos, M Keppler, J Guse, M Burnet, <b>S Laufer</b> Inflammatory Bowel Diseases 26 (Supplement_1), S12-S12	2020	
514	<a href="#">P139 EFFECT OF LYSOSOMAL SHORT CHAIN FATTY ACID DELIVERY ON IMMUNE RESPONSE</a>	2020	

	S Strass, C Heinzl, N Cloos, M Keppler, J Guse, M Burnet, <b>S Laufer</b> Gastroenterology 158 (3), S20		
513	<a href="#">Sorafenib activity and disposition in liver cancer does not depend on organic cation transporter 1</a> M Chen, C Neul, E Schaeffeler, F Frisch, S Winter, M Schwab, H Koepsell, S Hu, <b>S Laufer</b> , SD Baker, A Sparreboom, AT Nies Clinical Pharmacology & Therapeutics 107 (1), 227-237	2020	
512	<a href="#">In vitro activities of <i>Ceiba speciosa</i> (A.St.-Hil) Ravenna aqueous stem bark extract</a> JA Dörr, S Bitencourt, L Bortoluzzi, C Alves, J Silva, S Stoll, S Pinteus, AA Boligon, RC Vianna Santos, <b>S Laufer</b> , R Pedrosa, MI Goettert Natural Product Research 33 (23), 3441-3444	2019	
511	<a href="#">Evaluation of the therapeutic potential of the selective p38 MAPK inhibitor Skepinone-L and the dual p38/JNK 3 inhibitor LN 950 in experimental K/BxN serum transfer arthritis</a> P Guenthoer, K Fuchs, G Reischl, L Quintanilla-Martinez, I Gonzalez-Menendez, <b>S Laufer</b> , BJ Pichler, M Kneiling Inflammopharmacology 27 (6), 1217-1227	2019	
510	<a href="#">Discovery of potent p38<math>\alpha</math> MAPK inhibitors through a funnel like workflow combining in silico screening and in vitro validation</a> A Astolfi, M Kudolo, J Brea, G Manni, G Manfroni, D Palazzotti, S Sabatini, F Ceccetti, T Felicetti, R Cannalire, S Massari, O Tabarrini, MI Loza, F Fallarino, V Ceccetti, <b>SA Laufer</b> , ML Barreca European Journal of Medicinal Chemistry 182, 111624	2019	
509	<a href="#">Fast iterative synthetic approach toward identification of novel highly selective p38 MAP kinase inhibitors</a> S Röhm, BT Berger, M Schröder, A Chaikuad, R Winkel, KFW Hekking, JJC Benningshof, G Müller, R Tesch, M Kudolo, M Forster, <b>S Laufer</b> , S Knapp Journal of Medicinal Chemistry 62 (23), 10757-10782	2019	
508	<a href="#">Visual aptamer-based capillary assay for ethanolamine using magnetic particles and strand displacement</a> M Mahmoud, <b>S Laufer</b> , HP Deigner Microchimica Acta 186 (11), 1-8	2019	
507	<a href="#">Pyridinylimidazoles as GSK3<math>\beta</math> inhibitors: the impact of tautomerism on compound activity via water networks</a> F Heider, T Pantsar, M Kudolo, F Ansideri, A De Simone, L Pruccoli, T Schneider, MI Goettert, A Tarozzi, V Andrisano, <b>SA Laufer</b> , P Koch ACS Medicinal Chemistry Letters 10 (10), 1407-1414	2019	

506	<p><a href="#">Targeting the r-spine: Design, synthesis, and biological evaluation of novel type II/2 p38 alpha MAP kinase inhibitors with excellent selectivity, high potency, and prolonged target residence time. Implication for cancer- and CNS-applications</a></p> <p><b>S Laufer</b>, H Wentsch, N Walter, M Laemmerhofer, R Buijsman, D Rauh, L Zender  ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 258</p>	2019	
505	<p><a href="#">Pyridinylimidazoles as dual glycogen synthase kinase 3<math>\beta</math>/p38<math>\alpha</math> mitogen-activated protein kinase inhibitors</a></p> <p>F Heider, F Ansideri, R Tesch, T Pantsar, U Haun, E Döring, M Kudolo, A Poso, W Albrecht, <b>SA Laufer</b>, P Koch  European Journal of Medicinal Chemistry 175, 309-329</p>	2019	
504	<p><a href="#">Natural chromones as potential anti-inflammatory agents: Pharmacological properties and related mechanisms</a></p> <p>LCF Opretzka, RF do Espírito-Santo, OA Nascimento, LS Abreu, IM Alves, E Döring, MB Pereira Soares, E da Silva Velozo, <b>SA Laufer</b>, CF Villarreal  International Immunopharmacology 72, 31-39</p>	2019	
503	<p><a href="#">Liver X receptor mediated lipotoxicity represents a treatment option for liver cancer</a></p> <p>R Rudalska, J Harbig, M Snaebjoernsson, L Taranets, F Heinzmann, S Zwirner, WC Hu, T Kronenberger, TW Kang, A Poso, <b>S Laufer</b>, M Rosenfeldt, NP Malek, B Pichler, N Popov, A Schulze, L Zender, D Dauch  Cancer Research 79 (13_Supplement), 4377-4377</p>	2019	
502	<p><a href="#">Myricetin inhibits panel of kinases implicated in tumorigenesis</a></p> <p>S Stoll, S Bitencourt, <b>S Laufer</b>, M Inês Goettert  Basic &amp; Clinical Pharmacology &amp; Toxicology 125 (1), 3-7</p>	2019	
501	<p><a href="#">Design, Synthesis and Biological Evaluation of 7-Chloro-9H-pyrimido[4,5-b]indole-based Glycogen Synthase Kinase-3<math>\beta</math> Inhibitors</a></p> <p>S Andreev, T Pantsar, F Ansideri, M Kudolo, M Forster, D Schollmeyer, <b>SA Laufer</b>, P Koch  Molecules 24 (12), 2331</p>	2019	
500	<p><a href="#">Are peptides a solution for the treatment of hyperactivated JAK3 pathways?</a></p> <p>A Dullius, CM Rocha, <b>S Laufer</b>, CFV de Souza, MI Goettert  Inflammopharmacology 27 (3), 433-452</p>	2019	
499	<p><a href="#">Data for homogeneous thermofluorimetric assays for ethanolamine using aptamers and a PCR instrument</a></p> <p>M Mahmoud, <b>S Laufer</b>, HP Deigner  Data in Brief 24, 103946</p>	2019	

498	<a href="#">Adjunctive role of Calyptanthus tricona extract with probiotic Kluyveromyces marxianus on colorectal adenocarcinoma Caco-2 cells</a> DM Kich, S Bitencourt, D Faleiro, SM Immich, DJ Marmitt, T Baldasso, G Viegas Haute, J Rodrigues de Oliveira, <b>S Laufer</b> , R Pedrosa, CF Volken de Souza, MI Goettert Phytochemistry Letters 30, 1-5	2019	
497	<a href="#">An aptamer based thermofluorimetric assay for ethanolamine</a> M Mahmoud, <b>S Laufer</b> , HP Deigner Biochimie 158, 233-237	2019	
496	<a href="#">Selective targeting of JAK3 with new small molecular compounds</a> J Holstein, M Forster, <b>S Laufer</b> , K Ghoreschi EXPERIMENTAL DERMATOLOGY 28 (3), E72-E72	2019	
495	<a href="#">N<sup>1</sup>-{4-[2-(Methylthio)-1H-imidazol-5-yl]pyridin-2-yl}benzene-1,4-diamine</a> A El-Gokha, F Ansideri, S Andreev, D Schollmeyer, <b>S Laufer</b> , P Koch Molbank 2019 (1), M1048	2019	
494	<a href="#">Synthesis and structure-activity-relationship of 3, 4-Diaryl-1H-pyrrolo [2, 3-b] pyridines as irreversible Inhibitors of mutant EGFR-L858R/T790M</a> M Günther, J Laux, <b>S Laufer</b> European Journal of Pharmaceutical Sciences 128, 91-96	2019	
493	<a href="#">JAK3 and p38 MAPK inhibitors regulates hepatocellular carcinoma proliferation</a> M Goettert, T Schneider, <b>S Laufer</b> NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY 392, S51-S51	2019	
492	<a href="#">A smartphone readout system for gold nanoparticle-based lateral flow assays: Application to monitoring of digoxigenin</a> C Ruppert, N Phogat, <b>S Laufer</b> , M Kohl, HP Deigner Microchimica Acta 186 (2), 1-9 Electronic Supplementary Material (ESM) on “A Smartphone readout...”	2019	
491	<a href="#">Sorafenib therapy for treatment of liver cancer is independent from organic cation transporter 1 (OCT1/SLC22A1)</a> M Chen, C Neul, E Schaeffeler, F Frisch, S Winter, M Schwab, H Koepsell, S Hu, <b>S Laufer</b> , SD Baker, A Sparreboom, AT Nies NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY 392, S17-S18	2019	
490	<a href="#">A novel scaffold for EGFR inhibition: introducing N-(3-(3-phenylureido) quinoxalin-6-yl) acrylamide derivatives</a>	2019	

	DN do Amaral, J Lategahn, HH Fokoue, EMB da Silva, CMR Sant'Anna, D Rauh, EJ Barreiro, <b>S Laufer</b> , L Moreira Lim Scientific Reports 9 (1), 1-12 Supplementary Material on "A novel Scaffold for EGFR..."		
489	<a href="#">Cysteine-type cathepsins promote the effector phase of acute cutaneous delayed-type hypersensitivity reactions</a> J Schwenck, A Maurer, B Fehrenbacher, R Mehling, P Knopf, N Mucha, D Haupt, K Fuchs, CM Grissinger, D Bukala, J Holstein, M Schaller, I Gozalez Menendez, K Ghoreschi, L Quintanilla-Martinez, M Gütschow, <b>S Laufer</b> , T Reinheckel, M Röcken, H Kalbacher, BJ Pichler, M Kneiling Theranostics 9 (13), 3903	2019	
488	<a href="#">Emerging and re-emerging warheads for targeted covalent inhibitors: applications in medicinal chemistry and chemical biology</a> M Gehringer, <b>SA Laufer</b> Journal of Medicinal Chemistry 62 (12), 5673-5724	2018	
487	<a href="#">In vitro activities of Ceiba speciosa (A.St.-Hil) Ravenna aqueous stem bark extract</a> JA Dörr, S Bitencourt, L Bortoluzzi, C Alves, J Silva, SN Stoll, SF Goncalves Pinteus, A Augusti Boligon, RC Vianna Santos, <b>S Laufer</b> , R Pedrosa, MI Goettert Natural Product Research 33 (46): 1-4	2018	
486	<a href="#">Donated chemical probes for open science: Shown here are target and compound related criteria applied by the Structural Genomics Consortium.</a> S. Müller, S Ackloo, CH Arrowsmith, M Bauser, JL Baryza, J Blagg, J Böttcher, C Bountra, PJ Brown, ME Bunnage, AJ Carter, D Damerell, V Dötsch, DH Drewry, AM Edwards, J Edwards, JM Elkins, C Fischer, SV Frye, A Gollner, C Grimshaw, A IJzerman, T Hanke, IV Hartung, S Hitchcock, T Howe, TV Hughes, <b>S Laufer</b> , V Li, S Liras, BD Marsden, H Matsui, J Mathias, RC O'Hagan, DR Owen, V Pande, D Rauh, SH Rosenberg, B Roth, N Schneider, C Scholten, KS Saikatendu, A Simeonov, M Takizawa, C Tse, PR Thompson, DK Treiber, AY Viana, CI Wells, TM Willson, WJ Zuercher, S Knapp, A Mueller-Fahrnow eLife Sciences 7	2018	
485	<a href="#">Substituted benzamides from anti-inflammatory and p38 kinase inhibitors to antitubercular activity: design, synthesis and screening</a> R Kulkarni, U Mitkari, G Achaiiah, <b>S Laufer</b> , D Bikshapti, VM Chandrashekar, PB Gurav, SJ Joshi, VD Chipade Mini Reviews in Medicinal Chemistry 18 (17), 1486-1497	2018	
484	<a href="#">Kinase inhibitors</a> P Koch, <b>S Laufer</b> Molecules 23 (7), 1818	2018	

483	<p><a href="#">Structural Optimization of a Pyridinylimidazole scaffold: shifting the selectivity from p38<math>\alpha</math> mitogen-activated protein kinase to c-Jun N-terminal kinase 3</a></p> <p>F Ansideri, JT Macedo, M Eitel, A El-Gokha, DS Zinad, C Scarpellini, M Kudolo, D Schollmeyer, FM Boeckler, BS Blaum, <b>SA Laufer</b>, P Koch ACS Omega 3 (7), 7809-7831</p>	2018	
482	<p><a href="#">NB 06: From a simple lysosomotropic aSMase inhibitor to tools for elucidating the role of lysosomes in signaling apoptosis and LPS-induced inflammation</a></p> <p>M Blaess, N Bibak, RA Claus, M Kohl, GA Bonaterra, R Kinscherf, <b>S Laufer</b>, HP Deigner European Journal of Medicinal Chemistry 153, 73-104</p>	2018	
481	<p><a href="#">Development, Optimization, and Structure–Activity Relationships of Covalent-Reversible JAK3 Inhibitors Based on a Tricyclic Imidazo[5,4-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridine scaffold</a></p> <p>M Forster, A Chaikuad, T Dimitrov, E Döring, J Holstein, BT Berger, M Gehringer, K Ghoreschi, S Müller, S Knapp, <b>SA Laufer</b> Journal of Medicinal Chemistry 61 (12), 5350-5366</p>	2018	
480	<p><a href="#">The cysteinome of protein kinases as a target in drug development</a></p> <p>A Chaikuad, P Koch, <b>SA Laufer</b>, S Knapp Angewandte Chemie International Edition 57 (16), 4372-4385</p>	2018	
479	<p><a href="#">Das Cysteinom der Proteinkinasen als Zielstruktur in der Arzneistoffentwicklung</a></p> <p>A Chaikuad, P Koch, <b>SA Laufer</b>, S Knapp Angewandte Chemie 130 (16), 4456-4470</p>	2018	
478	<p><a href="#">A Diverse and Versatile Regiospecific Synthesis of Tetrasubstituted Alkylsulfanylimidazoles as p38<math>\alpha</math> Mitogen-Activated Protein Kinase Inhibitors</a></p> <p>F Ansideri, S Andreev, A Kuhn, W Albrecht, <b>SA Laufer</b>, P Koch Molecules 23 (1), 221</p>	2018	
477	<p><a href="#">Donated chemical probes for open science</a></p> <p>S Müller, S Ackloo, CH Arrowsmith, M Bauser, JL Baryza, J Blagg, J Böttcher, C Bountra, PJ Brown, ME Bunnage, AJ Carter, D Damerell, V Dötsch, DH Drewry, AM Edwards, J Edwards, JM Elkins, C Fischer, SV Frye, A Gollner, CE Grimshaw, A IJerman, T Hanke, IV Hartung, S Hitchcock, T Howe, TV Hughes <b>S Laufer</b>, VMJ Li, S Liras, BD Marsden, H Matsui, J Mathias, RC O’Hagan, DR Owen, V Pande, D Rauh, SH Rosenberg, BL Roth, NS Schneider, C Scholten, KS Saikatendu, A Simeonov, M Taikizawa, C Tse, PR Thompson, DK Treiber, AY Viana, CI Wells, TM Wilson, WJ Zuercher, S Knapp, A Müller-Farnow eLife 7</p>	2018	

476	<a href="#">Abstract B167: KRAS gene mutations are associated with tumor resistance toward the LN1222/AD736 p38 inhibitor</a> V Vuaroqueaux, G Kelter, HR Hendriks, <b>S Laufer</b> , HH Fiebig Molecular Cancer Therapeutics 17 (1_Supplement), B167-B167	2018	
475	<a href="#">Synthesis, X-ray diffraction study and pharmacological evaluation of 3-amino-4-methylthiophene-2-acylcarbohydrazones</a> S Herrmann, T Schübel, FN Costa, MLC Barbosa, FF Ferreira, TLMF Dias, MV Araujo, MS Alexandre-Moreira, LM Lima, <b>S Laufer</b> , EJ Barreiro Anais da Academia Brasileira de Ciências 90, 1073-1088	2018	
474	<a href="#">Neue Anwendungen der Klick-Chemie in Zellbiologie und Wirkstoffentwicklung</a> M Gehringer, <b>SA Laufer</b> Angewandte Chemie 129 (49), 15709-15711	2017	
473	<a href="#">Click chemistry: Novel applications in cell biology and drug discovery</a> M Gehringer, <b>SA Laufer</b> Angewandte Chemie International Edition 56 (49), 15504-15505	2017	
472	<a href="#">P38 Kinase, SGK1 and NF-κB Dependent Up-Regulation of Na<sup>+</sup>/Ca<sup>2+</sup> Exchanger Expression and Activity Following TGFβ1 Treatment of Megakaryocytes</a> T Al-Maghout, L Pelzl, I Sahu, B Sukkar, Z Hosseinzadeh, R Gutti, <b>S Laufer</b> , J Voelkl, B Pieske, M Gawaz, F Lang Cellular Physiology and Biochemistry 42 (6), 2169-2181	2017	
471	<a href="#">From 2-alkylsulfanylimidazoles to 2-alkylimidazoles: an approach towards metabolically more stable p38α MAP kinase inhibitors</a> F Heider, U Haun, E Döring, M Kudolo, C Sessler, W Albrecht, <b>S Laufer</b> , P Koch Molecules 22 (10), 1729	2017	
470	<a href="#">Design, Synthesis, and Biological Evaluation of Novel Type I<sup>1/2</sup> p38α MAP Kinase Inhibitors with Excellent Selectivity, High Potency, and Prolonged Target ...</a> NM Walter, HK Wentsch, M Bührmann, SM Bauer, E Döring, S Mayer-Wrangowski, A Sievers-Engler, N Willemsen-Seegers, G Zaman, R Buijsman, M Lämmerhofer, D Rauh, <b>SA Laufer</b> Journal of medicinal chemistry 60 (19), 8027-8054	2017	
469	<a href="#">Recent advances in JAK3 inhibition: Isoform selectivity by covalent cysteine targeting</a> M Forster, M Gehringer, <b>SA Laufer</b> Bioorganic & medicinal chemistry letters 27 (18), 4229-4237	2017	
468	<a href="#">EGFR triple mutant: Recent set-backs and new hopes in fighting mutant non-small cell lung cancer</a>	2017	

	<b>S Laufer</b> , M Guenther, M Juchum, E Doering, M Keul, J Lategahn, H Tumbrink, J Engel, D Rauh ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 254		
467	<a href="#">Progress towards a public chemogenomic set for protein kinases and a call for contributions</a> DH Drewry, CI Wells, DM Andrews, R Angell, H Al-Ali, AD Axtman, SJ Capuzzi, JM Elkins, P Ettmayer, M Frederiksen, O Gileadi, N Gray, A Hooper, S Knapp, <b>S Laufer</b> , U Luecking, M Michaelides, S Müller, E Muratov, RA Denny, KS Saikatendu, DK Treiber, WJ Zuercher, TM Wilson PloS one 12 (8), e0181585	2017	
466	<a href="#">Androgen-mediated sex bias impairs efficiency of leukotriene biosynthesis inhibitors in males</a> S Pace, C Pergola, F Dehm, A Rossi, J Gerstmeier, F Troisi, H Pein, AM Schaible, C Weinigel, S Rummler, H Northoff, <b>S Laufer</b> , TJ Maier, O Radmark, B Samuelsson, A Koeberle, L Sautebin, O Werz The Journal of clinical investigation 127 (8), 3167-3176	2017	
465	<a href="#">Discovery of <i>N</i>-{4-[5-(4-Fluorophenyl)-3-methyl-2-methylsulfanyl-3<i>H</i>-imidazol-4-yl]-pyridin-2-yl}-acetamide (CBS-3595), a Dual p38<math>\alpha</math> MAPK/PDE-4 Inhibitor with ...</a> W Albrecht, A Unger, SM Bauer, <b>SA Laufer</b> Journal of Medicinal Chemistry 60 (13), 5290-5305	2017	
464	<a href="#">Trisubstituted pyridinylimidazoles as potent inhibitors of the clinically resistant L858R/T790M/C797S EGFR mutant: targeting of both hydrophobic regions and the phosphate ...</a> M Gunther, J Lategahn, M Juchum, E Doring, M Keul, J Engel, HL Tumbrink, D Rauh, <b>S Laufer</b> Journal of medicinal chemistry 60 (13), 5613-5637	2017	
463	<a href="#">Proteasome activation by small molecules</a> Y Leestemaker, A de Jong, KF Witting, R Penning, K Schuurman, B Rodenko, EA Zaal, B van de Kooij, <b>S Laufer</b> AJR Heck, J Borst, W Scheper, CR Berkers, H Ovaa Cell chemical biology 24 (6), 725-736. e7	2017	
462	<a href="#">Trisubstituted imidazoles with a rigidized hinge binding motif act as single digit nM inhibitors of clinically relevant EGFR L858R/T790M and L858R/T790M/C797S mutants: an ...</a> M Juchum, M Günther, E Döring, A Sievers-Engler, M Lämmerhofer, <b>S Laufer</b> Journal of medicinal chemistry 60 (11), 4636-4656	2017	
461	<a href="#">Optimierte Bindungsdauer am Zielenzym: Typ-I-Inhibitoren der p38<math>\alpha</math>-MAP-Kinase mit verbesserter Bindungskinetik durch direkte Interaktion mit der R-Spine</a>	2017	

	HK Wentsch, NM Walter, M Bührmann, S Mayer-Wrangowski, D Rauh, GJR Zaman, N Willemsen-Seegers, RC Buijsman, M Henning, D Dauch, L Zender, <b>S Laufer</b> Angewandte Chemie 129 (19), 5448-5453		
460	<a href="#">Optimized Target Residence Time: Type I Inhibitors for p38<math>\alpha</math> MAP Kinase with Improved Binding Kinetics through Direct Interaction with the R-Spine</a> HK Wentsch, NM Walter, M Bührmann, S Mayer-Wrangowski, D Rauh, GJR Zaman, N Willemsen-Seegers, RC Buijsman, M Henning, D Dauch, L Zender, <b>S Laufer</b> Angewandte Chemie International Edition 56 (19), 5363-5367	2017	
459	<a href="#">In vivo hypoxia PET imaging quantifies the severity of arthritic joint inflammation in line with overexpression of hypoxia-inducible factor and enhanced reactive oxygen species ...</a> K Fuchs, A Kuehn, M Mahling, P Guenthoer, A Hector, J Schwenck, D Hartl, <b>S Laufer</b> , U Kohlhofer, L Quintanilla-Martinez, G Reischl, M Röcken, BJ Pichler, M Kneiling Journal of Nuclear Medicine 58 (5), 853-860	2017	
458	<a href="#">In vivo hypoxia PET imaging quantifies the severity of arthritic joint inflammation in line with overexpression of HIF and enhanced ROS generation</a> K Fuchs, A Kuehn, M Mahling, P Guenthoer, A Hector, D Hartl, <b>S Laufer</b> , U Kohlhofer, L Quintanilla-Martinez, G Reischl, M Röcken, BJ Pichler, M Kneiling Journal of Nuclear Medicine	2017	
457	<a href="#">Tri-and tetrasubstituted pyridinylimidazoles as covalent inhibitors of c-Jun N-terminal kinase 3</a> F Muth, A El-Gokha, F Ansideri, M Eitel, E Döring, A Sievers-Engler, A Lange, FM Boeckler, M Lämmerhofer, P Koch, <b>SA Laufer</b> Journal of Medicinal Chemistry 60 (2), 594-607	2017	
456	<a href="#">Are Two Better Than One in Rheumatoid Arthritis? Development of Dual p38<math>\alpha</math> MAPK/PDE-4 Inhibitors for Treatment of TNF<math>\alpha</math>-Driven Diseases</a> W Albrecht, SM Bauer, <b>SA Laufer</b> Elsevier	2017	
455	<a href="#">Multi-gram Preparation of 7-Nitroquinoxalin-2-amine</a> DN Amaral, FR Alves, EJ Barreiro, <b>SA Laufer</b> , LM Lima Journal of the Brazilian Chemical Society 28, 1874-1878	2017	
454	<a href="#">Neuromodulatory effects of Calypttranthes grandifolia extracts against 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y cells</a> DM Kich, S Bitencourt, C Alves, J Silva, S Pinteus, R Pedrosa, <b>S Laufer</b> , CF Volken de Souza, MI Goettert Biomedicine & Pharmacotherapy 84, 382-386	2016	

453	<a href="#">IL-1<math>\beta</math>, IL-18, and eicosanoids promote neutrophil recruitment to pore-induced intracellular traps following pyroptosis</a> I Jorgensen, JP Lopez, <b>SA Laufer</b> , EA Miao European journal of immunology 46 (12), 2761-2766	2016	
452	<a href="#">Selective JAK3 inhibitors with a covalent reversible binding mode targeting a new induced fit binding pocket</a> M Forster, A Chaikuad, SM Bauer, J Holstein, MB Robers, CR Corona, M Gehringer, E Pfaffenrot, K Ghoreschi, S Knapp, <b>SA Laufer</b> Cell chemical biology 23 (11), 1335-1340	2016	
451	<a href="#">Impact of membrane drug transporters on resistance to small-molecule tyrosine kinase inhibitors</a> C Neul, E Schaeffeler, A Sparreboom, <b>S Laufer</b> , M Schwab, AT Nies Trends in pharmacological sciences 37 (11), 904-932	2016	
450	<a href="#">Tofacitinib and analogs as inhibitors of the histone kinase PRK1 (PKN1)</a> D Ostrovskiy, T Rumpf, J Eib, A Lumbroso, I Slynko, S Klaeger, S Heinzlmeir, M Forster, M Gehringer, E Pfaffenrot, SM Bauer, K Schmidtkunz, S Wenzler, E Metzger, B Kuster, <b>S Laufer</b> , R Schüle, W Sippl, B Breit, M Jung Future Medicinal Chemistry 8 (13), 1537-1551	2016	
449	<a href="#">Lungenkrebs: EGFR-Inhibitoren mit hoher Wirksamkeit gegen die therapieresistente L858R/T790M/C797S-Mutante.</a> M Günther, M Juchum, G Kelter, H Fiebig, <b>S Laufer</b> Angewandte Chemie 128 (36), 11050-11054	2016	
448	<a href="#">Lung cancer: EGFR inhibitors with low nanomolar activity against a therapy-resistant L858R/T790M/C797S mutant</a> M Günther, M Juchum, G Kelter, H Fiebig, <b>S Laufer</b> Angewandte Chemie International Edition 55 (36), 10890-10894	2016	
447	<a href="#">Why antidiabetic vanadium complexes are not in the pipeline of “big pharma” drug research? A critical review</a> T Scior, J Antonio Guevara-Garcia, QT Do, P Bernard, <b>S Laufer</b> Current medicinal chemistry 23 (25), 2874-2891	2016	
446	<a href="#">Stimulating effect of sclareol on suicidal death of human erythrocytes</a> E Signoreto, <b>SA Laufer</b> , F Lang Cellular Physiology and Biochemistry 39 (2), 554-564	2016	
445	<a href="#">Poly [[tetramethanolbis [4-oxo-3-(pyridin-4-yl)-1-(2, 4, 6-trichlorophenyl)-4, 5-dihydro-1H-pyrazolo [3, 4-d] pyrimidin-6-olato] disodium]-diethyl ether-methanol (1/1/2)]</a> B Abu Thaher, D Schollmeyer, <b>S Laufer</b> IUCrData 1 (7), x161081	2016	

444	<a href="#">A MYC-Aurka protein complex represents an actionable target in p53 altered liver cancer</a> D Daniel, R Rudalska, G Cossa, JC Nault, S Imbeaud, NP Malek, T Longerich, <b>S Laufer</b> , A Poso, J Zucman-Rossi, M Eilers, L Zender Cancer Research 76 (14_Supplement), 1257-1257	2016	
443	<a href="#">Evaluation of organic cation transporter 1 (OCT1, SLC22A1) as transporter for sorafenib</a> C Neul, SD Baker, A Sparreboom, E Schaeffeler, <b>S Laufer</b> , M Schwab, AT Nies Cancer Research 76 (14_Supplement), 257-257	2016	
442	<a href="#">Design and Development of Microsomal Prostaglandin E<sub>2</sub> Synthase-1 Inhibitors: Challenges and Future Directions</a> A Koeberle, <b>SA Laufer</b> , O Werz Journal of medicinal chemistry 59 (13), 5970-5986	2016	
441	<a href="#">Spinal inhibition of p38 MAP kinase reduces inflammatory and neuropathic pain in male but not female mice: Sex-dependent microglial signaling in the spinal cord</a> S Taves, T Berta, DL Liu, S Gan, G Chen, YH Kim, T Van de Ven, <b>S Laufer</b> , RR Ji Brain, behavior, and immunity 55, 70-81	2016	
440	<a href="#">SCISSOR—Spinal Cord Injury Study on Small molecule-derived Rho inhibition: a clinical study protocol</a> MA Kopp, T Liebscher, R Watzlawick, P Martus, <b>S Laufer</b> , C Blex, R Schindler, GJ Jungehulsing, S Knüppel, M Kreuzträger, A Ekkernkamp, U Dirnagl, SM Strittmatter, A Niedeggen, JM Schwab BMJ open 6 (7), e010651	2016	
439	<a href="#">A MYC–aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer</a> D Dauch, R Rudalska, G Cossa, JC Nault, TW Kang, T Wuestefeld, A Hohmeyer, S Imbeaud, T Yevsa, L Hoenicke, T Pantsar, P Bozko, NP Malek, T Longerich, <b>S Laufer</b> , A Poso, J Zucman-Rossi, M Eilers, L Zender Nature medicine 22 (7), 744-753	2016	
438	<a href="#">Fine-tuned PEGylation of chitosan to maintain optimal siRNA-nanoplex bioactivity</a> A Guțoaia, L Schuster, S Margutti, <b>S Laufer</b> , B Schlosshauer, R Krastev, D Stoll, H Hartmann Carbohydrate polymers 143, 25-34	2016	
437	<a href="#">Salinomycin, a candidate drug for the salinomycin, a candidate drug for the elimination of cancer stem cells elimination of cancer stem cells</a> C Naujokat, <b>S Laufer</b> Role of Cancer Stem Cells in Cancer Biology and Therapy 227	2016	

436	<a href="#">Fine-tuned PEGylation of chitosan to maintain optimal siRNA-nanoplex bioactivity</a> B Schlosshauer, D Stoll, H Hartmann, L Schuster, R Krastev, S Margutti, <b>S Laufer</b> Carbohydrate polymers 143	2016	
435	<a href="#">From enzyme to whole blood: sequential screening procedure for identification and evaluation of p38 MAPK inhibitors</a> SM Bauer, JM Kubiak, U Rothbauer, <b>S Laufer</b> Kinase Screening and Profiling: Methods and Protocols, 123-148	2016	
434	<a href="#">Fucoxanthin induced suicidal death of human erythrocytes</a> M Briglia, S Calabró, E Signoretto, K Alzoubi, <b>S Laufer</b> , C Faggio, F Lang Cellular Physiology and Biochemistry 37 (6), 2464-2475	2015	
433	<a href="#">Targeting the gatekeeper MET146 of C-Jun N-terminal kinase 3 induces a bivalent halogen/chalcogen bond</a> A Lange, M Günther, FM Büttner, MO Zimmermann, J Heidrich, S Hennig, S Zahn, C Schall, a Sievers-Engler, F Ansideri, P Koch, M Laemmerhofer, T Stehle, <b>SA Laufer</b> , FM Boeckler Journal of the American Chemical Society 137 (46), 14640-14652	2015	
432	<a href="#">The Pyrazolobenzothiazine Core as a New Chemotype of p38 Alpha Mitogen-Activated Protein Kinase Inhibitors</a> S Sabatini, G Manfroni, ML Barreca, SM Bauer, M Gargaro, R Cannalire, A Astolfi, J Brea, C Vacca, M Pirro, S Massari, O Tabarrini, MI Loza, F Fallarino, <b>SA Laufer</b> , V Cecchetti Chemical biology & drug design 86 (4), 531-545	2015	
431	<a href="#">Triggering of suicidal erythrocyte death by ruxolitinib</a> M Briglia, A Fazio, C Faggio, <b>S Laufer</b> , K Alzoubi, F Lang Cellular Physiology and Biochemistry 37 (2), 768-778	2015	
430	<a href="#">c-Jun N-terminal kinase inhibitors: a patent review (2010 – 2014)</a> M Gehringer, F Muth, P Koch, <b>SA Laufer</b> Expert opinion on therapeutic patents 25 (8), 849-872	2015	
429	<a href="#">Anti-inflammatory activities of phenoxyphenyl ureas mediated by inhibition of p38 kinase</a> R Kulkarni, S Diwyani, <b>S Laufer</b> , C VM, P Gurav, P Habbu Current Enzyme Inhibition 11 (2), 116-123	2015	
428	<a href="#">Impact of p38 MAP kinase inhibitors on LPS-induced release of TNF-<math>\alpha</math> in whole blood and primary cells from different species</a> S Fehr, A Unger, E Schaeffeler, S Herrmann, <b>S Laufer</b> , M Schwab, W Albrecht Cellular Physiology and Biochemistry 36 (6), 2237-2249	2015	

427	<a href="#">Triggering of suicidal erythrocyte death following boswellic acid exposure</a> S Calabrò, K Alzoubi, C Faggio, <b>S Laufer</b> , F Lang Cellular Physiology and Biochemistry 37 (1), 131-142	2015	
426	<a href="#">New insights into novel inhibitors against deoxyhypusine hydroxylase from Plasmodium falciparum: compounds with an iron chelating potential</a> I von Koschitzky, H Gerhardt, M Lämmerhofer, M Kohout, M Gehringer, <b>S Laufer</b> , M Pink, S Schmitz-Spanke, C Strube, A Kaiser Amino Acids 47, 1155-1166	2015	
425	<a href="#">Role of p38 mitogen-activated protein kinase in linking stearyl-CoA desaturase-1 activity with endoplasmic reticulum homeostasis</a> A Koeberle, C Pergola, H Shindou, SC Koeberle, T Shimizu, <b>SA Laufer</b> , O Werz The FASEB Journal 29 (6), 2439-2449	2015	
424	<a href="#">Effect of TGFβ on calcium signaling in megakaryocytes</a> J Yan, E Schmid, A Almilaji, E Shumilina, O Borst, <b>S Laufer</b> , M Gawaz, F Lang Biochemical and Biophysical Research Communications 461 (1), 8-13	2015	
423	<a href="#">Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors</a> M Juchum, M Günther, <b>SA Laufer</b> Drug Resistance Updates 20, 12-28	2015	
422	<a href="#">Influence of annexin A7 on insulin sensitivity of cellular glucose uptake</a> D Luo, A Fajol, AT Umbach, AA Noegel, <b>S Laufer</b> , F Lang, M Föller Pflügers Archiv-European Journal of Physiology 467, 641-649	2015	
421	<a href="#">Proteinkinase-Inhibitoren: selektiv und wirksam</a> A Freitag, <b>S Laufer</b> Nachrichten aus der Chemie 63 (4), 420-425	2015	
420	<a href="#">Flavonoids inhibit COX-1 and COX-2 enzymes and cytokine/chemokine production in human whole blood</a> D Ribeiro, M Freitas, SM Tomé, AMS Silva, <b>S Laufer</b> , JLFC Lima, E Fernandes Inflammation 38, 858-870	2015	
419	<a href="#">Solution-phase parallel synthesis of Ruxolitinib-derived Janus kinase inhibitors via copper-catalyzed Azide-Alkyne cycloaddition</a> M Gehringer, M Forster, <b>SA Laufer</b> ACS Combinatorial Science 17 (1), 5-10	2015	

418	<a href="#">Tetra-Substituted Pyridinylimidazoles As Dual Inhibitors of p38<math>\alpha</math> Mitogen-Activated Protein Kinase and c-Jun N-Terminal Kinase 3 for Potential Treatment of ...</a> F Muth, M Günther, SM Bauer, E Döring, S Fischer, J Maier, P Drückes, J Köppler, J Trappe, U Rothbauer, P Koch, <b>SA Laufer</b> Journal of medicinal chemistry 58 (1), 443-456	2015	
417	<a href="#">Advancing the kinase field: new targets and second generation inhibitors</a> <b>S Laufer</b> , J Bajorath Journal of Medicinal Chemistry 58 (1), 1-1	2015	
416	<a href="#">Development of first lead structures for phosphoinositide 3-kinase-C2<math>\gamma</math> inhibitors</a> A Freitag, P Prajwal, A Shymanets, C Harteneck, B Nürnberg, C Schächtele, M Kubbutat, F Trotzke, <b>SA Laufer</b> Journal of medicinal chemistry 58 (1), 212-221	2015	
415	<a href="#">Inhibitors of c-Jun N-terminal kinases: an update</a> P Koch, M Gehringer, <b>SA Laufer</b> Journal of medicinal chemistry 58 (1), 72-95	2015	
414	<a href="#">New Frontiers in Kinases: Second Generation Inhibitors—Going beyond Cancer</a> <b>S Laufer</b> ACS Medicinal Chemistry Letters 6 (1), 1-1	2015	
413	<a href="#">An optimized and versatile synthesis to pyridinylimidazole-type p38<math>\alpha</math> mitogen activated protein kinase inhibitors</a> A El-Gokha, <b>SA Laufer</b> , P Koch Organic & Biomolecular Chemistry 13 (43), 10699-10704	2015	
412	<a href="#">Design and synthesis of novel quinazoline derivatives and their evaluation as PI3Ks inhibitors</a> OM El-Said, MM Hamed, <b>S Laufer</b> , AH Abadi Chemical and Pharmaceutical Bulletin 62 (12), 1166-1172	2014	
411	<a href="#">Antinociceptive, anti-inflammatory and gastroprotective effects of a hydroalcoholic extract from the leaves of Eugenia punicifolia (Kunth) DC. in rodents</a> RT Basting, CM Nishijima, JA Lopes, RC Santos, LL Périco, <b>S Laufer</b> , S Bauer, MF Costa, LC Santos, LRM Rocha, W Vilegas, ARS Santos, C Dos Santos, CA Hiruma-Lima Journal of ethnopharmacology 157, 257-267	2014	
410	<a href="#">Novel Hinge-Binding Motifs for Janus Kinase 3 Inhibitors: A Comprehensive Structure–Activity Relationship Study on Tofacitinib Bioisosteres</a> M Gehringer, M Forster, E Pfaffenrot, SM Bauer, <b>SA Laufer</b> ChemMedChem 9 (11), 2516-2527	2014	

409	<a href="#">Anti-inflammatory macrolides to manage chronic neutrophilic inflammation</a> M Burnet, JH Guse, HJ Gutke, L Guillot, <b>S Laufer</b> , U Hahn, MP Seed, E Vallejo, M Eggers, D McKenzie, W Albrecht, MJ Parnham Macrocycles in Drug Discovery, 206-234	2014	
408	<a href="#">Monitoring of therapeutic Cathepsin B inhibition of in vivo by a specific activateable optical probe and ex vivo by active site labeling</a> J Schwenck, A Maurer, K Fuchs, CM Griessinger, D Bukala, H Kalbacher, B Fehrenbacher, <b>S Laufer</b> , M Roecken, C la Fougere, BJ Pichler, M Kneilling EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 41, S411-S412	2014	
407	<a href="#">In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer</a> R Rudalska, D Dauch, T Longerich, K McJunkin, T Wuestefeld, TW Kang, A Hohmeyer, M Pesic, J Leibold, A Von Thun, P Schirmacher, J Zuber, KH Weiss, S Powers, NP Malek, M Eilers, B Sipos, SW Lowe, R Geffers, <b>S Laufer</b> , L Zender Nature medicine 20 (10), 1138-1146	2014	
406	<a href="#">Effect of TGFβ on Na<sup>+</sup>/K<sup>+</sup> ATPase activity in megakaryocytes</a> Z Hosseinzadeh, E Schmid, E Shumilina, <b>S Laufer</b> , O Borst, M Gawaz, F Lang Biochemical and Biophysical Research Communications 452 (3), 537-541	2014	
405	<a href="#">Compostos 2-cloro-4-anilinoquinazolinicos inibidores de proteínas Tirosina cinases, composições farmacêuticas compreendendo os mesmos, processo para sua produção e método para ...</a> CMR Sant'Anna, E JL Barreiro, LM Lima, MLC Barbosa, R Tesch, <b>SA Laufer</b> Brasil	2014	
404	<a href="#">C-Jun N-terminal kinase 3 (JNK3) as target for halogen bonding</a> A Lange, M Guenther, <b>SA Laufer</b> , FM Boeckler ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 248	2014	
403	<a href="#">Modeling of compound profiling experiments using support vector machines</a> J Balfer, K Heikamp, <b>S Laufer</b> , J Bajorath Chemical Biology & Drug Design 84 (1), 75-85	2014	
402	<a href="#">Discovery of a Novel Series of Tetrahydro-β-carbolines Inducing Autophagic Cell Death in Human Metastatic Melanoma</a> NS Ahmed, M Elgendy, <b>S Laufer</b> , AH Abadi Archiv der Pharmazie 347 (6), 398-406	2014	

401	<a href="#">Four New Flavonol Glycosides from the Leaves of <i>Brugmansia suaveolens</i></a> F Geller, R Murillo, L Steinhauser, B Heinzmann, K Albert, I Merfort, <b>S Laufer</b> Molecules 19 (5), 6727-6736	2014	
400	<a href="#">Extract from gum resin of <i>Boswellia serrata</i> decreases [IA. sub. 2]-antibody in a patient with "Late onset Autoimmune Diabetes of the Adult"(LADA)</a> E Schrott, <b>S Laufer</b> , M Lammerhofer, HPT Ammon Phytomedicine: International Journal of Phytotherapy & Phytopharmacology 21	2014	
399	<a href="#">p38 MAPK inhibitors: a patent review (2012–2013)</a> S Bühler, <b>SA Laufer</b> Expert opinion on therapeutic patents 24 (5), 535-554	2014	
398	<a href="#">A p38 substrate-specific MK2-EGFP translocation assay for identification and validation of new p38 inhibitors in living cells: a comprising alternative for acquisition of ...</a> R Anton, SM Bauer, PR Keck, <b>S Laufer</b> , U Rothbauer PloS one 9 (4), e95641	2014	
397	<a href="#">2-(3-((3R, 4R)-4-Methyl-3-[methyl (7H-pyrrolo [2, 3-d] pyrimidin-4-yl) amino] piperidin-1-yl) oxetan-3-yl) acetonitrile monohydrate</a> M Gehringer, E Pfaffenrot, P Keck, D Schollmeyer, <b>SA Laufer</b> Acta Crystallographica Section E: Structure Reports Online 70 (4), o382-o383	2014	
396	<a href="#">New frontiers in kinases: second generation inhibitors</a> <b>S Laufer</b> , J Bajorath Journal of Medicinal Chemistry 57 (6), 2167-2168	2014	
395	<a href="#">Interference of boswellic acids with the ligand binding domain of the glucocorticoid receptor</a> T Scior, M Verhoff, I Gutierrez-Aztatzi, HPT Ammon, <b>S Laufer</b> , O Werz Journal of chemical information and modeling 54 (3), 978-986	2014	
394	<a href="#">Specific inhibition of p38-MAPK signaling suppresses experimental arthritis and inflammation induced hypoxia</a> P Guenthoer, K Fuchs, D Lamparter, G Reischl, S Aidone, M Koenig, <b>S Laufer</b> , M Roecken, BJ Pichler, M Kneilling EXPERIMENTAL DERMATOLOGY 23 (3), E29-E29	2014	
393	<a href="#">Efficacy and gastrointestinal tolerability of ML3403, a selective inhibitor of p38 MAP kinase and CBS-3595, a dual inhibitor of p38 MAP kinase and phosphodiesterase 4 in CFA ...</a> DA Koch, RBM Silva, AH de Souza, CE Leite, NF Nicoletti, MM Campos, <b>S Laufer</b> , FB Morrone Rheumatology 53 (3), 425-432	2014	

392	<a href="#">Back Cover: Design and Synthesis of Tricyclic JAK3 Inhibitors with Picomolar Affinities as Novel Molecular Probes (ChemMedChem 2/2014)</a> M Gehringer, E Pfaffenrot, S Bauer, <b>SA Laufer</b> ChemMedChem 9 (2), 412-412	2014	
391	<a href="#">Design and synthesis of tricyclic JAK3 inhibitors with picomolar affinities as novel molecular probes</a> M Gehringer, E Pfaffenrot, S Bauer, <b>SA Laufer</b> ChemMedChem 9 (2), 277-281	2014	
390	<a href="#">Dibenzocycloheptatone derivatives and pharmaceutical agents containing said compounds</a> <b>S Laufer</b> , W Albrecht US Patent 8,633,312	2014	
389	<a href="#">Novel 2-chloro-4-anilino-quinazoline derivatives as EGFR and VEGFR-2 dual inhibitors</a> ML de Castro Barbosa, LM Lima, R Tesch, CMR Sant'Anna, F Totzke, MHG Kubbutat, C Schaechtele, <b>SA Laufer</b> , EJ Barreiro European journal of medicinal chemistry 71, 1-14	2014	
388	<a href="#">Metabolism of a novel skepinone l-like p38 mitogen-activated protein kinase inhibitor</a> K Storch, M Gehringer, B Baur, <b>SA Laufer</b> MedChemComm 5 (6), 808-815	2014	
387	<a href="#">A direct enzyme-linked immunosorbent assay (ELISA) for the quantitative evaluation of Janus Kinase 3 (JAK3) inhibitors</a> SM Bauer, M Gehringer, <b>SA Laufer</b> Analytical Methods 6 (21), 8817-8822	2014	
386	<a href="#">Multiplex in vivo RNAi screening instructs combination therapies to increase the therapeutic efficacy of the multikinase inhibitor sorafenib</a> R Rudalska, D Dauch, K McJunkin, TW Kang, T Wuestefeld, R Geffers, P Schirmacher, S Lowe, T Longerich, <b>S Laufer</b> , L Zender Zeitschrift für Gastroenterologie 52 (01), P_4_31	2014	
385	<a href="#">A New In Vitro Model to Study Cellular Responses after Thermomechanical Damage in Monolayer Cultures</a> A Hettler, S Werner, S Eick, <b>S Laufer</b> , F Weise PLoS One 8 (12), e82635	2013	
384	<a href="#">Entada africana fraction CH<sub>2</sub>Cl<sub>2</sub>/MEOH 5% inhibits inducible nitric oxide synthase and pro-inflammatory cytokines gene expression induced by ...</a> BA Owona, NF Njayou, <b>SA Laufer</b> , HJ Schluesener, PF Moundipa BMC Complementary and Alternative Medicine 13, 1-7	2013	

383	<a href="#">Metabolically Stable Dibenzo[<i>b,e</i>]oxepin-11(6<i>H</i>)-ones as Highly Selective p38 MAP Kinase Inhibitors: Optimizing Anti-Cytokine Activity in Human Whole Blood</a> B Baur, K Storch, KE Martz, MI Goettert, A Richters, D Rauh, <b>SA Laufer</b> Journal of medicinal chemistry 56 (21), 8561-8578	2013	
382	<a href="#">Effects of a Combined Cyclooxygenase/Lipoxygenase Inhibitor in Pancreatic Cancer</a> HMA Kader, N Nalin, M El-Zeirry, <b>S Laufer</b> , TE Adrian PANCREAS 42 (8), 1357-1357	2013	
381	<a href="#">Induction but not inhibition of COX-2 confers human lung cancer cell apoptosis by celecoxib</a> R Ramer, U Walther, P Borchert, <b>S Laufer</b> , M Linnebacher, B Hinz Journal of lipid research 54 (11), 3116-3129	2013	
380	<a href="#">Choline and tromethamine salt of licofelone</a> W Albrecht, HG Striegel, <b>S Laufer</b> US Patent 8,519,155	2013	
379	<a href="#">A fraction of stem bark extract of Entada africana suppresses lipopolysaccharide-induced inflammation in RAW 264.7 cells</a> BA Owona, NF Njayou, <b>S Laufer</b> , PF Moundipa, HJ Schluesener Journal of ethnopharmacology 149 (1), 162-168	2013	
378	<a href="#">Skepinone-L, a novel potent and highly selective inhibitor of p38 MAP kinase, effectively impairs platelet activation and thrombus formation</a> O Borst, B Walker, P Münzer, A Russo, E Schmid, C Faggio, B Bigalke, <b>S Laufer</b> , M Gawaz, F Lang Cellular Physiology and Biochemistry 31 (6), 914-924	2013	
377	<a href="#">tert-Butyl N-[(3R, 4R)-1-(2-cyanoacetyl)-4-methylpiperidin-3-yl]-N-methylcarbamate</a> M Gehringer, M Forster, D Schollmeyer, <b>S Laufer</b> Acta Crystallographica Section E: Structure Reports Online 69 (6), o935-o935	2013	
376	<a href="#">Drug discovery: a modern decathlon</a> <b>S Laufer</b> , U Holzgrave, D Steinhilber Angewandte Chemie International Edition 52 (15), 4072-4076	2013	
375	<a href="#">Arzneistoffentwicklung, ein moderner Zehnkampf</a> <b>S Laufer</b> , U Holzgrave, D Steinhilber Angewandte Chemie 125 (15), 4164-4168	2013	
374	<a href="#">Deoxyhypusine Hydroxylase from Plasmodium vivax, the Neglected Human Malaria Parasite: Molecular Cloning, Expression and Specific Inhibition by the 5-LOX ...</a>	2013	

	VA Atemnkeng, M Pink, S Schmitz-Spanke, XJ Wu, LL Dong, KH Zhao, C May, <b>S Laufer</b> , B Langer, A Kaiser PLoS One 8 (3), e58318		
373	<a href="#">Design, Synthesis and Characterization of N', N''-Diaryl Ureas as p38 Kinase Inhibitors</a> R G Kulkarni, <b>S Laufer</b> , C Mangannavar, A Garlapati Medicinal Chemistry 9 (2), 213-221	2013	
372	<a href="#">Salinomycin, a candidate drug for the elimination of cancer stem cells</a> C Naujokat, <b>S Laufer</b> Role of Cancer Stem Cells in Cancer Biology and Therapy	2013	
371	<a href="#">Arachidonoyl-phosphatidylcholine oscillates during the cell cycle and counteracts proliferation by suppressing Akt membrane binding</a> A Koeberle, H Shindou, SC Koeberle, <b>SA Laufer</b> , T Shimizu, O Werz Proceedings of the National Academy of Sciences 110 (7), 2546-2551	2013	
370	<a href="#">Targeting cancer stem cells with defined compounds and drugs</a> C Naujokata, <b>S Laufer</b> Journal of Cancer Research Updates 2 (1), 36-67	2013	
369	<a href="#">Dibenzosuberones as p38 mitogen-activated protein kinase inhibitors with low ATP competitiveness and outstanding whole blood activity</a> S Fischer, HK Wentsch, SC Mayer-Wrangowski, M Zimmermann, SM Bauer, K Storch, R Niess, SC Koeberle, C Grütter, FM Boeckler, D Rauh, <b>S Laufer</b> Journal of medicinal chemistry 56 (1), 241-253	2013	
368	<a href="#">tert-Butyl-(3R, 4R)-1-(2-cyanoacetyl)-4-methylpiperidin-3-yl (methyl)-carbamate</a> <b>S Laufer</b> , M Gehringer, M Forster Acta Crystallographica Section E 69	2013	
367	<a href="#">Assessing the target differentiation potential of imidazole-based protein kinase inhibitors</a> D Dimova, P Iyer, M Vogt, F Totzke, MHG Kubbutat, C Schächtele, <b>S Laufer</b> , J Bajorath Journal of Medicinal Chemistry 55 (24), 11067-11071	2012	
366	<a href="#">2-[5-Bromo-1-(3-chlorobenzyl)-2-methyl-1H-indol-3-yl] acetic acid</a> M Elkady, P Keck, D Schollmeyer, <b>S Laufer</b> Acta Crystallographica Section E: Structure Reports Online 68 (12), o3396-o3396	2012	
365	<a href="#">3-(4-Bromophenyl)-1-phenyl-1H-pyrazole-4-carbaldehyde</a> M Elkady, P Keck, D Schollmeyer, <b>S Laufer</b> Acta Crystallographica Section E: Structure Reports Online 68 (12), o3397-o3397	2012	

364	<a href="#">Modified acidic nonsteroidal anti-inflammatory drugs as dual inhibitors of mPGES-1 and 5-LOX</a> M Elkady, R Nieß, AM Schaible, J Bauer, S Luderer, G Ambrosi, O Werz, <b>SA Laufer</b> Journal of medicinal chemistry 55 (20), 8958-8962	2012	
363	<a href="#">A frozen analogue approach to aminopyridinylimidazoles leading to novel and promising p38 MAP kinase inhibitors</a> R Selig, M Goettert, V Schattel, D Schollmeyer, W Albrecht, <b>S Laufer</b> Journal of Medicinal Chemistry 55 (19), 8429-8439	2012	
362	<a href="#">Discovery of Novel Orally Active Anti-Inflammatory N-Phenylpyrazolyl-N-Glyciny-Hydrazone Derivatives That Inhibit TNF-<math>\alpha</math> Production</a> RB Lacerda, LL Da Silva, CKF de Lima, E Miguez, ALP Miranda, <b>SA Laufer</b> , EJ Barreiro, CAM Fraga Public Library of Science 7 (10), e46925	2012	
361	<a href="#">1-[(3RS, 4RS)-1-Benzyl-4-methylpiperidin-3-yl]-1, 6-dihydroimidazo [4, 5-d] pyrrolo [2, 3-b] pyridine hemihydrate</a> E Pfaffenrot, D Schollmeyer, <b>S Laufer</b> Acta Crystallographica Section E: Structure Reports Online 68 (10), o3052-o3052	2012	
360	<a href="#">N-[(3RS, 4RS)-1-Benzyl-4-methylpiperidin-3-yl]-5-nitro-1-phenylsulfonyl-1H-pyrrolo [2, 3-b] pyridine-4-amine</a> E Pfaffenrot, D Schollmeyer, <b>S Laufer</b> Acta Crystallographica Section E: Structure Reports Online 68 (10), o3051-o3051	2012	
359	<a href="#">N-[(3RS, 4SR)-1-Benzyl-4-methylpiperidin-3-yl]-1-(4-methylphenylsulfonyl)-5-nitro-1H-pyrrolo [2, 3-b] pyridin-4-amine</a> E Pfaffenrot, D Schollmeyer, <b>S Laufer</b> Acta Crystallographica Section E: Structure Reports Online 68 (10), o3000-o3000	2012	
358	<a href="#">Targeting the hinge glycine flip and the activation loop: novel approach to potent p38<math>\alpha</math> inhibitors</a> KE Martz, A Dorn, B Baur, V Schattel, MI Goettert, SC Mayer-Wrangowski, D Rauh, <b>SA Laufer</b> Journal of medicinal chemistry 55 (17), 7862-7874	2012	
357	<a href="#">On the Reaction of Triphenylphosphane with Thionyl Chloride</a> HF Klein, A Kuhn, N Kuhn, <b>S Laufer</b> , M Ströbele Zeitschrift für anorganische und allgemeine Chemie 638 (11), 1784-1786	2012	

356	<a href="#">4-(4-Fluorophenyl)-3-(pyridin-4-yl)-1-(2, 4, 6-trichlorophenyl)-1H-pyrazol-5-amine</a> B Abu Thaher, P Koch, D Schollmeyer, <b>S Laufer</b> Acta Crystallographica Section E: Structure Reports Online 68 (9), o2603-o2603	2012	
355	<a href="#">PRE-CONDITIONED MAPK ACTIVATED PROTEIN KINASE-2 (MK-2) RESPONSES OF MACROPHAGES TO p38 INHIBITION IN THE ABSENCE OF INTRACELLULAR INHIBITOR, SB203580</a> N Yousaf, N Malik, M Lees, V Moradi, <b>S Laufer</b> , W Albrecht, G Schett, M Burnett, M Seed INFLAMMATION RESEARCH 61, S24-S24	2012	
354	<a href="#">The decrease of cell membrane fluidity by the non-steroidal anti-inflammatory drug Licofelone inhibits epidermal growth factor receptor signalling and triggers apoptosis in HCA ...</a> S Tavolari, A Munarini, G Storci, <b>S Laufer</b> , P Chieco, T Guarnieri Cancer letters 321 (2), 187-194	2012	
353	<a href="#">Identification of new <math>\gamma</math>-hydroxybutenolides that preferentially inhibit the activity of mPGES-1</a> R De Simone, I Bruno, R Riccio, K Stadler, J Bauer, AM Schaible, <b>S Laufer</b> , O Werz Bioorganic & medicinal chemistry 20 (16), 5012-5016	2012	
352	<a href="#">Anti-Inflammatory drug discovery</a> JI Levin, <b>S Laufer</b> Royal Society of Chemistry	2012	
351	<a href="#">Dual Inhibition of Phosphodiesterase-4 and p38 MAP Kinase: A Strategy for Treatment of Chronic Inflammatory Diseases</a> W ALBRECHT, <b>S LAUFER</b> Anti-Inflammatory Drug Discovery, 137	2012	
350	<a href="#">Small-molecule-induced Rho-inhibition: NSAIDs after spinal cord injury</a> MA Kopp, T Liebscher, A Niedeggen, <b>S Laufer</b> , B Brommer, GJ Jungehulsing, SM Strittmatter, U Dirnagl, JM Schwab Cell and tissue research 349 (1), 119-132	2012	
349	<a href="#">Development of a p38<math>\delta</math> mitogen activated protein kinase ELISA assay for the quantitative determination of inhibitor activity</a> M Goettert, N Shaalan, R Graeser, <b>SA Laufer</b> Journal of pharmaceutical and biomedical analysis 66, 349-351	2012	
348	<a href="#">Design, synthesis, and biological evaluation of novel disubstituted dibenzosuberones as highly potent and selective inhibitors of p38 mitogen activated protein kinase</a> SC Koeberle, S Fischer, D Schollmeyer, V Schattel, C Grütter, D Rauh, <b>SA Laufer</b>	2012	

	Journal of medicinal chemistry 55 (12), 5868-5877		
347	<a href="#">Abietane diterpenes induce cytotoxic effects in human pancreatic cancer cell line MIA PaCa-2 through different modes of action</a> M Fronza, E Lamy, S Günther, B Heinzmann, <b>S Laufer</b> , I Merfort Phytochemistry 78, 107-119	2012	
346	<a href="#">{<i>n</i>BuMg(OR)}<sub>2</sub> and {Mg(OR)}<sub>2</sub> (R = 2, 4, 6-<i>t</i>Bu<sub>3</sub>C<sub>6</sub>H<sub>2</sub>) – Sterically Congested Magnesium Alcoholates</a> U Flörke, G Henkel, A Kuhn, N Kuhn, <b>S Laufer</b> , C Maichle-Mößmer Zeitschrift für anorganische und allgemeine Chemie 638 (5), 730-732	2012	
345	<a href="#">4-[5-Amino-4-(4-fluorophenyl)-3-(pyridin-4-yl)-1H-pyrazol-1-yl] benzonitrile</a> B Abu Thaher, P Koch, D Schollmeyer, <b>S Laufer</b> Acta Crystallographica Section E: Structure Reports Online 68 (4), o935-o935	2012	
344	<a href="#">2-sulfanyl-substituted imidazole derivatives and their use as cytokine inhibitors</a> M Burnet, <b>S Laufer</b> , P Koch US Patent 8,143,294	2012	
343	<a href="#">Inferential NMR/X-ray-Based Structure Determination of a Dibenzo[<i>a,d</i>]cycloheptenone Inhibitor-p38<math>\alpha</math> MAP Kinase Complex in Solution</a> VS Honndorf, N Coudevylle, <b>S Laufer</b> , S Becker, C Griesinger, M Habeck Angewandte Chemie International Edition 51 (10), 2359-2362	2012	
342	<a href="#">Ethyl 5-amino-3-(pyridin-4-yl)-1-(2, 4, 6-trichlorophenyl)-1H-pyrazole-4-carboxylate dimethyl sulfoxide hemisolvate</a> BA Thaher, P Koch, D Schollmeyer, <b>S Laufer</b> Acta Crystallographica Section E: Structure Reports Online 68 (Pt 3), o917	2012	
341	<a href="#">4-(4-Fluorophenyl)-1-phenyl-3-(pyridin-4-yl)-1H-pyrazol-5-amine</a> B Abu Thaher, P Koch, D Schollmeyer, <b>S Laufer</b> Acta Crystallographica Section E: Structure Reports Online 68 (3), o632-o632	2012	
340	<a href="#">Ethyl 5-amino-3-(pyridin-4-yl)-1-(2, 4, 6-trichlorophenyl)-1H-pyrazole-4-carboxylate dimethyl sulfoxide hemisolvate</a> B Abu Thaher, P Koch, D Schollmeyer, <b>S Laufer</b> Acta Crystallographica Section E: Structure Reports Online 68 (3), o917-o918	2012	
339	<a href="#">4-(4-Fluorophenyl)-1-(4-nitrophenyl)-3-(pyridin-4-yl)-1H-pyrazol-5-amine</a> B Abu Thaher, P Koch, D Schollmeyer, <b>S Laufer</b>	2012	

	Acta Crystallographica Section E: Structure Reports Online 68 (3), o633-o633		
338	<a href="#">Therapeutic Potential of Small Molecules Modulating the Cyclooxygenase–5-Lipoxygenase Pathway</a> W Albrecht, <b>S Laufer</b> Polypharmacology in Drug Discovery, 383-408	2012	
337	<a href="#">Regulation of coronary venular barrier function by blood borne inflammatory mediators and pharmacological tools: insights from novel microvascular wall models</a> G Juchem, DR Weiss, M Knott, A Senftl, S Förch, T Fischlein, E Kreuzer, B Reichart, <b>S Laufer</b> , S Nees American Journal of Physiology-Heart and Circulatory Physiology 302 (3), H567-H581	2012	
336	<a href="#">A Multicomponent Carba-Betti Strategy to Alkylidene Heterodimers–Total Synthesis and Structure–Activity Relationships of Arzanol</a> A Minassi, L Cicione, A Koeberle, J Bauer, <b>S Laufer</b> , O Werz, G Appendino European journal of organic chemistry 2012 (4), 772-779	2012	
335	<a href="#">Skepinone-L is a selective p38 mitogen-activated protein kinase inhibitor</a> SC Koeberle, J Romir, S Fischer, A Koeberle, V Schattel, W Albrecht, C Grütter, O Werz, D Rauh, T Stehle, <b>SA Laufer</b> Nature chemical biology 8 (2), 141-143	2012	
334	<a href="#">Tri-and tetrasubstituted pyrazole derivates: regioisomerism switches activity from p38MAP kinase to important cancer kinases</a> BA Thaher, M Arnsmann, F Totzke, JE Ehlert, MHG Kubbutat, C Schächtele, MO Zimmermann, P Koch, FM Boeckler, <b>SA Laufer</b> Journal of Medicinal Chemistry 55 (2), 961-965	2012	
333	<a href="#">Mechanistic role of p38 MAPK in gastric cancer dissemination in a rodent model peritoneal metastasis</a> L Graziosi, A Mencarelli, C Santorelli, B Renga, S Cipriani, E Cavazzoni, G Palladino, <b>S Laufer</b> , M Burnett, A Donini, S Fiorucci European journal of pharmacology 674 (2-3), 143-152	2012	
332	<a href="#">p38<math>\alpha</math> mitogen-activated protein kinase inhibitors, a patent review (2005–2011)</a> S Fischer, SC Koeberle, <b>SA Laufer</b> Expert opinion on therapeutic patents 21 (12), 1843-1866	2011	
331	<a href="#">The application of Stille cross-coupling reactions with multiple nitrogen containing heterocycles</a> R Selig, D Schollmeyer, W Albrecht, <b>S Laufer</b> Tetrahedron 67 (47), 9204-9213	2011	

330	<a href="#">Polymorphic form of 6-(4-chlorophenyl)-2, 2-dimethyl-7-phenyl-2, 3-dihydro-1h-pyrrolizin-5-ylacetic acid</a> W Albrecht, T Kammermeier, HG Striegel, P Merckle, <b>S Laufer</b> US Patent 8,034,837	2011	
329	<a href="#">1, 4-Dimethyl-2-phenyl-6, 7-dihydro-1H-pyrazolo [4, 3-b] pyridine-3, 5 (2H, 4H)-dione</a> M Weisser, D Schollmeyer, <b>S Laufer</b> Acta Crystallographica Section E: Structure Reports Online 67 (10), o2586-o2586	2011	
328	<a href="#">6-(4-Chlorophenyl)-7-phenyl-2, 3-dihydro-1H-pyrrolizine-5-carbaldehyde</a> P Keck, D Schollmeyer, <b>S Laufer</b> Acta Crystallographica Section E: Structure Reports Online 67 (9), o2292-o2292	2011	
327	<a href="#">6-(4-Methoxyphenyl)-7-phenyl-2, 3-dihydro-1H-pyrrolizine-5-carbaldehyde</a> P Keck, D Schollmeyer, <b>S Laufer</b> Acta Crystallographica Section E: Structure Reports Online 67 (9), o2417-o2417	2011	
326	<a href="#">In vitro cytotoxic activity of abietane diterpenes from Peltodon longipes as well as Salvia miltiorrhiza and Salvia sahendica</a> M Fronza, R Murillo, S Ślusarczyk, M Adams, M Hamburger, B Heinzmann, <b>S Laufer</b> , I Merfort Bioorganic & medicinal chemistry 19 (16), 4876-4881	2011	
325	<a href="#">Four new kaempferol glycosides from the leaves of Brugmansia suaveolens</a> F Geller, R Murillo, L Steinhauser, B Heinzmann, K Albert, I Merfort, <b>S Laufer</b> Planta Medica 77 (12), PG62	2011	
324	<a href="#">Alkoxymagnesium Iodide Complexes</a> P Haiss, A Kuhn, N Kuhn, C Maichle-Mößmer, <b>S Laufer</b> , M Steimann, KP Zeller European Journal of Inorganic Chemistry 2011 (22), 3284-3287	2011	
323	<a href="#">Structural and Conformational Analysis of Proanthocyanidins from Parapiptadenia rigida and Their Wound-Healing Properties</a> CA Schmidt, R Murillo, B Heinzmann, <b>S Laufer</b> , V Wray, I Merfort Journal of natural products 74 (6), 1427-1436	2011	
322	<a href="#">Chiral sulfoxides as metabolites of 2-thioimidazole-based p38<math>\alpha</math> mitogen-activated protein kinase inhibitors: Enantioselective synthesis and biological evaluation</a> S Bühler, M Goettert, D Schollmeyer, W Albrecht, <b>SA Laufer</b> Journal of medicinal chemistry 54 (9), 3283-3297	2011	

321	<a href="#">A direct ELISA assay for quantitative determination of the inhibitory potency of small molecules inhibitors for JNK3</a> M Goettert, S Luik, R Graeser, <b>SA Laufer</b> Journal of pharmaceutical and biomedical analysis 55 (1), 236-240	2011	
320	<a href="#">Cell receptor-ligand interaction, signalling, activation and apoptosis: 21. Pregnenolone Sulphate is Similar to Dexamethasone in Suppressing the Unfettered Secretion of ...</a> C Ciurtin, Y Majeed, J Naylor, P Sukumar, A English, P Emery, D Beech Rheumatology 50 (suppl 3), iii50-iii52	2011	
319	<a href="#">Modeling and benchmark data set for the inhibition of c-Jun N-terminal kinase-3</a> V Schattel, G Hinselmann, A Jahn, A Zell, <b>S Laufer</b> Journal of chemical information and modeling 51 (3), 670-679	2011	
318	<a href="#">Design, Synthesis and Structure–Activity Relationship of Functionalized Tetrahydro-<math>\beta</math>-carboline Derivatives as Novel PDE5 Inhibitors</a> NS Ahmed, BD Gary, HN Tinsley, GA Piazza, <b>S Laufer</b> , AH Abadi Archiv der Pharmazie 344 (3), 149-157	2011	
317	<a href="#">Transient exposure of macrophages to P38 map kinase inhibition conditions cell responses through MAPK activated protein kinase-2 regulation</a> N Malik, M Lees, V Moradi, <b>S Laufer</b> , G Schett, M Burnet, M Seed Annals of the Rheumatic Diseases 70 (Suppl 2), A17-A17	2011	
316	<a href="#">3-(2, 4-Difluoroanilino)-9-nitrodibenzo [b, e] oxepin-11 (6H)-one</a> B Baur, D Schollmeyer, <b>S Laufer</b> Acta Crystallographica Section E: Structure Reports Online 67 (3), o555-o555	2011	
315	<a href="#">3-(2, 4-Dimethoxyanilino)-8-methoxydibenz [b, e] oxepin-11 (6H)-one</a> B Baur, D Schollmeyer, <b>S Laufer</b> Acta Crystallographica Section E: Structure Reports Online 67 (2), o487-o487	2011	
314	<a href="#">Regulation of coronary venular barrier function by blood borne inflammatory mediators and pharmacological tools: insights from 2 novel microvascular wall models 3</a> EK Fischlein, B Reichart, <b>S Laufer</b> , S Nees	2011	
313	<a href="#">Conformational effects on potency of thioimidazoles and dihydrothiazolines</a> R Selig, V Schattel, M Goettert, D Schollmeyer, W Albrecht, <b>S Laufer</b> MedChemComm 2 (4), 261-269	2011	

312	<a href="#">Catechin Derivatives from <i>Parapiptadenia rigida</i> with <i>in Vitro</i> Wound-Healing Properties</a> CA Schmidt, R Murillo, T Bruhn, G Bringmann, M Goettert, B Heinzmann, V Brecht, <b>SA Laufer</b> , I Merfort Journal of natural Products 73 (12), 2035-2041	2010	
311	<a href="#">Biological evaluation and structural determinants of p38<math>\alpha</math> mitogen-activated-protein kinase and c-Jun-N-terminal kinase 3 inhibition by flavonoids</a> M Goettert, V Schattel, P Koch, I Merfort, <b>S Laufer</b> Chembiochem 11 (18), 2579-2588	2010	
310	<a href="#">N-(4-Chloropyridin-2-yl)-N-(4-methylphenylsulfonyl) acetamide</a> S Bühler, D Schollmeyer, W Albrecht, <b>S Laufer</b> Acta Crystallographica Section E: Structure Reports Online 66 (12), o3320-o3320	2010	
309	<a href="#">N-(4-Chloropyridin-2-yl)-N-methoxymethyl-4-methylbenzenesulfonamide</a> S Bühler, D Schollmeyer, W Albrecht, <b>S Laufer</b> Acta Crystallographica Section E: Structure Reports Online 66 (12), o3321-o3321	2010	
308	<a href="#">Tri- and tetrasubstituted imidazoles as p38<math>\alpha</math> mitogen-activated protein kinase inhibitors</a> <b>S Laufer</b> , D Hauser, T Stegmiller, C Bracht, K Ruff, V Schattel, W Albrecht, P Koch Bioorganic & medicinal chemistry letters 20 (22), 6671-6675	2010	
307	<a href="#">Optimization of a nonradioactive immunosorbent assay for p38<math>\alpha</math> mitogen-activated protein kinase activity</a> M Goettert, R Graeser, <b>SA Laufer</b> Analytical biochemistry 406 (2), 233-234	2010	
306	<a href="#">A novel access to arylated and heteroarylated beta-carboline based PDE5 inhibitors</a> N S Ahmed, B D Gary, G A Piazza, H N Tinsley, <b>S Laufer</b> , A H Abadi Medicinal Chemistry 6 (6), 374-387	2010	
305	<a href="#">2-sulfinyl- and 2-sulfonyl-substituted imidazole derivatives and their use as cytokine inhibitors</a> W Albrecht, C Greim, HG Striegel, K Tollmann, P Merkle, <b>S Laufer</b> US Patent App. 11/817,298	2010	
304	<a href="#">Cytotoxic abietane diterpenes from <i>Peltodon longipes</i> and their mode of action</a> M Fronza, S Günther, R Murillo, E Lamy, B Heinzmann, <b>S Laufer</b> , I Merfort Planta Medica 76 (12), SL_22	2010	

303	<a href="#">Catechin derivatives from Parapiptadenia rigida: biological studies and conformational analysis</a> C Schmidt, M Fronza, R Murillo, V Wray, G Bringmann, T Bruhn, B Heinzmann, <b>S Laufer</b> , I Merfort Planta Medica 76 (12), O_1	2010	
302	<a href="#">Rosmarinic acid as the effective compound in Cordia americana</a> F Geller, C Schmidt, M Goettert, M Fronza, B Heinzmann, O Werz, I Merfort, <b>S Laufer</b> Planta Medica 76 (12), P584	2010	
301	<a href="#">One-pot synthesis of 4, 6-diaryl-2-oxo (imino)-1, 2-dihydropyridine-3-carbonitrile; a new scaffold for p38<math>\alpha</math> MAP Kinase Inhibition</a> AM Serry, S Luik, <b>S Laufer</b> , AH Abadi Journal of Combinatorial Chemistry 12 (4), 559-565	2010	
300	<a href="#">Inside Cover: Synthesis and Biological Testing of N-Aminoimidazole-Based p38<math>\alpha</math> MAP Kinase Inhibitors (ChemMedChem 7/2010)</a> C Bracht, DRJ Hauser, V Schattel, W Albrecht, <b>SA Laufer</b> ChemMedChem 5 (7), 966-966	2010	
299	<a href="#">Synthesis and Biological Testing of N-Aminoimidazole-Based p38<math>\alpha</math> MAP Kinase Inhibitors</a> C Bracht, DRJ Hauser, V Schattel, W Albrecht, <b>SA Laufer</b> ChemMedChem 5 (7), 1134-1142	2010	
298	<a href="#">Differential effects of p38MAP kinase inhibitors on the expression of inflammation-associated genes in primary, interleukin-1<math>\beta</math>-stimulated human chondrocytes</a> H Joos, W Albrecht, <b>S Laufer</b> , RE Brenner British journal of pharmacology 160 (5), 1252-1262	2010	
297	<a href="#">2-(Bicyclo [2.2. 1] hept-5-en-2-yl)-1H-pyrrolo [2, 3-b] pyridine</a> R Selig, D Schollmeyer, W Albrecht, <b>S Laufer</b> Acta Crystallographica Section E: Structure Reports Online 66 (7), o1800-o1800	2010	
296	<a href="#">N-{2-Methyl-5-[(5-oxo-10, 11-dihydro-5H-dibenzo [a, d] cyclohepten-2-yl) amino] phenyl} benzamide</a> A Dorn, D Schollmeyer, <b>SA Laufer</b> Acta Crystallographica Section E: Structure Reports Online 66 (7), o1867-o1867	2010	
295	<a href="#">Unexpected reaction of 2-alkylsulfanylimidazoles to imidazol-2-ones: Pyridinylimidazol-2-ones as novel potent p38<math>\alpha</math> mitogen-activated protein kinase inhibitors</a> P Koch, <b>S Laufer</b> Journal of medicinal chemistry 53 (12), 4798-4802	2010	

294	<a href="#">Novel p38 MAPK inhibitor ML3403 has potent anti-inflammatory activity in airway smooth muscle</a> L Munoz, EE Ramsay, M Manetsch, Q Ge, C Peifer, <b>S Laufer</b> , AJ Ammit European journal of pharmacology 635 (1-3), 212-218	2010	
293	<a href="#">Fluorescence polarization binding assay to develop inhibitors of inactive p38<math>\alpha</math> mitogen-activated protein kinase</a> L Munoz, R Selig, YT Yeung, C Peifer, D Hauser, <b>S Laufer</b> Analytical biochemistry 401 (1), 125-133	2010	
292	<a href="#">Design, synthesis and SAR of phenylamino-substituted 5, 11-dihydro-dibenzo [a, d] cyclohepten-10-ones and 11H-dibenzo [b, f] oxepin-10-ones as p38 MAP kinase inhibitors</a> A Dorn, V Schattel, <b>S Laufer</b> Bioorganic & medicinal chemistry letters 20 (10), 3074-3077	2010	
291	<a href="#">2-(4-Fluorophenyl)-N-{4-[6-(4-fluorophenyl)-2, 3-dihydroimidazo [2, 1-b][1, 3] thiazol-5-yl] pyridin-2-yl} acetamide</a> R Selig, D Schollmeyer, W Albrecht, <b>S Laufer</b> Acta Crystallographica Section E: Structure Reports Online 66 (5), o1132-o1132	2010	
290	<a href="#">N-[3-(5-Oxo-10, 11-dihydro-5H-dibenzo [a, d] cyclohepten-2-ylamino) phenyl] furan-3-carboxamide</a> A Dorn, D Schollmeyer, <b>SA Laufer</b> Acta Crystallographica Section E: Structure Reports Online 66 (5), o1100-o1100	2010	
289	<a href="#">1-[4-(2-Aminoanilino) phenyl]-2, 2, 2-trifluoroethanone</a> A Dorn, D Schollmeyer, <b>SA Laufer</b> Acta Crystallographica Section E: Structure Reports Online 66 (5), o1149-o1149	2010	
288	<a href="#">Annellated pyrrole compounds for cancer management</a> <b>S Laufer</b> , T Guarnieri, S Tavolari, V Tomasi, E Palazzini, M Barbanti US Patent App. 12/375,305	2010	
287	<a href="#">Identification of rosmarinic acid as the major active constituent in Cordia americana</a> F Geller, C Schmidt, M Göttert, M Fronza, V Schattel, B Heinzmann, O Werz, EMM Flores, I Merfort, <b>S Laufer</b> Journal of ethnopharmacology 128 (3), 561-566	2010	
286	<a href="#">4-Chloro-7-methoxymethyl-2-phenyl-7H-pyrrolo [2, 3-b] pyridine</a> R Selig, D Schollmeyer, W Albrecht, <b>S Laufer</b> Acta Crystallographica Section E: Structure Reports Online 66 (4), o822-o822	2010	

285	<a href="#">5-(4-Fluorophenyl)-4-(4-pyridyl)-1, 3-oxazol-2-amine</a> P Koch, D Schollmeyer, <b>S Laufer</b> Acta Crystallographica Section E: Structure Reports Online 66 (4), o917-o917	2010	
284	<a href="#">Imidazole compounds having an antiinflammatory effect</a> W Albrecht, D Hauser, <b>S Laufer</b> , HG Striegel, K Tollmann US Patent App. 12/310,305	2010	
283	<a href="#">Pyridinylquinoxalines and pyridinylpyridopyrazines as lead compounds for novel p38<math>\alpha</math> mitogen-activated protein kinase inhibitors</a> P Koch, H Jahns, V Schattel, M Goettert, <b>S Laufer</b> Journal of medicinal chemistry 53 (3), 1128-1137	2010	
282	<a href="#">7-[4-(4-Fluorophenyl)-2-methylsulfanyl-1H-imidazol-5-yl] tetrazolo [1, 5-a] pyridine</a> R Selig, D Schollmeyer, J Schlosser, W Albrecht, <b>S Laufer</b> Acta Crystallographica Section E: Structure Reports Online 66 (2), o451-o451	2010	
281	<a href="#">N-{4-[4-(4-Fluorophenyl)-1-methyl-2-[(R)-methylsulfinyl]-1H-imidazol-5-yl]-2-pyridyl} acetamide dihydrate</a> S Bühler, D Schollmeyer, D Hauser, W Albrecht, <b>S Laufer</b> Acta Crystallographica Section E: Structure Reports Online 66 (1), o121-o121	2010	
280	<a href="#">Different methods for testing potential cyclooxygenase-1 and cyclooxygenase-2 inhibitors</a> <b>S Laufer</b> , S Luik Cyclooxygenases: Methods and Protocols, 91-116	2010	
279	<a href="#">M1739 MI3403, a New p38 MAPK Inhibitor, Corrects Immune Dysfunction in Rodent Models of Chronic Inflammatory Disorders</a> S Fiorucci, <b>SA Laufer</b> , A Mencarelli, B Renga, C Booth, GL Tudor, E Distrutti, M Burnet Gastroenterology 5 (138), S-409	2010	
278	<a href="#">3, 4-Diaryl-isoxazoles and-imidazoles as potent dual inhibitors of p38<math>\alpha</math> mitogen activated protein kinase and casein kinase 1<math>\delta</math></a> C Peifer, M Abadleh, J Bischof, D Hauser, V Schattel, H Hirner, U Knippschild, <b>S Laufer</b> Journal of medicinal chemistry 52 (23), 7618-7630	2009	
277	<a href="#">Determination of the wound healing effect of Calendula extracts using the scratch assay with 3T3 fibroblasts</a> M Fronza, B Heinzmann, M Hamburger, <b>S Laufer</b> , I Merfort Journal of ethnopharmacology 126 (3), 463-467	2009	

276	<a href="#">Prediction of breast cancer by profiling of urinary RNA metabolites using Support Vector Machine-based feature selection</a> C Hennekes, D Bullinger, R Fux, N Friese, H Seeger, H Neubauer, <b>S Laufer</b> , CH Gleiter, M Schwab, A Zell, B Kammerer BMC cancer 9, 1-11	2009	
275	<a href="#">(2Z)-2-Fluoro-N-{4-[5-(4-fluorophenyl)-2-methylsulfanyl-1H-imidazol-4-yl]-2-pyridyl}-3-phenylacrylamide</a> R Selig, D Schollmeyer, T Stegmiller, W Albrecht, <b>S Laufer</b> Acta Crystallographica Section E: Structure Reports Online 65 (12), o3284-o3284	2009	
274	<a href="#">4-Chloro-1-(4-methylphenylsulfonyl)-1H-pyrrolo [2, 3-b] pyridine</a> R Selig, D Schollmeyer, W Albrecht, <b>S Laufer</b> Acta Crystallographica Section E: Structure Reports Online 65 (12), o3018-o3018	2009	
273	<a href="#">N-{4-[4-(4-Fluorophenyl)-1-(2-methoxyethyl)-2-methylsulfanyl-1H-imidazol-5-yl]-2-pyridyl}-2-methyl-3-phenylpropionamide</a> K Ziegler, D Schollmeyer, <b>S Laufer</b> Acta Crystallographica Section E: Structure Reports Online 65 (12), o3128-o3128	2009	
272	<a href="#">2-(3, 4, 5-Trimethoxyphenyl)-1H-pyrrolo [2, 3-b] pyridine</a> R Selig, D Schollmeyer, W Albrecht, <b>S Laufer</b> Acta Crystallographica Section E: Structure Reports Online 65 (12), o3097-o3097	2009	
271	<a href="#">Accelerated Clearance of Plasmodium-infected Erythrocytes in Sickle Cell Trait and Annexin-A7 Deficiency</a> PA Lang, RS Kasinathan, VB Brand, C Duranton, C Lang, S Koka, E Shumilina, DS Kempe, V Tanneur, A Akel, KS Lang, M Föller, JFJ Kun, PG Kremsner, S Wesselborg, <b>S Laufer</b> , CS Clemen, C Herr, AA Noegel, T Wieder, E Gulbins, F Lang, SM Huber Cellular Physiology and Biochemistry 24 (5-6), 415-428	2009	
270	<a href="#">2-Acylaminopyridin-4-ylimidazoles as p38 MAP Kinase Inhibitors: Design, Synthesis, and Biological and Metabolic Evaluations</a> K Ziegler, DRJ Hauser, A Unger, W Albrecht, <b>SA Laufer</b> ChemMedChem: Chemistry Enabling Drug Discovery 4 (11), 1939-1948	2009	
269	<a href="#">4-(4-Fluorophenyl)-1-methoxymethyl-2-phenyl-1H-imidazole</a> R Selig, D Schollmeyer, W Albrecht, <b>S Laufer</b> Acta Crystallographica Section E: Structure Reports Online 65 (11), o2803-o2803	2009	
268	<a href="#">3-(4-Fluorophenyl)-2-(4-pyridyl) pyrido [2, 3-b] pyrazine</a> P Koch, D Schollmeyer, <b>S Laufer</b> Acta Crystallographica Section E: Structure Reports Online 65 (10), o2546-o2546	2009	

267	<a href="#">N-{4-[3-(4-Fluorophenyl) pyrido [2, 3-b] pyrazin-2-yl]-2-pyridyl} isopropylamine</a> P Koch, D Schollmeyer, <b>S Laufer</b> Acta Crystallographica Section E: Structure Reports Online 65 (10), o2557-o2557	2009	
266	<a href="#">2-(4-Fluorophenyl)-3-(4-pyridyl) pyrido [2, 3-b] pyrazine</a> P Koch, D Schollmeyer, <b>S Laufer</b> Acta Crystallographica Section E: Structure Reports Online 65 (10), o2512-o2512	2009	
265	<a href="#">2-[(1-Methyl-1H-pyrrol-2-yl) carbonylmethyl] isoindoline-1, 3-dione</a> J Schlosser, D Schollmeyer, <b>S Laufer</b> , C Peifer Acta Crystallographica Section E: Structure Reports Online 65 (10), o2375-o2375	2009	
264	<a href="#">2-thio-substituted imidazole derivatives and their use in pharmaceuticals</a> <b>S Laufer</b> , HG Striegel, K Tollmann, W Albrecht US Patent 7,582,660	2009	
263	<a href="#">Participation of leukotriene C4 in the regulation of suicidal erythrocyte death</a> M Foller, H Mahmud, S Gu, K Wang, E Floride, Y Kucherenko, S Luik, <b>S Laufer</b> , F Lang Acta physiologica Polonica 12 (3), 135	2009	
262	<a href="#">Arylpyrrolizines as Inhibitors of Microsomal Prostaglandin E<sub>2</sub> Synthase-1 (mPGES-1) or as Dual Inhibitors of mPGES-1 and 5-Lipoxygenase (5-LOX)</a> AJ Liedtke, PR Keck, F Lehmann, A Koeberle, O Werz, <b>SA Laufer</b> Journal of medicinal chemistry 52 (15), 4968-4972	2009	
261	<a href="#">Novel lead structures for p38 MAP kinase via FieldScreen virtual screening</a> TJ Cheeseright, M Holm, F Lehmann, S Luik, M Gottert, JL Melville, <b>S Laufer</b> Journal of medicinal chemistry 52 (14), 4200-4209	2009	
260	<a href="#">3-(4-Fluorophenyl)-6-methoxy-2-(4-pyridyl) quinoxaline</a> H Jahns, P Koch, D Schollmeyer, <b>S Laufer</b> Acta Crystallographica Section E: Structure Reports Online 65 (7), o1626-o1626	2009	
259	<a href="#">Protective effects of licofelone, a 5-lipoxygenase and cyclooxygenase inhibitor, versus naproxen on cartilage loss in knee osteoarthritis: a first multicentre clinical trial ...</a>	2009	

	JP Raynauld, J Martel-Pelletier, P Bias, <b>S Laufer</b> , B Haraoui, D Choquette, AD Beaulieu, F Abram, M Dorais, E Vignon, JP Pelletier, Canadian Licofelone Study Group Annals of the rheumatic diseases 68 (6), 938-947		
258	<a href="#">4-[3-(4-Fluorophenyl) quinoxalin-2-yl]-N-isopropylpyridin-2-amine</a> P Koch, D Schollmeyer, <b>S Laufer</b> Acta Crystallographica Section E: Structure Reports Online 65 (6), o1344-o1344	2009	
257	<a href="#">1-[2-(Benzylamino)-4-pyridyl]-2-(4-fluorophenyl) ethane-1, 2-dione</a> H Jahns, P Koch, D Schollmeyer, <b>S Laufer</b> Acta Crystallographica Section E: Structure Reports Online 65 (6), o1451-o1451	2009	
256	<a href="#">Colocalization of the VEGF-R2 and the common IL-3/GM-CSF receptor beta chain to lipid rafts leads to enhanced p38 activation</a> E Saulte, R Riccioni, S Coppola, I Parolini, D Diverio, V Riti, G Mariani, <b>S Laufer</b> , M Sargiacomo, U Testa British journal of haematology 145 (3), 399-411	2009	
255	<a href="#">Successful structure-based design of recent p38 MAP kinase inhibitors</a> SC Karcher, <b>SA Laufer</b> Current Topics in Medicinal Chemistry 9 (7), 655-676	2009	
254	<a href="#">Influence of p38MAPK inhibition on IL-1<math>\beta</math>-stimulated human chondrocytes: A microarray approach</a> H Joos, W Albrecht, <b>S Laufer</b> , RE Brenner International journal of molecular medicine 23 (5), 685-693	2009	
253	<a href="#">Role of the hydrogen bonding heteroatom– Lys53 interaction between the p38<math>\alpha</math> mitogen-activated protein (MAP) kinase and pyridinyl-substituted 5-membered heterocyclic ring inhibitors</a> BA Thaher, P Koch, V Schattel, <b>S Laufer</b> Journal of medicinal chemistry 52 (8), 2613-2617	2009	
252	<a href="#">Dibenzocycloheptane compounds and pharmaceuticals containing these compounds</a> <b>S Laufer</b> , W Albrecht, C Greim, HG Striegel, K Tollmann US Patent App. 11/914,078	2009	
251	<a href="#">Biological studies on Brazilian plants used in wound healing</a> C Schmidt, M Fronza, M Goettert, F Geller, S Luik, EMM Flores, CF Bittencourt, GD Zanetti, BM Heinzmann, <b>S Laufer</b> , I Merfort Journal of ethnopharmacology 122 (3), 523-532	2009	
250	<a href="#">Method for subgroup analysis in subjects having or being suspected of having inflammatory disease, use of anti-p38MAPK antibodies, kits and their use</a>	2009	

	G Schett, W Albrecht, <b>S Laufer</b> US Patent App. 11/871,565		
249	<a href="#">Rapid and easy access to indoles via microwave-assisted Hemetsberger–Knittel synthesis</a> F Lehmann, M Holm, <b>S Laufer</b> Tetrahedron Letters 50 (15), 1708-1709	2009	
248	<a href="#">Design, synthesis and characterization of N9/N7-substituted 6-aminopurines as VEGF-R and EGF-R inhibitors</a> C Peifer, S Bühler, D Hauser, K Kinkel, F Totzke, C Schächtele, <b>S Laufer</b> European journal of medicinal chemistry 44 (4), 1788-1793	2009	
247	<a href="#">Aza-analogue dibenzepinone scaffolds as p38 mitogen-activated protein kinase inhibitors: design, synthesis, and biological data of inhibitors with improved physicochemical ...</a> SC Karcher, <b>SA Laufer</b> Journal of medicinal chemistry 52 (6), 1778-1782	2009	
246	<a href="#">Targeting Proteinkinases: The Selectivity Problem</a> <b>S LAUFER</b> , G AHRENS, S KARCHER, R NIESS, J HERING Scientia Pharmaceutica 77 (5), 165	2009	
245	<a href="#">4-[2-(4-Fluorophenyl)-1H-pyrrol-3-yl] pyridine</a> B Abu Thaher, P Koch, D Schollmeyer, <b>S Laufer</b> Acta Crystallographica Section E: Structure Reports Online 65 (3), o457-o457	2009	
244	<a href="#">4-[2-(4-Fluorophenyl) furan-3-yl] pyridine</a> B Abu Thaher, P Koch, D Schollmeyer, <b>S Laufer</b> Acta Crystallographica Section E: Structure Reports Online 65 (3), o458-o458	2009	
243	<a href="#">Investigations of SCIO-469-like compounds for the inhibition of p38 MAP kinase</a> <b>S Laufer</b> , F Lehmann Bioorganic & Medicinal Chemistry Letters 19 (5), 1461-1464	2009	
242	<a href="#">4-[5-(4-Fluorophenyl)-1H-imidazol-4-yl] pyridine</a> P Koch, D Schollmeyer, <b>S Laufer</b> Acta Crystallographica Section E: Structure Reports Online 65 (3), o573-o573	2009	
241	<a href="#">Analysis of the precision and sensitivity to change of different approaches to assess cartilage loss by quantitative MRI in a longitudinal multicentre clinical trial in ...</a> JP Raynauld, J Martel-Pelletier, F Abram, M Dorais, B Haraoui, D Choquette, P Bias, KH Emmert, <b>S Laufer</b> , JP Pelletier Arthritis research & therapy 10 (6), 1-8	2008	

240	<a href="#">tert-Butyl N-benzyl-N-(4-methyl-2-pyridyl) carbamate</a> P Koch, D Schollmeyer, <b>S Laufer</b> Acta Crystallographica Section E: Structure Reports Online 64 (11), o2222-o2222	2008	
239	<a href="#">tert-Butyl N-(4-methyl-2-pyridyl) carbamate</a> P Koch, D Schollmeyer, <b>S Laufer</b> Acta Crystallographica Section E: Structure Reports Online 64 (11), o2216-o2216	2008	
238	<a href="#">tert-Butyl N-benzyl-N-[4-(4-fluorobenzoylmethyl)-2-pyridyl] carbamate</a> P Koch, D Schollmeyer, <b>S Laufer</b> Acta Crystallographica Section E: Structure Reports Online 64 (11), o2221-o2221	2008	
237	<a href="#">Związki pirolizynowe, środek farmaceutyczny i zastosowanie związków pirolizynowych</a> <b>S Laufer</b> , K Neher, HG Striegel	2008	
236	<a href="#">2-thio-substituted imidazole derivatives and their use in pharmaceuticals</a> <b>S Laufer</b> , HG Striegel, W Albrecht, K Tollmann US Patent 7,442,713	2008	
235	<a href="#">Identification of urinary modified nucleosides and ribosylated metabolites in humans via combined ESI-FTICR MS and ESI-IT MS analysis</a> D Bullinger, R Fux, G Nicholson, S Plontke, C Belka, <b>S Laufer</b> , CH Gleiter, B Kammerer Journal of the American Society for Mass Spectrometry 19, 1500-1513	2008	
234	<a href="#">Targeting the ribose and phosphate binding site of p38 mitogen-activated protein (MAP) kinase: Synthesis and biological testing of 2-alkylsulfanyl-, 4 (5)-aryl-, 5 (4 ...</a> P Koch, C Bäuerlein, H Jank, <b>S Laufer</b> Journal of medicinal chemistry 51 (18), 5630-5640	2008	
233	<a href="#">Medizinische Chemie und molekulare Hemmmechanismen der Tyrosinkinase-Inhibitoren. Schwerpunkt pharmazeutischer Forschung</a> M Holm, F Lehmann, <b>S Laufer</b> Pharmazie in unserer Zeit 37 (5), 382-392	2008	
232	<a href="#">Metabolic signature of breast cancer cell line MCF-7: Profiling of modified nucleosides via LC-IT MS coupling</a> H Neubauer, D Bullinger, T Fehm, <b>S Laufer</b> , C Gleiter, B Kammerer Geburtshilfe und Frauenheilkunde 68 (S 01), PO_Onko_01_19	2008	

231	<a href="#">Metabolische Signatur der Mammakarzinomzell-Linie MCF-7: Profiling modifizierter Nucleoside mittels LC-IT MS</a> H Neubauer, D Bullinger, T Fehm, <b>S Laufer</b> , C Gleiter, B Kammerer Senologie-Zeitschrift für Mammadiagnostik und-therapie 5 (03), A103	2008	
230	<a href="#">Licofelone suppresses prostaglandin E2 formation by interference with the inducible microsomal prostaglandin E2 synthase-1</a> A Koeberle, U Siemoneit, U Bühring, H Northoff, <b>S Laufer</b> , W Albrecht, O Werz Journal of Pharmacology and Experimental Therapeutics 326 (3), 975-982	2008	
229	<a href="#">Human whole blood assay for rapid and routine testing of non-steroidal anti-inflammatory drugs (NSAIDs) on cyclo-oxygenase-2 activity</a> <b>S Laufer</b> , C Greim, S Luik, SS Ayoub, F Dehner Inflammopharmacology 16, 155-161	2008	
228	<a href="#">Design, synthesis, and biological evaluation of novel Tri-and tetrasubstituted imidazoles as highly potent and specific ATP-mimetic inhibitors of p38 MAP kinase: Focus on ...</a> <b>SA Laufer</b> , DRJ Hauser, DM Domeyer, K Kinkel, AJ Liedtke Journal of medicinal chemistry 51 (14), 4122-4149	2008	
227	<a href="#">Design, Synthesis, and Biological Evaluation of Novel 3-Aryl-4-(1H-indole-3yl)-1,5-dihydro-2H-pyrrole-2-ones as Vascular Endothelial Growth Factor Receptor ...</a> C Peifer, R Selig, K Kinkel, D Ott, F Totzke, C Schächtele, R Heidenreich, M Röcken, D Schollmeyer, <b>S Laufer</b> Journal of medicinal chemistry 51 (13), 3814-3824	2008	
226	<a href="#">Methyl 4-[5-(4-fluorophenyl)-4-(pyridin-4-yl)-1H-imidazol-2-ylsulfanyl] butanoate</a> P Koch, C Bäuerlein, D Schollmeyer, <b>S Laufer</b> Acta Crystallographica Section E: Structure Reports Online 64 (7), o1183-o1184	2008	
225	<a href="#">The scratch assay: A suitable in vitro tool for studying wound healing effects</a> M Fronza, F Geller, C Bittencourt, E Flores, B Heinzmann, <b>S Laufer</b> , I Merfort Planta Medica 74 (09), PD4	2008	
224	<a href="#">Bioinformatical evaluation of modified nucleosides as biomedical markers in diagnosis of breast cancer</a> D Bullinger, H Fröhlich, F Klaus, H Neubauer, A Frickenschmidt, C Henneges, A Zell, <b>S Laufer</b> , CH Gleiter, H Liebich, B Kammerer Analytica Chimica Acta 618 (1), 29-34	2008	

223	<a href="#">In vitro metabolism of 2-[6-(4-chlorophenyl)-2, 2-dimethyl-7-phenyl-2, 3-dihydro-1H-pyrrolizin-5-yl] acetic acid (licofelone, ML3000), an inhibitor of cyclooxygenase-1 and-2 ...</a> W Albrecht, A Unger, AK Nussler, <b>S Laufer</b> Drug metabolism and disposition 36 (5), 894-903	2008	
222	<a href="#">Dynamics in the p38<math>\alpha</math> MAP Kinase–SB203580 Complex Observed by Liquid-State NMR Spectroscopy</a> VS Honndorf, N Coudeville, <b>S Laufer</b> , S Becker, C Griesinger Angewandte Chemie 120 (19), 3604-3607	2008	
221	<a href="#">Isoxazolone based inhibitors of p38 MAP kinases</a> <b>SA Laufer</b> , S Margutti Journal of medicinal chemistry 51 (8), 2580-2584	2008	
220	<a href="#">Inhibition of GSK3 differentially modulates NF-<math>\kappa</math>B, CREB, AP-1 and <math>\beta</math>-catenin signaling in hepatocytes, but fails to promote TNF-<math>\alpha</math>-induced apoptosis</a> F Götschel, C Kern, S Lang, T Sparna, C Markmann, J Schwager, S McNelly, F von Weizsäcker, <b>S Laufer</b> , A Hecht, I Merfort Experimental cell research 314 (6), 1351-1366	2008	
219	<a href="#">3-(2-Fluorophenyl)-6-(phenoxyethyl)-1, 2, 4-triazolo [3, 4-b][1, 3, 4] thiadiazole</a> M Holm, D Schollmeyer, <b>S Laufer</b> Acta Crystallographica Section E: Structure Reports Online 64 (4), o700-o700	2008	
218	<a href="#">6-Amino-1-benzyl-4-(4-chlorophenyl)-3-(4-pyridyl)-1, 4-dihydropyrano [2, 3-c] pyrazole-5-carbonitrile</a> F Lehmann, D Schollmeyer, <b>S Laufer</b> Acta Crystallographica Section E: Structure Reports Online 64 (4), o701-o701	2008	
217	<a href="#">The dual inhibitor of lipoxygenase and cyclooxygenase ML3000 decreases the expression of CXCR3 ligands</a> C Ospelt, M Kurowska-Stolarska, M Neidhart, BA Michel, RE Gay, <b>S Laufer</b> , S Gay Annals of the rheumatic diseases 67 (4), 524-529	2008	
216	<a href="#">Protizápalové oxo-a hydroxyderiváty pyrrolizínov a ich použitie vo farmácii</a> <b>S Laufer</b> , K Tollmann, HG Striegel	2008	
215	<a href="#">A Software Solution Automatically Assigns Formulae for Construction of Fragmentation Pathways Accelerating Drug Elucidation with ESI-TOF.</a> G Zurek, I Krebs, S Goetz, H Scheible, <b>S Laufer</b> , B Kammerer, W Albrecht LC-GC Europe	2008	

214	<a href="#">IL-1<math>\beta</math> regulates FHL2 and other cytoskeleton-related genes in human chondrocytes</a> H Joos, W Albrecht, <b>S Laufer</b> , H Reichel, RE Brenner Molecular medicine 14, 150-159	2008	
213	<a href="#">Implications for selectivity of 3, 4-diarylquinolinones as p38<math>\alpha</math>MAP kinase inhibitors</a> C Peifer, R Urich, V Schattel, M Abadleh, M Röttig, O Kohlbacher, <b>S Laufer</b> Bioorganic & medicinal chemistry letters 18 (4), 1431-1435	2008	
212	<a href="#">In vitro metabolism of Licofelone (ML3000), an Inhibitor of Cyclooxygenases-1 and-2 and 5-Lipoxygenase</a> W Albrecht, A Unger, AK Nuessler, <b>S Laufer</b> Drug Metabolism and Disposition	2008	
211	<a href="#">Licofelone, a dual COX/5-LOX inhibitor, induces apoptosis in HCA-7 colon cancer cells through the mitochondrial pathway independently from its ability to affect the arachidonic ...</a> S Tavolari, M Bonafe, M Marini, C Ferreri, G Bartolini, E Brighenti, S Manara, V Tomasi, <b>S Laufer</b> , T Guarnieri Carcinogenesis 29 (2), 371-380	2008	
210	<a href="#">4-(4-Fluorophenyl)-2-methyl-3-(1-oxy-4-pyridyl) isoxazol-5 (2H)-one</a> S Margutti, D Schollmeyer, <b>S Laufer</b> Acta Crystallographica Section E: Structure Reports Online 64 (2), o504-o504	2008	
209	<a href="#">4-[4-(4-Fluorophenyl)-2-methyl-5-oxo-2, 5-dihydroisoxazol-3-yl]-1-methylpyridinium iodide-4-[3-(4-fluorophenyl)-2-methyl-5-oxo-2, 5-dihydroisoxazol-4-yl]-1-methylpyridinium ...</a> S Margutti, D Schollmeyer, <b>S Laufer</b> Acta Crystallographica Section E: Structure Reports Online 64 (1), o298-o299	2008	
208	<a href="#">Inhibition of GSK3 differentially modulates NF-<math>\kappa</math>B, CREB, AP-1 and<math>\beta</math>-catenin signaling in hepatocytes, but fails to promote TNF-<math>\alpha</math>-induced apoptosis</a> F G tschel, C Kern, S Lang, T Sparna, C Markmann, J Schwager, S McNelly, F von Weizsäcker, <b>S Laufer</b> , A Hecht, I Merfort Experimental Cell Research 314 (6), 1351-1366	2008	
207	<a href="#">Metabonomics in cancer diagnosis: mass spectrometry-based profiling of urinary nucleosides from breast cancer patients</a> A Frickenschmidt, H Fröhlich, D Bullinger, A Zell, <b>S Laufer</b> , CH Gleiter, H Liebich, B Kammerer Biomarkers 13 (4), 435-449	2008	
206	<a href="#">Medical chemistry and molecular mechanisms of tyrosine kinase inhibitors. The viewpoint of pharmaceutical research</a>	2008	

	M Holm, F Lehmann, <b>S Laufer</b> Pharmazie in unserer Zeit 37 (5), 382-392		
205	<a href="#">A Convenient Synthesis of 1-(4-Fluorophenyl)-2-(4-pyridyl) cyclopentene from Cyclopentanone</a> BA Thaher, P Koch, V Del Amo, P Knochel, <b>S Laufer</b> Synthesis 2008 (02), 225-228	2008	
204	<a href="#">Inhibitory effect of inflammatory mediator by Orostachys japonicus in mouse peritoneal macrophages</a> P Koch, JH Guse, M Burnet, <b>S Laufer</b> INFLAMMATION RESEARCH 57, S99-S99	2008	
203	<a href="#">Three-component combinatorial synthesis of novel dihydropyrano [2, 3-c] pyrazoles</a> F Lehmann, M Holm, <b>S Laufer</b> Journal of Combinatorial Chemistry 10 (3), 364-367	2008	
202	<a href="#">4-aryl-5-heteroaryl-2-thio-substituted imidazoles: Approach to p38 MAP kinase inhibitor prodrugs</a> P Koch, JH Guse, M Burnet, <b>S Laufer</b> INFLAMMATION RESEARCH 57, S99-S100	2008	
201	<a href="#">Regiospecific and highly flexible synthesis of 1, 4, 5-trisubstituted 2-sulfanylimidazoles from structurally diverse ethanone precursors</a> <b>SA Laufer</b> , DRJ Hauser, AJ Liedtke Synthesis 2008 (02), 253-266	2008	
200	<a href="#">Preconditioning lymphocytes with p38 MAPK inhibitors, and not accessory cells, prevents Con-A-induced lymphocyte responses</a> V Moradi, E Johnson, L Dugo, V Holan, M Burnet, <b>S Laufer</b> , M Seed INFLAMMATION RESEARCH 57, S106	2008	
199	<a href="#">Towards the improvement of the synthesis of novel 4 (5)-aryl-5 (4)-heteroaryl-2-thio-substituted imidazoles and their p38 MAP kinase inhibitory activity</a> <b>S Laufer</b> , P Koch Organic & Biomolecular Chemistry 6 (3), 437-439	2008	
198	<a href="#">Metabolic signature of breast cancer cell line MCF-7: profiling of modified nucleosides via LC-IT MS coupling</a> D Bullinger, H Neubauer, T Fehm, <b>S Laufer</b> , CH Gleiter, B Kammerer BMC biochemistry 8, 1-14	2007	
197	<a href="#">2-(6-Amino-7H-purin-7-yl)-1-phenylethanone</a> S Buehler, D Schollmeyer, D Hauser, <b>S Laufer</b> , C Peifer Acta Crystallographica Section E: Structure Reports Online 63 (12), o4646-o4647	2007	

196	<a href="#">2-(6-Methoxy-7H-purin-7-yl)-1-phenylethanone monohydrate</a> S Buehler, D Schollmeyer, D Hauser, <b>S Laufer</b> , C Peifer Acta Crystallographica Section E: Structure Reports Online 63 (10), o4154-o4155	2007	
195	<a href="#">Are MAP kinases drug targets? Yes, but difficult ones</a> S Margutti, <b>SA Laufer</b> ChemMedChem: Chemistry Enabling Drug Discovery 2 (8), 1116- 1140	2007	
194	<a href="#">2-thio-substituted imidazole derivatives and the use thereof in the pharmaceutical industry</a> <b>S Laufer</b> , D Kotschenreuther, P Merckle, K Tollmann, HG Striegel US Patent 7,253,191	2007	
193	<a href="#">2-(4-Fluorophenyl)-1-(4-pyridyl) cyclopentan-1-ol</a> B Abu Thaher, D Schollmeyer, <b>S Laufer</b> Acta Crystallographica Section E: Structure Reports Online 63 (8), o3531-o3531	2007	
192	<a href="#">Chondroprotective effects of licofelone, a fop00728 b-llpvxyutnase and cyclooxygenase inhibitor, vis-a-vis naproxen in knee osteoarthritis (OA): A two-year study using ...</a> JP Pelletier, JR Raynauld, P Bias, <b>S Laufer</b> , B Haraoui, D Choquette, F Abram, E Vignon, J Martel-Pelletier ANNALS OF THE RHEUMATIC DISEASES 66, 59-59	2007	
191	<a href="#">Isoxazoles as p38 MAPk inhibitors. interaction with atp binding site</a> S Margutti, <b>S Laufer</b> INFLAMMATION RESEARCH 56, S446-S447	2007	
190	<a href="#">Synthesis and structure-activity relationships of [1, 2, 4] triazolo [3, 4-B][1, 3, 4] thiadiazole derivates as novel p38 mapk-inhibitors</a> M Holm, <b>S Laufer</b> INFLAMMATION RESEARCH 56, S446-S446	2007	
189	<a href="#">Dendritic cell: T cell interactions and p38 mapkinase inhibition</a> M Seed, E Johnson, M Burnet, V Holan, <b>S Laufer</b> INFLAMMATION RESEARCH 56, S433-S434	2007	
188	<a href="#">4-Aryl-5-heteroaryl-2-thio-imidazoles: warhead for a macrocycle-based drug targeting</a> P Koch, <b>S Laufer</b> INFLAMMATION RESEARCH 56, S446-S446	2007	
187	<a href="#">p38 map kinase inhibitor prodrugs tropic for macrophages and neutrophils exert enhanced anti-inflammatory activity in IBD and collagen induced arthritis models</a> JH Guse, M Burnet, S Luik, <b>S Laufer</b> , M Seed, V Holan, S Fiorucci	2007	

	INFLAMMATION RESEARCH 56, S434-S434		
186	<a href="#">Validation of a diluted whole blood assay to evaluate cytokine release inhibitors</a> S Luik, <b>S Laufer</b> INFLAMMATION RESEARCH 56, S446-S446	2007	
185	<a href="#">Pharmacokinetics of ML3403 ({4-[5-(4-fluorophenyl)-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-(1-phenylethyl)-amine), a 4-pyridinylimidazole-type p38 mitogen-activated ...</a> B Kammerer, H Scheible, W Albrecht, CH Gleiter, <b>S Laufer</b> Drug metabolism and disposition 35 (6), 875-883	2007	
184	<a href="#">Synthesis, biological testing, and binding mode prediction of 6, 9-diarylpurin-8-ones as p38 MAP kinase inhibitors</a> DRJ Hauser, T Scior, DM Domeyer, B Kammerer, <b>SA Laufer</b> Journal of medicinal chemistry 50 (9), 2060-2066	2007	
183	<a href="#">(2aRS, 3RS, 4aSR, 6aRS, 6bSR)-3-Hydroxy-2a, 3, 4a, 6, 6a, 6b-hexahydro-1, 4-dioxacyclopenta [cd] pentalen-2 (5H)-one</a> C Peifer, D Schollmeyer, M Tschertsche, <b>S Laufer</b> Acta Crystallographica Section E: Structure Reports Online 63 (5), o2249-o2251	2007	
182	<a href="#">3-(4-Fluorophenyl)-1-methyl-4-(4-pyridyl) quinolin-2 (1H)-one</a> C Peifer, D Schollmeyer, K Kinkel, <b>S Laufer</b> Acta Crystallographica Section E: Structure Reports Online 63 (5), o2457-o2459	2007	
181	<a href="#">2, 2-Dimethyl-N-[3-(3, 4, 5-trimethoxybenzoyl) pyridin-4-yl] propanamide</a> K Kinkel, <b>S Laufer</b> , D Schollmeyer, C Peifer Acta Crystallographica Section E: Structure Reports Online 63 (4), o1887-o1889	2007	
180	<a href="#">rac-(3E, 3aR, 6aR)-3-(Hydroxymethylene)-3, 3a, 6, 6a-tetrahydro-2H-cyclopenta [b] furan-2-one</a> C Peifer, D Schollmeyer, M Tschertsche, <b>S Laufer</b> Acta Crystallographica Section E: Structure Reports Online 63 (4), o1551-o1553	2007	
179	<a href="#">From five-to six-membered rings: 3, 4-diarylquinolinone as lead for novel p38MAP kinase inhibitors</a> C Peifer, K Kinkel, M Abadleh, D Schollmeyer, <b>S Laufer</b> Journal of medicinal chemistry 50 (6), 1213-1221	2007	
178	<a href="#">Pharmacokinetics of ML3403, a 4-pyridinylimidazole-type p38 MAP kinase inhibitor</a> B Kammerer, H Scheible, W Albrecht, C Gleiter, <b>S Laufer</b> Drug Metabolism and Disposition	2007	

177	<a href="#">N-{(Z)-2-[1-(Triisopropylsilyl)-1H-indol-3-yl]-2-(triisopropylsilyloxy) vinyl}-2-(3, 4, 5-trimethoxyphenyl) acetamide</a> C Peifer, R Selig, D Schollmeyer, <b>S Laufer</b> Acta Crystallographica Section E: Structure Reports Online 63 (3), o1266-o1268	2007	
176	<a href="#">(1aR, 2aS, 5aS, 5bS)-Perhydro-4H-oxireno [3, 4] cyclopenta [1, 2-b] furan-4-one</a> C Peifer, M Tschertsche, D Schollmeyer, <b>S Laufer</b> Acta Crystallographica Section E: Structure Reports Online 63 (3), o1359-o1360	2007	
175	<a href="#">In vitro metabolite identification of ML3403, a 4-pyridinylimidazole-type p38 MAP kinase inhibitor by LC-Qq-TOF-MS and LC-SPE-cryo-NMR/MS</a> B Kammerer, H Scheible, G Zurek, M Godejohann, KP Zeller, CH Gleiter, W Albrecht, <b>S Laufer</b> Xenobiotica 37 (3), 280-297	2007	
174	<a href="#">Ethyl (2, 3-dihydro-1H, 1' H-2, 3'-biindol-1-yl) glyoxylate</a> C Peifer, D Ott, D Schollmeyer, <b>S Laufer</b> Acta Crystallographica Section E: Structure Reports Online 63 (3), o1415-o1417	2007	
173	<a href="#">4-[5-(4-Fluorophenyl)-3-isopropylisoxazol-4-yl] pyridin-2 (1H)-one</a> M Abadleh, C Peifer, K Kinkel, D Schollmeyer, <b>S Laufer</b> Acta Crystallographica Section E: Structure Reports Online 63 (3), o1423-o1425	2007	
172	<a href="#">Macrolide conjugates of pyrrolizine and indolizine compounds as inhibitors of 5-lipoxygenase and cyclooxygenase</a> <b>S Laufer</b> , W Albrecht, M Burnet, HJ Gutke	2007	
171	<a href="#">Design, Synthesis, and Biological Evaluation of Phenylamino-Substituted 6,11-Dihydro-dibenzo[b,e]oxepin-11-ones and Dibenzo[a,d]cycloheptan-5-ones ...</a> <b>SA Laufer</b> , GM Ahrens, SC Karcher, JS Hering, R Niess Journal of medicinal chemistry 49 (26), 7912-7915	2006	
170	<a href="#">Profile and Molecular Modeling of 3-(Indole-3-yl)-4-(3,4,5-trimethoxyphenyl)-1H-pyrrole-2,5dione (1) as a Highly Selective VEGF-R2/3 Inhibitor</a> C Peifer, A Krasowski, N Hämmerle, O Kohlbacher, G Dannhardt, F Trotzke, C Schächtele, <b>S Laufer</b> Journal of medicinal chemistry 49 (25), 7549-7553	2006	
169	<a href="#">Licofelone, a 5-lipoxygenase and cyclooxygenase inhibitor, reduces the progression of knee osteoarthritis (OA): A double blind, multicenter 2-year study using quantitative MRI.</a>	2006	

	JP Pelletier, JP Raynauld, P Bias, <b>S Laufer</b> , B Haraoui, D Choquette, F Abram, E Vignon, J Martel-Pelletier ARTHRITIS AND RHEUMATISM 54 (12), 4119-4119		
168	<a href="#">Stimulation of suicidal erythrocyte death by lipoxygenase inhibitor Bay-Y5884</a> E Shumilina, V Kiedaisch, A Akkel, P Lang, T Hermle, D Kempe, S Huber, T Wieder, <b>S Laufer</b> , F Lang Cellular Physiology and Biochemistry 18 (4-5), 233-242	2006	
167	<a href="#">Dibenzocycloheptanverbindungen und pharmazeutische mittel, welche diese verbindungen enthalten</a> <b>S Laufer</b> , W Albrecht, C Greim, HG Striegel, K Tollmann	2006	
166	<a href="#">3, 4-Bis (4-fluorophenyl)-1, 2, 5-oxadiazole 2-oxide</a> C Peifer, M Abadleh, D Schollmeyer, <b>S Laufer</b> Acta Crystallographica Section E: Structure Reports Online 62 (11), o4827-o4828	2006	
165	<a href="#">(4R)-4-Hydroxy-1-[(2S)-2-hydroxydodecyl]-l-proline monohydrate</a> C Peifer, O Werz, D Poeckel, D Schollmeyer, <b>S Laufer</b> Acta Crystallographica Section E: Structure Reports Online 62 (11), o5138-o5140	2006	
164	<a href="#">A concise and optimized four-step approach toward 2-(aryl-) alkylsulfanyl-, 4 (5)-aryl-, 5 (4)-heteroaryl-substituted imidazoles using alkyl-or arylalkyl thiocyanates</a> <b>SA Laufer</b> , AJ Liedtke Tetrahedron letters 47 (40), 7199-7203	2006	
163	<a href="#">Inhibition of P38 kinase prevents T-cell responsiveness to allogenic dendritic cells</a> E Johnson, <b>S Laufer</b> , V Holan, M Burnet, MP Seed INFLAMMATION RESEARCH 55, S118-S118	2006	
162	<a href="#">Development and optimization of a non-radioactive JNK3 assay</a> C Peifer, S Luik, S Thuma, Y Herweh, <b>S Laufer</b> Combinatorial Chemistry & High Throughput Screening 9 (8), 613-618	2006	
161	<a href="#">4-[5-(4-Fluorophenyl)-3-isopropylisoxazol-4-yl] pyridine</a> C Peifer, M Abadleh, D Schollmeyer, <b>S Laufer</b> Acta Crystallographica Section E: Structure Reports Online 62 (9), o3647-o3649	2006	
160	<a href="#">4-[3-(4-Fluorophenyl)-5-isopropylisoxazol-4-yl] pyridine</a> C Peifer, M Abadleh, D Schollmeyer, <b>S Laufer</b> Acta Crystallographica Section E: Structure Reports Online 62 (9), o3707-o3709	2006	

159	<a href="#">Development of a Microsphere-Based p38<math>\alpha</math> MAP Kinase No-Wash Assay</a> <b>S Laufer</b> , S Linsenmaier SLAS Discovery 11 (5), 528-536	2006	
158	<a href="#">Method for the production of 6-(4-chlorophenyl)-2, 2-dimethyl-7-phenyl-2, 3-dihydro-1h-pyrrolizin-5-ylacetic acid</a> G Dannhardt, T Kammermeier, P Merckle, HG Striegel, <b>S Laufer</b> US Patent 7,078,535	2006	
157	<a href="#">4-(4-Fluorophenyl)-3-(4-pyridyl) quinolin-2 (1H)-one</a> C Peifer, D Schollmeyer, R Selig, <b>S Laufer</b> Acta Crystallographica Section E: Structure Reports Online 62 (7), o2648-o2650	2006	
156	<a href="#">Substituted isoxazole derivatives and their use in pharmaceuticals</a> <b>S Laufer</b> , HG Striegel, W Albrecht, K Tollmann US Patent App. 10/524,839	2006	
155	<a href="#">3-(4-Fluorophenyl)-4-(4-pyridyl) quinolin-2 (1H)-one</a> C Peifer, D Schollmeyer, S Laudage, <b>S Laufer</b> Acta Crystallographica Section E: Structure Reports Online 62 (6), o2475-o2477	2006	
154	<a href="#">Licofelone reduces progression of structural changes in a canine model of osteoarthritis under curative conditions: effect on protease expression and activity.</a> M Moreau, C Boileau, J Martel-Pelletier, J Brunet, <b>S Laufer</b> , JP Pelletier The Journal of Rheumatology 33 (6), 1176-1183	2006	
153	<a href="#">Sesquiterpene lactones as inhibitors of IL-8 expression in HeLa cells</a> MT Lindenmeyer, A Hrenn, C Kern, V Castro, R Murillo, S Müller, <b>S Laufer</b> , J Schulte-Mönting, B Siedle, I Merfort Bioorganic & Medicinal Chemistry 14 (8), 2487-2497	2006	
152	<a href="#">Discovery and development of LICOFELONE (ML3000)</a> <b>S Laufer</b> PROSTAGLANDINS & OTHER LIPID MEDIATORS 79 (1-2), 161-161	2006	
151	<a href="#">Substituted isoxazoles as potent inhibitors of p38 MAP kinase</a> <b>SA Laufer</b> , S Margutti, MD Fritz ChemMedChem: Chemistry Enabling Drug Discovery 1 (2), 197-207	2006	
150	<a href="#">Identification of urinary nucleosides by ESI-TOF-MS</a> M Pelzing, T Zey, G Zurek, D Bullinger, A Frickenschmidt, <b>S Laufer</b> , B Kammerer LC GC NORTH AMERICA 24 (2), 14	2006	

149	<a href="#">Quantitative determination of piritramide in human plasma and urine by off-and on-line solid-phase extraction liquid chromatography coupled to tandem mass spectrometry</a> R Kahlich, CH Gleiter, <b>S Laufer</b> , B Kammerer Rapid Communications in Mass Spectrometry: An International Journal Devoted ...	2006	
148	<a href="#">High anti-inflammatory activity of harpagoside-enriched extracts obtained from solvent-modified super-and subcritical carbon dioxide extractions of the roots of Harpagophytum ...</a> M Günther, <b>S Laufer</b> , PC Schmidt Phytochemical Analysis: An International Journal of Plant Chemical and ...	2006	
147	<a href="#">A novel naturally occurring tripyrrole with potential nuclease and anti-tumour properties pp 2480–2486</a> M Subramanian, R Chander, S Chattopadhyay, MT Lindenmeyer, A Hrenn, C Kern, V Castro, R Murillo, S Müller, <b>S Laufer</b> , J Schulte-Mönting, B Siedle, I Merfort Bioorganic & Medicinal Chemistry 14 (8)	2006	
146	<a href="#">Small molecular anti-cytokine agents</a> G Wagner, <b>S Laufer</b> Medicinal research reviews 26 (1), 1-62	2006	
145	<a href="#">Small Molecule Inhibitors of p38 MAP Kinase</a> C Peifer, G Wagner, <b>S Laufer</b> Current Topics in Medicinal Chemistry 6, 000-000	2006	
144	<a href="#">Complete Characterization of ML 3403 Metabolites from Liver Microsomes using ESI-Qq-TOF-MS and LC-SPE-cryo NMR/MS</a> H Scheible, <b>S Laufer</b> , W Albrecht, CH Gleiter, G Zurek, M Spraul, M Godejohann, B Kammerer 54 th ASMS Conference Proceedings	2006	
143	<a href="#">New approaches to the treatment of inflammatory disorders small molecule inhibitors of p38 MAP kinase</a> C Peifer, G Wagner, <b>S Laufer</b> Current topics in medicinal chemistry 6 (2), 113-149	2006	
142	<a href="#">The effect of single-dose naproxen on eicosanoid formation in human gastroduodenal mucosa</a> G Treiber, T Wex, A Link, M Vieth, <b>S Laufer</b> , P Malfertheiner Alimentary pharmacology & therapeutics 23 (1), 155-167	2006	
141	<a href="#">Identification of urinary nucleosides by ESI-TOF-MS</a> D Bullinger, A Frickenschmidt, M Pelzing, G Zurek, <b>S Laufer</b> , T Zey, B Kammerer Advanstar Communications Inc.	2005	

140	<a href="#">Stereospecific pharmacokinetic characterisation of phenprocoumon metabolites, and mass-spectrometric identification of two novel metabolites in human plasma and liver microsomes</a> B Kammerer, R Kahlich, M Ufer, A Schenkel, <b>S Laufer</b> , CH Gleiter Analytical and bioanalytical chemistry 383, 909-917	2005	
139	<a href="#">Are vanadium compounds drugable? Structures and effects of antidiabetic vanadium compounds: a critical review</a> T Scior, A Guevara-García, P Bernard, QT Do, D Domeyer, <b>S Laufer</b> Mini reviews in medicinal chemistry 5 (11), 995-1008	2005	
138	<a href="#">The protective effect of licofelone on experimental osteoarthritis is correlated with the downregulation of gene expression and protein synthesis of several major cartilage ...</a> JP Pelletier, C Boileau, M Boily, J Brunet, F Mineau, C Geng, P Reboul, <b>S Laufer</b> , D Lajeunesse, M Martel-Pelletier Arthritis research & therapy 7 (5), 1-12	2005	
137	<a href="#">Fused pyrrole compounds, pharmaceutical agents containing the same, and the use thereof</a> HG Striegel, <b>S Laufer</b> , K Tollmann, S Tries US Patent 6,936,632	2005	
136	<a href="#">Licofelone, a novel 5-LOX/COX-inhibitor, attenuates leukocyte rolling and adhesion on endothelium under flow</a> H Ulbrich, O Soehnlein, X Xie, EE Eriksson, L Lindbom, W Albrecht, <b>S Laufer</b> , G Dannhardt Biochemical pharmacology 70 (1), 30-36	2005	
135	<a href="#">The regulation of human MMP-13 by licofelone, an inhibitor of cyclo-oxygenases and 5-lipoxygenase, in human osteoarthritic chondrocytes is mediated by the inhibition of the p38 ...</a> C Boileau, JP Pelletier, G Tardif, H Fahmi, <b>S Laufer</b> , M Lavigne, J Martel-Pelletier Annals of the rheumatic diseases 64 (6), 891-898	2005	
134	<a href="#">Mass spectrometric identification of modified urinary nucleosides used as potential biomedical markers by LC-ITMS coupling</a> B Kammerer, A Frickenschmidt, CE Müller, <b>S Laufer</b> , CH Gleiter, H Liebich Analytical and bioanalytical chemistry 382, 1017-1026	2005	
133	<a href="#">MALDI-TOF MS analysis of urinary nucleosides</a> B Kammerer, A Frickenschmidt, CH Gleiter, <b>S Laufer</b> , H Liebich Journal of the American Society for Mass Spectrometry 16, 940-947	2005	
132	<a href="#">Cytokines and growth factors in the treatment of osteoarthritis: what could be the best disease modifying drugs</a> J Martel-Pelletier, G Tardif, <b>S Laufer</b> , JP Pelletier Current Medicinal Chemistry-Anti-Inflammatory & Anti-Allergy Agents 4 (3 ...	2005	

131	<a href="#">Naproxen induziert einen indirekten Cyclooxygenase-Lipoxygenase Shunt in der gastroduodenalen humanen Mucosa</a> A Link, T Wex, M Vieth, <b>S Laufer</b> , P Malfertheiner, G Treiber Zeitschrift für Gastroenterologie 43 (05), P024	2005	
130	<a href="#">PGE2 in the regulation of programmed erythrocyte death</a> PA Lang, DS Kempe, S Myssina, V Tanneur, C Birka, <b>S Laufer</b> , F Lang, T Wieder, SM Huber Cell Death & Differentiation 12 (5), 415-428	2005	
129	<a href="#">Achiral–chiral LC/LC–MS/MS coupling for determination of chiral discrimination effects in phenprocoumon metabolism</a> B Kammerer, R Kahlich, M Ufer, <b>S Laufer</b> , CH Gleiter Analytical biochemistry 339 (2), 297-309	2005	
128	<a href="#">Anti-inflammatory oxo derivatives and hydroxy derivatives of pyrrolizines, and their pharmaceutical use</a> <b>S Laufer</b> , K Tollmann, HG Striegel US Patent 6,878,738	2005	
127	<a href="#">Leukotriene and prostaglandin synthesis pathways in osteoarthritic synovial membranes: regulating factors for interleukin 1beta synthesis.</a> P Marcouiller, JP Pelletier, M Guévremont, J Martel-Pelletier, P Ranger, <b>S Laufer</b> , P Reboul The Journal of rheumatology 32 (4), 704-712	2005	
126	<a href="#">(3RS, 1SR)-3-Bromo-3-(1-phenylpropyl) chroman-2, 4-dione</a> D Schollmeyer, B Kammerer, C Peifer, <b>S Laufer</b> Acta Crystallographica Section E: Structure Reports Online 61 (4), o868-o869	2005	
125	<a href="#">4-Pyridyl-and 2, 4-pyrimidinyl-substituted pyrrole derivatives and their use in pharmacy</a> HG Striegel, <b>S Laufer</b> , K Tollmann, S Tries US Patent 6,867,211	2005	
124	<a href="#">Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors</a> <b>SA Laufer</b> , DM Domeyer, TRF Scior, W Albrecht, DRJ Hauser Journal of medicinal chemistry 48 (3), 710-722	2005	
123	<a href="#">An immunosorbent, nonradioactive p38 MAP kinase assay comparable to standard radioactive liquid-phase assays</a> <b>S Laufer</b> , S Thuma, C Peifer, C Greim, Y Herweh, A Albrecht, F Dehner Analytical biochemistry 1 (344), 135-137	2005	

122	<a href="#">Tetrasubstituted imidazole inhibitors of cytokine release: probing substituents in the N-1 position</a> <b>SA Laufer</b> , W Zimmermann, KJ Ruff Journal of medicinal chemistry 47 (25), 6311-6325	2004	
121	<a href="#">Mass spectrometric pathway monitoring of secondary metabolites: systematic analysis of culture extracts of Streptomyces species</a> B Kammerer, R Kahlich, <b>S Laufer</b> , SM Li, L Heide, CH Gleiter Analytical biochemistry 335 (1), 17-29		
120	<a href="#">Regulation of the expression of 5-lipoxygenase-activating protein/5-lipoxygenase and the synthesis of leukotriene B<sub>4</sub> in osteoarthritic chondrocytes: Role of ...</a> J Martel-Pelletier, F Mineau, H Fahmi, <b>S Laufer</b> , P Reboul, C Boileau, M Lavigne, JP Pelletier Arthritis & Rheumatism 50 (12), 3925-3933	2004	
119	<a href="#">Regulation of the expression of FLAP/5-LOX and synthesis of LTB<sub>4</sub> in osteoarthritic chondrocytes: Role of TGF-beta and eicosanoids</a> J Martel-Pelletier, F Mincau, H Fahmi, <b>S Laufer</b> , P Reboul, C Boileau, M Lavigne, JP Pelletier Arthritis and Rheumatism 50 (9), S286-S286	2004	
118	<a href="#">Licofelone, a novel 5-LOX/COX-inhibitor, attenuates leukocyte rolling and adhesion on endothelium under flow</a> H Ulbrich, EE Eriksson, X Xie, O Soehnlein, L Lindbom, <b>S Laufer</b> , G Dannhardt ANNALS OF THE RHEUMATIC DISEASES 63, 137-137	2004	
117	<a href="#">NSAIDs and lipo-oxygenase/cyclo-oxygenase products modulate dendritic cell function</a> S Fiorucci, A Di Lorenzo, S Farneti, M Barbanti, <b>S Laufer</b> , E Palazzini ANNALS OF THE RHEUMATIC DISEASES 63, 132-133	2004	
116	<a href="#">The gastrointestinal tolerability of the LOX/COX inhibitor, licofelone, is similar to placebo and superior to naproxen therapy in healthy volunteers: results from a randomized ...</a> P Bias, A Buchner, B Klessner, <b>S Laufer</b> Official journal of the American College of Gastroenterology  ACG 99 (4), 611-618	2004	
115	<a href="#">2-Tiosubstituované imidazolové deriváty a ich použitie vo farmácii</a> <b>S Laufer</b> , D Kotschenreuther, P Merckle, K Tollmann	2004	
114	<a href="#">The inhibition of subchondral bone resorption in the early phase of experimental dog osteoarthritis by licofelone is associated with a reduction in the synthesis of MMP-13 and ...</a> JP Pelletier, C Boileau, J Brunet, M Boily, D Lajeunesse, P Reboul, <b>S Laufer</b> , J Martel-Pelletier Bone 34 (3), 527-538	2004	

113	<a href="#">Determination of (R)- and (S)-phenprocoumon in human plasma by enantioselective liquid chromatography/electrospray ionisation tandem mass spectrometry</a> B Kammerer, R Kahlich, M Ufer, <b>S Laufer</b> , CH Gleiter Rapid communications in mass spectrometry 18 (4), 458-464	2004	
112	<a href="#">Composto, composição farmacêutica, uso de pelo menos um composto, e, método para tratar distúrbios associados com um sistema imune perturbado</a> <b>S Laufer</b> , D Kotschenreuther, P Merckle, K Tollmann, HG Striegel	2004	
111	<a href="#">Osteoarthritis therapy—are there still unmet needs?</a> <b>S Laufer</b> Rheumatology 43 (suppl_1), i9-i15	2004	
110	<a href="#">Treatment with licofelone prevents abnormal subchondral bone cell metabolism in experimental dog osteoarthritis</a> D Lajeunesse, J Martel-Pelletier, JC Fernandes, <b>S Laufer</b> , JP Pelletier Annals of the rheumatic diseases 63 (1), 78-83	2004	
109	<a href="#">Combined approach for analysis of biological activity of compounds</a> MA Grishina, VA Potemkin, KM Mikuchina, GV Pozhilenkova, <b>S Laufer</b> Biomeditsinskaya khimiya 50 (app1), 68-76	2004	
108	<a href="#">The regulation of human metalloprotease-13 by licofelone, an inhibitor of cyclooxygenases and 5-lipoxygenase, in human osteoarthritic chondrocytes is mediated by the inhibition ...</a> C Boileau, JP Pelletier, F Mineau, G Tardif, H Fahmi, <b>S Laufer</b> , M Lavigne, J Martel-Pelletier OSTEOARTHRITIS AND CARTILAGE 12, S100-S100	2004	
107	<a href="#">Genetic algorithm for molecular 3D drug design</a> VA Potemkin, MA Grishina, GV Pozhilenkova, KM Mikuchina, <b>S Laufer</b> Biomeditsinskaya khimiya 50 (app1), 42-48	2004	
106	<a href="#">COX-3—a virtual pain target in humans?</a> JM Schwab, T Beiter, JU Linder, <b>S Laufer</b> , JE Schulz, R Meyermann, HJ Schluesener The FASEB journal 17 (15), 2174-2175	2003	
105	<a href="#">Inhibition of human MMP-13 expression by licofelone, a dual inhibitor of cyclooxygenase/5-lipoxygenase in human osteoarthritic (OA) chondrocytes.</a> C Boileau, JP Pelletier, <b>S Laufer</b> , P Ranger, J Martel-Pelletier ARTHRITIS AND RHEUMATISM 48 (9), S283-S283	2003	
104	<a href="#">Role of eicosanoids in structural degradation in osteoarthritis</a>	2003	

	<b>S Laufer</b> Current opinion in rheumatology 15 (5), 623-627		
103	<a href="#">Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes</a> <b>SA Laufer</b> , GK Wagner, DA Kotschenreuther, W Albrecht Journal of medicinal chemistry 46 (15), 3230-3244	2003	
102	<a href="#">Study of cross talking between leukotriene and prostaglandin synthetic pathways in human OA synovial membranes: Mechanisms of regulation</a> P Reboul, P Marcouiller, <b>S Laufer</b> , J Martel-Pelletier, JP Pelletier ANNALS OF THE RHEUMATIC DISEASES 62, 114-115	2003	
101	<a href="#">Selective COX-2 inhibitors, but not licofelone, a LOX/COX inhibitor, inhibit anti-adhesive activity of aspirin</a> S Fiorucci, A Mencarelli, E Distrutti, <b>S Laufer</b> , M Barbanti, E Palazzini, A Morelli, JL Wallace ANNALS OF THE RHEUMATIC DISEASES 62, 116-116	2013	
100	<a href="#">Inhibition of human MMP-13 expression by licofelone, a dual inhibitor of cyclooxygenases/5-lipoxygenase in human osteoarthritic chondrocytes</a> C Boileau, JP Pelletier, <b>S Laufer</b> , P Ranger, J Martel-Pelletier ANNALS OF THE RHEUMATIC DISEASES 62, 262-263	2003	
99	<a href="#">International Conference on Inflammopharmacology–VIII Side-Effects of Anti-Inflammatory Drugs Symposium</a> <b>S Laufer</b> Expert Opinion on Investigational Drugs 12 (7), 1239-1241	2003	
98	<a href="#">Identification of Regioisomers in a Series of N-Substituted Pyridin-4-yl Imidazole Derivatives by Regiospecific Synthesis, GC/MS, and <sup>1</sup>H NMR</a> GK Wagner, D Kotschenreuther, W Zimmermann, <b>SA Laufer</b> The Journal of organic chemistry 68 (11), 4527-4530	2003	
97	<a href="#">COX-3: just another COX or the solitary elusive target of paracetamol?</a> JM Schwab, HJ Schluesener, <b>S Laufer</b> The Lancet 361 (9362), 981-982	2003	
96	<a href="#">Influence of willow bark extract on cyclooxygenase activity and on tumor necrosis factor alpha or interleukin 1 beta release in vitro and ex vivo.</a> I Wagner, C Greim, <b>S Laufer</b> , L Heide, CH Gleiter Clinical pharmacology and therapeutics 73 (3), 272-274	2003	

95	<a href="#">NO-Donors. Part 7. Synthesis and Cyclooxygenase Inhibitory Properties of N-and S-Nitrooxypivaloyl-cysteine Derivatives of Naproxen—A Novel Type of NO-NSAID.</a> RE Kartasasmita, <b>S Laufer</b> , J Lehmann ChemInform 34 (4), no-no	2003	
94	<a href="#">Inflammation and rheumatic diseases. The molecular basis of novel therapies</a> F Calanni, <b>S Laufer</b> Biochemistry and mediators of inflammation. Georg Thieme Verlag, Stuttgart	2003	
93	<a href="#">Inflammation and Rheumatic Diseases: The molecular basis of novel therapies</a> <b>S Laufer</b> , S Gay, K Brune Georg Thieme Verlag	2003	
92	<a href="#">Biochemistry and mediators of inflammation</a> F Calanni, <b>S Laufer</b> Inflammation and Rheumatic Diseases. The Molecular Basis of Novel Therapies. Georg Thieme Verlag	2003	
91	<a href="#">LETTERS TO THE EDITOR-Influence of willow bark extract on cyclooxygenase activity and on tumor necrosis factor a or interleukin 1b release in vitro and ex vivo</a> I Wagner, C Greim, <b>S Laufer</b> , L Heide, CH Gleiter Clinical Pharmacology and Therapeutics 73 (3), 272-273	2003	
90	<a href="#">Antitubercular Isoniazid and Drug Resistance of Mycobacterium tuberculosis — A Review</a> T Scior, I Meneses Morales, SJ Garcés Eisele, D Domeyer, <b>S Laufer</b> Archiv der Pharmazie: An International Journal Pharmaceutical and Medicinal Chemistry 335 (11-12), 511-525	2002	
89	<a href="#">An in-vitro screening assay for the detection of inhibitors of proinflammatory cytokine synthesis: a useful tool for the development of new antiarthritic and disease modifying ...</a> <b>S Laufer</b> , C Greim, T Bertsche Osteoarthritis and cartilage 10 (12), 961-967	2002	
88	<a href="#">NO-Donors (VII [1]): Synthesis and Cyclooxygenase Inhibitory Properties of N-and S-Nitrooxypivaloyl-cysteine Derivatives of Naproxen — A Novel Type of NO ...</a> RE Kartasasmita, <b>S Laufer</b> , J Lehmann Archiv der Pharmazie: An International Journal Pharmaceutical and Medicinal Chemistry 335 (8) 363-366	2002	
87	<a href="#">Imidazole inhibitors of cytokine release: probing substituents in the 2 position</a> <b>SA Laufer</b> , HG Striegel, GK Wagner Journal of medicinal chemistry 45 (21), 4695-4705	2002	

86	<a href="#">Discovery and development of LICOFELONE (ML3000)</a> <b>S Laufer</b> , S Tries, HG Striegel, P Bias, A Buchner EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY 58 (7), S100-S100	2002	
85	<a href="#">2-Thio-substituierte Imidazolderivate und ihre Verwendung in der Pharmazie</a> <b>S Laufer</b> , D Kotschenreuther, P Merckle, K Tollmann, HG Striegel	2002	
84	<a href="#">2-arylalkylthio-imidazoles, 2-arylalkenyl-thio-imidazoles and 2-arylalkinyl-thio-imidazoles as anti-inflammatory substances and substances inhibiting the release of cytokine</a> <b>S Laufer</b> , HG Striegel, K Neher US Patent 6,432,988	2002	
83	<a href="#">Process for preparing 6-(4-chlorophenyl)-2, 2-dimethyl-7-phenyl-2, 3-dihydro-1H-pyrrolizin-5-yl-acetic acid</a> T Kammermeier, <b>S Laufer</b> , P Merckle, HG Striegel US Patent 6,417,371	2002	
82	<a href="#">Ones, Thiones, and N-Oxides: An Exercise in Imidazole Chemistry</a> <b>S Laufer</b> , G Wagner, D Kotschenreuther Angewandte Chemie International Edition 41 (13), 2290-2293	2002	
81	<a href="#">One, Thione und N-Oxide: ein allgemeiner Zugang zu Imidazolderivaten</a> <b>S Laufer</b> , G Wagner, D Kotschenreuther Angewandte Chemie 114 (13), 2408-2411	2002	
80	<a href="#">Licofelone (ML-3000), a dual inhibitor of 5-lipoxygenase and cyclooxygenase, reduces the level of cartilage chondrocyte death in vivo in experimental dog osteoarthritis ...</a> C Boileau, J Martel-Pelletier, JY Jouzeau, P Netter, F Moldovan, <b>S Laufer</b> , S Tries, JP Pelletier The Journal of Rheumatology 29 (7), 1446-1453	2002	
79	<a href="#">Study of the role of leukotriene B<sub>4</sub> in abnormal function of human subchondral osteoarthritis osteoblasts: Effects of cyclooxygenase and/or 5-lipoxygenase inhibition</a> Y Paredes, F Massicotte, JP Pelletier, J Martel-Pelletier, <b>S Laufer</b> , D Lajeunesse Arthritis & Rheumatism: Official Journal of the American College of Rheumatology 46 (7) 1804-1812	2002	
78	<a href="#">From imidazoles to pyrimidines: new inhibitors of cytokine release</a> <b>SA Laufer</b> , GK Wagner Journal of medicinal chemistry 45 (13), 2733-2740	2002	

77	<a href="#">Studies on the anti-inflammatory activity of phytopharmaceuticals prepared from Arnica flowers</a> CA Klaas, G Wagner, <b>S Laufer</b> , S Sosa, R Della Loggia, U Bomme, HL Pahl, I Merfort Planta medica 68 (05), 385-391	2002	
76	<a href="#">Synthesis of interleukin 1beta, tumor necrosis factor-alpha, and interstitial collagenase (MMP-1) is eicosanoid dependent in human osteoarthritis synovial membrane explants ...</a> W He, JP Pelletier, J Martel-Pelletier, <b>S Laufer</b> , JA Di Battista The Journal of Rheumatology 29 (3), 546-553	2002	
75	<a href="#">Antithrombotic and platelet function inhibiting effects of ML3000, a new antiinflammatory drug with Cox/5-LOX inhibitory activity</a> S Tries, <b>S Laufer</b> , P Radziwon, HK Breddin Inflammation Research 51, 129-134	2002	
74	<a href="#">The mechanism of action of the new antiinflammatory compound ML3000: inhibition of 5-LOX and COX-1/2</a> S Tries, W Neupert, <b>S Laufer</b> Inflammation Research 51, 135-143	2002	
73	<a href="#">Neue NSAR: Was bietet die Zukunft?</a> <b>S Laufer</b> Pharmazie in unserer Zeit 31 (2), 164-169	2002	
72	<a href="#">Synthesis of IL-1b, TNF-a, and Interstitial Collagenase (MMP-1) Is Eicosanoid Dependent in Human OA Synovial Membrane Explants: Interactions with Antiinflammatory Cytokines</a> W He, JP Pelletier, J Martel-Pelletier, <b>S Laufer</b> , JA DiBattista Journal of Rheumatology 29 (3), 546-553	2002	
71	<a href="#">Biochemie und Mediatoren der Entzündung</a> <b>S Laufer</b> Rheumatische Erkrankungen und Entzündung: Von den molekularen Grundlagen zur medikamentösen Therapie, Georg Thieme Verlag	2002	
70	<a href="#">Rheumatische Erkrankungen und Entzündung: von den molekularen Grundlagen zur medikamentösen Therapie; 26 Tabellen</a> <b>S Laufer</b> , S Gay, K Brune Georg Thieme Verlag	2002	
69	<a href="#">Osteoarthritis and Cartilage-Study of the Role of Leukotriene B4 in Abnormal Function of Human Subchondral Osteoarthritis Osteoblasts: Effects of Cyclooxygenase and/or 5 ...</a> Y Paredes, F Massicotte, JP Pelletier, J Martel-Pelletier, <b>S Laufer</b> , D Lajeunesse Arthritis and Rheumatism 46 (7), 1804-1812	2002	
68	<a href="#">Neue und zukünftige Therapieansätze</a>	2002	

	<p><b>S Laufer</b> Laufer, S., Gay, G., Brune K.: Rheumatische Erkrankungen und Entzündung. Georg Thieme Verlag</p>		
67	<p><a href="#">In vivo dual inhibition of cyclooxygenase and lipoxygenase by ML-3000 reduces the progression of experimental osteoarthritis: Suppression of collagenase 1 and interleukin-1<math>\beta</math> ...</a> DV Jovanovic, JC Fernandes, J Martel-Pelletier, FC Jolicoeur, P Reboul, <b>S Laufer</b>, S Tries, JP Pelletier Arthritis &amp; Rheumatism 44 (10), 2320-2330</p>	2001	
66	<p><a href="#">The in vivo dual inhibition of cyclooxygenase and lipoxygenase by ML-3000 reduces the progression of experimental osteoarthritis: Suppression of collagenase-1 and interleukin-1 ...</a> JP Pelletier, JC Fernandes, FC Jolicoeur, P Reboul, S Laufer, S Tries, J Martel-Pelletier ARTHRITIS AND RHEUMATISM 44 (9), S307-S307</p>	2001	
65	<p><a href="#">Dual inhibition of 5-lipoxygenase and cyclooxygenases 1 and 2 by ML3000 reduces joint destruction in adjuvant arthritis.</a> RE Gay, M Neidhart, F Pataky, S Tries, <b>S Laufer</b>, S Gay The Journal of Rheumatology 28 (9), 2060-2065</p>	2001	
64	<p><a href="#">Role of leukotriene B-4 in abnormal function of osteoarthritic osteoblasts.</a> D Lajeunesse, Y Paredes, F Massicotte, J Martel-Pelletier, <b>S Laufer</b>, JP Pelletier ARTHRITIS AND RHEUMATISM 44 (9), S308-S308</p>	2001	
63	<p><a href="#">Discovery and development of ML3000</a> <b>S Laufer</b> Inflammopharmacology 9, 101-112</p>	2001	
62	<p><a href="#">The pharmacological profile of ML3000: A new pyrrolizine derivative inhibiting the enzymes cyclo-oxygenase and 5-lipoxygenase</a> S Tries, <b>S Laufer</b> Inflammopharmacology 9, 113-124</p>	2001	
61	<p><a href="#">Anti-inflammatory drugs: new multitarget compounds to face an old problem. The dual inhibition concept</a> F Celotti, <b>S Laufer</b> Pharmacological Research 43 (5), 429-436</p>	2001	
60	<p><a href="#">Synthesis and Cyclooxygenase Inhibitory Properties of Novel (+) 2-(6-Methoxy-2-naphthyl) propanoic Acid (Naproxene) Derivatives</a> AH Abadi, <b>S Laufer</b>, J Lehmann Archiv der Pharmazie 334 (3), 104-106</p>	2001	

59	<a href="#">Antiinflammatorische oxo-und hydroxyderivate von pyrrolizinen und deren anwendung in der pharmazie</a> <b>S Laufer</b> , K Neher, HG Striegel	2001	
58	<a href="#">Effects of natural products containing acylresorcinol partial structures on cyclooxygenases and 5-lipoxygenase</a> F Bracher, J Krauss, <b>S Laufer</b> Pharmazie 56 (5)	2001	
57	<a href="#">Copyright WILEY-VCH Verlag GmbH, D-69451 Weinheim, 2001. Supporting Information for Angew. Chem. Int. Ed. Z18173</a> <b>S Laufer</b> , G Wagner, D Kotschenreuther	2001	
56	<a href="#">Osteoarthritis and Cartilage-In Vivo Dual Inhibition of Cyclooxygenase and Lipoxygenase by ML-3000 Reduces the Progression of Experimental Osteoarthritis: Suppression of ...</a> DV Jovanovic, JC Fernandes, J Martel-Pelletier, FC Jolicoeur, P Reboul, <b>S Laufer</b> , S Tries, JP Pelletier Arthritis and Rheumatism 44 (10), 2320-2330	2001	
55	<a href="#">Structural approaches to explain the selectivity of COX-2 inhibitors: is there a common pharmacophore?</a> G Dannhardt, <b>S Laufer</b> Current Medicinal Chemistry 7 (11), 1101-1112	2000	
54	<a href="#">A NOVEL AND VERSATILE SYNTHETIC APPROACH TOWARDS NI-SUBSTITUTED IMIDAZOLE DERIVATIVES</a> D Kotschenreuther, <b>S Laufer</b> ARCHIV DER PHARMAZIE 333, 43-43	2000	
53	<a href="#">In-vitro screening assay to evaluate cytokine release inhibitors</a> C Donat, <b>S Laufer</b> ARCHIV DER PHARMAZIE 333, 15-15	2000	
52	<a href="#">TOWARDS NEW INHIBITORS OF CYTOKINE RELEASE</a> G Wagner, <b>S Laufer</b> ARCHIV DER PHARMAZIE 333, 97-97	2000	
51	<a href="#">A!-annelated pyrrole derivatives and their use in pharmacology</a> <b>S Laufer</b> , HG Striegel, G Dannhardt US Patent 5,958,943	1999	
50	<a href="#">a!-Annelated pyrrole derivatives and pharmaceutical use thereof</a> <b>S Laufer</b> , HG Striegel, G Dannhardt US Patent 5,942,535	1999	
49	<a href="#">A!-annelated pyrrole derivatives and their use in pharmacology</a> <b>S Laufer</b> , HG Striegel, G Dannhardt US Patent 5,939,415	1999	

48	<a href="#">Development of an in-vitro test system for the evaluation of cyclooxygenase-2 inhibitors</a> <b>S Laufer</b> , P Zechmeister, T Klein Inflammation research 48, 133-138	1999	
47	<a href="#">Anti-inflammatory activity of myricetin-3-O-<math>\beta</math>-D-glucuronide and related compounds</a> A Hiermann, HW Schramm, <b>S Laufer</b> Inflammation research 47, 421-427	1998	
46	<a href="#">Uricosurisch wirksame Metabolite des Benzbromarons</a> <b>S Laufer</b> , J Manner, S Tries, V Luckow, P Arnold SCIENTIA PHARMACEUTICA 66, S76-S76	1998	
45	<a href="#">The effects of ML 3000 on antigen-induced responses in sheep</a> WM Abraham, <b>S Laufer</b> , S Tries Pulmonary pharmacology & therapeutics 10 (3), 167-173	1997	
44	<a href="#">Bioequivalence evaluation of two flutamide preparations in healthy female subjects.</a> K Doser, R Guserle, R Kramer, <b>S Laufer</b> , K Lichtenberger Arzneimittel-forschung 47 (2), 213-217	1997	
43	<a href="#">Synthesis and evaluation of a novel series of pyrrolizine derivatives as dual cyclooxygenase-1 and 5-lipoxygenase inhibitors</a> <b>S Laufer</b> , HG Striegel, K Neher, P Zechmeister, C Donat, K Stolingwa, S Baur, S Tries, T Kammermeier, G Dannhardt, W Kiefer Archiv der Pharmazie 330 (9-10), 307-312	1997	
42	<a href="#">Synthesis and biological identification of the acyl glucuronide of the antiinflammatory drug ML-3000</a> A Kirschning, M Ries, S Domann, W Martin, W Albrecht, P Arnold, <b>S Laufer</b> Bioorganic & Medicinal Chemistry Letters 7 (7), 903-906	1997	
41	<a href="#">Efficient Synthesis of New 2-Cycloalk(en)ylpropanoic Acid Derivatives—Medium and Large Rings as Bioisosteres of Alkylphenyl Moieties?</a> B Greve, P Imming, <b>S Laufer</b> Angewandte Chemie International Edition in English 35 (11), 1221-1223	1996	
40	<a href="#">Effiziente Synthese neuer 2-Cycloalk(en)yl-propansäure-Derivate—mittlere und große Ringe als Bioisostere von Alkylphenylresten?</a> B Greve, P Imming, <b>S Laufer</b> Angewandte Chemie 108 (11), 1312-1314	1996	
39	<a href="#">Regioisomeric 5 (3)-aminomethyl-3 (5)-phenylisoxazoles: synthesis, spectroscopic discrimination, and muscarinic activity.</a> G Dannhardt, G Lambrecht, <b>S Laufer</b> , E Mutschler, J Schweiger	1995	

	Archiv der Pharmazie 328 (5), 437-443		
38	<a href="#">Studies on the in vitro and in vivo genotoxicity of [2, 2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2, 3-dihydro-1H-pyrrolizine-5-yl]-acetic acid</a> A Heidemann, S Tries, <b>S Laufer</b> , J Augustin Arzneimittel-Forschung 45 (4), 486-490	1995	
37	<a href="#">Distribution and excretion of [14C]-labelled [2, 2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2, 3-dihydro-1H-pyrrolizine-5-yl]-[2'-14C]-acetic acid in rats.</a> HP Deigner, CE Freyberg, <b>S Laufer</b> Arzneimittel-forschung 45 (3), 272-276	1995	
36	<a href="#">General pharmacology of [2, 2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2, 3-dihydro-1H-pyrrolizine-5-yl]-acetic acid in experimental animals.</a> DR Algate, J Augustin, PR Atterson, DJ Beard, CM Jobling, <b>S Laufer</b> , PL Munt, S Tries Arzneimittel-forschung 45 (2), 159-165	1995	
35	<a href="#">Acute and chronic anti-inflammatory properties of [2, 2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2, 3-dihydro-1H-pyrrolizine-5-yl]-acetic acid.</a> <b>S Laufer</b> , S Tries, J Augustin, R Elsässer, W Albrecht, R Guserle, DR Algate, PR Atterson, PL Munt Arzneimittel-forschung 45 (1), 27-32	1995	
34	<a href="#">In-vitro test system for the evaluation of dual cyclooxygenase and 5-lipoxygenase inhibitors</a> <b>S Laufer</b> , K Neher, B Bayer, J Homann, E Reutter, S Tries Pharmaceutical and Pharmacological Letters 5 (4), 166-169	1995	
33	<a href="#">Regioisomeric 3-, 4-and 5-aminomethyl isoxazoles: synthesis and muscarinic activity</a> G Dannhardt, W Kiefer, G Lambrecht, <b>S Laufer</b> , E Mutschler, J Schweiger, HG Striegel European journal of medicinal chemistry 30 (11), 839-850	1995	
32	<a href="#">ML 3000 reduces gastric prostaglandin synthesis without causing mucosal injury</a> JL Wallace, L Carter, W McKnight, S Tries, <b>S Laufer</b> European journal of pharmacology 271 (2-3), 525-531	1994	
31	<a href="#">Gastrointestinal tolerance of [2, 2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2, 3-dihydro-1H-pyrrolizine-5-yl]-acetic acid in the rat.</a> <b>S Laufer</b> , S Tries, J Augustin, R Elsässer, DR Algate, PR Atterson, PL Munt Arzneimittel-forschung 44 (12), 1329-1333	1994	

30	<a href="#">P59 Diarylpyrrolizines; dual inhibitors of CO and 5-LO</a> <b>S Laufer</b> , S Tries, J Augustin European Journal of Pharmaceutical Sciences 2 (1-2), 133	1994	
29	<a href="#">(6, 7-Diaryldihydropyrrolizin-5-yl) acetic acids, a novel class of potent dual inhibitors of both cyclooxygenase and 5-lipoxygenase</a> <b>SA Laufer</b> , J Augustin, G Dannhardt, W Kiefer Journal of medicinal chemistry 37 (12), 1894-1897	1994	
28	<a href="#">Pharmacological profile of a new pyrrolizine derivative inhibiting the enzymes cyclo-oxygenase and 5-lipoxygenase.</a> <b>S Laufer</b> , S Tries, J Augustin, G Dannhardt Arzneimittel-forschung 44 (5), 629-636	1994	
27	<a href="#">Duale Hemmstoffe der Cyclooxygenase und 5-Lipoxygenase; ein neuer Ansatz zur Entwicklung nebenwirkungsarmer NSAR</a> <b>S Laufer</b> , S Tries, J Augustin, G Dannhardt SCIENTIA PHARMACEUTICA 62, 167-167	1994	
26	<a href="#">Hypertensive effects and structure-activity relationships of 5-omega-aminoalkyl isoxazoles.</a> G Dannhardt, P Dominiak, <b>S Laufer</b> Arzneimittel-forschung 43 (4), 441-444	1993	
25	<a href="#">5-(β-Aminoethyl) aminoisoxazoles with Hypertensive Activity: Synthesis and Screening of Isoxazolopyrazines and Isoxazolodiazepines.</a> G DANNHARDT, P DOMINIAK, <b>S LAUFER</b> ChemInform 22 (28), no-no	1991	
24	<a href="#">5-((β-Aminoethyl) amino) isoxazoles with Hypertensive Activity: Synthesis and Screening of Derivatives with Partially Rigid C-5 Side Chains and Heterocycles at the ω-Position ...</a> G Dannhardt, P DOMINIAK, <b>S LAUFER</b> ChemInform 22 (2), no-no	1991	
23	<a href="#">Hypertensiv wirksame 5-(β-Aminoethyl) aminoisoxazole: Synthese und Prüfung von Isoxazolopyrazinen und Isoxazolodiazepinen</a> G Dannhardt, P Dominiak, <b>S Laufer</b> Archiv der Pharmazie 324 (3), 141-148	1991	
22	<a href="#">Hypertensive acting 5-(beta-aminoethyl) aminoisoxazoles: synthesis and screening of derivatives with with partially rigid C-5 side chains and omega-position heterocyclics</a> G Dannhardt, P Dominiak, <b>S Laufer</b> Archiv der Pharmazie 323 (9), 571-578	1990	
21	<a href="#">Hypertensive action of 5-(omega-aminoalkyl) aminoisoxazole: synthesis and testing of compounds with a sulfamide or carboxyl group on the end of side chain</a>	1990	

	G Dannhardt, P Dominiak, <b>S Laufer</b> Archiv der Pharmazie 323 (8), 517-519		
20	<a href="#">5-(OMEGA-AMINOALKYL) AMINOISOXAZOLES WITH HYPERTENSIVE ACTIVITY-SYNTHESIS AND SCREENING OF COMPOUNDS WITH A SULFAMIDE OR CARBOXYL FUNCTION AT THE END OF THE SIDE-CHAIN</a> G DANNHARDT, P DOMINIAK, <b>S LAUFER</b> ARCHIV DER PHARMAZIE 323 (8), 517-519	1990	
19	<a href="#">Ring Transformations of 2-Phenacylidenimidazolidines: Synthesis of 5-(<math>\beta</math>-Aminoethyl) anilinopyrazoles and 2-Acyl-3-(<math>\beta</math>-aminoethyl) aminothiophenes.</a> G Dannhardt, <b>S Laufer</b> ChemInform 21 (7), no-no	1990	
18	<a href="#">Hypertensiv wirksame 5-(<math>\omega</math>-Aminoalkyl) aminoisoxazole: Synthese und Prüfung von Verbindungen mit einer Sulfamid-oder Carboxyl-Gruppe am Ende der Seitenkette</a> G Dannhardt, P Dominiak, <b>S Laufer</b> Archiv der Pharmazie 323 (8), 517-519	1990	
17	<a href="#">Hypertensiv wirksame 5-(<math>\beta</math>-Aminoethyl) aminoisoxazole: Synthese und Prüfung von Derivaten mit teilrigidisierter C-5-Seitenkette bzw. <math>\omega</math>-ständigem Heterocyclus</a> G Dannhardt, P Dominiak, <b>S Laufer</b> Archiv der Pharmazie 323 (9), 571-578	1990	
16	<a href="#">A New Synthesis of 3, 4-Diaryl-5-oxo-4, 5-dihydroisoxazoles and Their Transformation to 5-(N-(<math>\omega</math>-Aminoalkyl) amino) isoxazoles and 5-(2-Aminoethylthio) isoxazoles.</a> G Dannhardt, <b>S Laufer</b> , I Obergrusberger ChemInform 20 (37), no-no	1989	
15	<a href="#">Ring Transformation of 2-Phenacylidenimidazolidines into 5-(2-Aminoethyl)-3-aryl-5-phenylaminoisoxazoles.</a> G Dannhardt, <b>S Laufer</b> ChemInform 20 (23), no-no	1989	
14	<a href="#">5-(2-Aminoethyl)-3-aryl-5-phenylaminoisoxazole durch Ringtransformation von 2-Phenacylidenimidazolidinen</a> G Dannhardt, <b>S Laufer</b> Synthesis 1989 (01), 12-15	1989	
13	<a href="#">Eine neue Synthese für 3, 4-Diaryl-5-oxo-4, 5-dihydroisoxazole und ihre Überführung in 5-[N-(<math>\omega</math>-Aminoalkyl) amino) isoxazole und 5-(2-Aminoethylthio) isoxazole</a> G Dannhardt, <b>S Laufer</b> , I Obergrusberger Synthesis 1989 (04), 275-280	1989	

12	<a href="#">HPLC determination of etofenamate and flufenamic acid in biological material.</a> G Dannhardt, <b>S Laufer</b> , M Lehr Clinical chemistry 34 (12), 2580-2581	1988	
11	<a href="#">PREPARATION AND CARDIOVASCULAR ACTIVITY OF 5-OMEGA-AMINO-ALKYL (-HETEROALKYL) ISOXAZOLENE</a> G DANNHARDT, P DOMINIAC, <b>S LAUFER</b> ARCHIV DER PHARMAZIE 321 (9), 576-576	1988	
10	<a href="#">Enaminodiester and Monoesters with a Semicyclic C=C Bond of the Pyrrolidine and Imidazolidine Series</a> G Dannhardt, <b>S Laufer</b> , K Zierys Archiv der Pharmazie 321 (7), 429-430	1988	
9	<a href="#">Unselective COX Inhibitors</a> <b>SA Laufer</b>	1988	
8	<a href="#">TÍTULO DO TRABALHO: TRITERPENÓIDE ISOLADO DAS PARTES AÉREAS DE Senecio selloi Spreng. DC.: AVALIAÇÃO DAS ATIVIDADES ANTIINFLAMATÓRIA E ANESTÉSICA GERAL.</a> GNS DA SILVA, MA DA CUNHA, B BALDISSEROTTO, <b>S LAUFER</b> , CA MALLMANN, BM HEINZMANN		
7	<a href="#">Identification of Urinary Nucleosides</a> D Bullinger, A Frickenschmidt, M Pelzing, T Zey, G Zurek, <b>S Laufer</b> , B Kammerer		
6	<a href="#">Structure and Metabolic Function of COX-1</a> <b>SA Laufer</b>		
5	<a href="#">PHYTOCHEMICAL AND BIOLOGICAL STUDIES OF THE BARK FROM PARAPIPTADENIA RIGIDA</a> CA Schmidt, M Fronza, M Goettert, R Murillo, V Brecht, B Heinzmann, <b>S Laufer</b> , I Merfort		
4	<a href="#">COX-3Oa virtual pain target in humans?</a> J SCHWAB, T BEITER, JU LINDER, <b>S LAUFER</b> , JE SCHULZ, R MEYERMANN, HJ SCHLUESENER		
3	<a href="#">p38 MAP-KINASE INHIBITORS AND THEIR CYP-450 INTERFERENCE: AN OPTIMIZATION</a> K Ruff, D Kotschenreuther, <b>S Laufer</b>		
2	<a href="#">Small Molecule Inhibitors OF Cytokine Release Bioisosteric Replacement</a> MD Fritz, <b>S Laufer</b>		
1	<a href="#">Covalent Inhibitors re-invented</a>		

	P Koch, F Muth, M Günther, M Juchum, M Forster, D Rauh, S Knapp, <b>SA Laufer</b>		
	Artikel 1–633		